# EDGAR Filing Document

**Accession Number:** 0001571123
**File Stem:** 0001571123-26-000029
**Filing Date:** 2026-3
**Character Count:** 411997
**Document Hash:** 2176b596154f3cda422790f08329a7c6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001571123-26-000029.hdr.sgml**: 20260316

**ACCESSION NUMBER**: 0001571123-26-000029

**CONFORMED SUBMISSION TYPE**: 10-K

**PUBLIC DOCUMENT COUNT**: 117

**CONFORMED PERIOD OF REPORT**: 20260130

**FILED AS OF DATE**: 20260316

**DATE AS OF CHANGE**: 20260316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Science Applications International Corp
- **CENTRAL INDEX KEY:** 0001571123
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 461932921
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0130

**FILING VALUES:**
- **FORM TYPE:** 10-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35832
- **FILM NUMBER:** 26755461

**BUSINESS ADDRESS:**
- **STREET 1:** 12010 SUNSET HILLS ROAD
- **CITY:** RESTON
- **STATE:** VA
- **ZIP:** 20190
- **BUSINESS PHONE:** 703-676-4300

**MAIL ADDRESS:**
- **STREET 1:** 12010 SUNSET HILLS ROAD
- **CITY:** RESTON
- **STATE:** VA
- **ZIP:** 20190

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SAIC Gemini, Inc.
- **DATE OF NAME CHANGE:** 20130305

?xml version='1.0' encoding='ASCII'? saic-20260130

&nbsp;&nbsp;&nbsp;&nbsp;

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

**Washington, D.C. 20549**

Form 10-K

**(Mark One)**

☒ **ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the fiscal year ended January 30, 2026

or

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the transition period from _____ to _____ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Commission file number** | **Commission file number** | **Commission file number** | **Commission file number** | **001-35832** |
| **Science Applications International Corporation** | **Science Applications International Corporation** | **Science Applications International Corporation** | **Science Applications International Corporation** | **Science Applications International Corporation** |
| (Exact name of registrant as specified in its charter) | (Exact name of registrant as specified in its charter) | (Exact name of registrant as specified in its charter) | (Exact name of registrant as specified in its charter) | (Exact name of registrant as specified in its charter) |
| **Delaware** | **Delaware** | **Delaware** |  | **46-1932921** |
| (State or other jurisdiction of incorporation or organization) | (State or other jurisdiction of incorporation or organization) | (State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.) |
| **12010 Sunset Hills Road** | **Reston,** | **Virginia** |  | **20190** |
| (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) |  | (Zip Code) |
| **(703)** | **(703)** | **(703)** | **676-4300** | **676-4300** |
| (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) | (Registrant's telephone number, including area code) |

---

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<u>Title of each class</u>** | **<u>Trading Symbol(s)</u>** | **<u>Name of each exchange on which registered</u>** |
| **Common Stock, Par Value $.0001 Per Share** | **SAIC** | **The Nasdaq Stock Market LLC** |

---

**Securities registered pursuant to Section 12(g) of the Act: None**

---

| | | | | |
|:---|:---|:---|:---|:---|
| Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. | Yes | ☒ | No | ☐ |
| Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. | Yes | ☐ | No | ☒ |
| Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. | Yes | ☒ | No | ☐ |
| Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). | Yes | ☒ | No | ☐ |
| Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. |  |  |  |  |

---

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| Large accelerated filer | ☒ | &nbsp;&nbsp;&nbsp;&nbsp;Accelerated filer | ☐ | &nbsp;&nbsp;&nbsp;&nbsp;Non-accelerated filer | ☐ | &nbsp;&nbsp;&nbsp;&nbsp;Smaller reporting company | ☐ |
| | | | | | | &nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company | ☐ |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |  |  |  | ☐ |
| Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. |  |  |  | ☒ |
| If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. |  |  |  | ☐ |
| Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to §240.10D-1(b). |  |  |  | ☐ |
| Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). | Yes | ☐ | No | ☒ |

---

As of August 1, 2025 (the last business day of the registrant's most recently completed second quarter), the aggregate market value of the registrant's common stock (based upon the closing stock price) held by non-affiliates was $5.0 billion.

The number of shares issued and outstanding of the registrant's common stock as of March 6, 2026 was 43,419,313 shares ($.0001 par value per share).

**DOCUMENTS INCORPORATED BY REFERENCE**

Portions of Science Applications International Corporation's Definitive Proxy Statement for the 2026 Annual Meeting of Stockholders are incorporated by reference in Part III of this report.

------

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**FORM 10-K**<br>**TABLE OF CONTENTS**<br>

---

| | | |
|:---|:---|:---|
| | | Page |
| **Part I** | | |
| Item 1. | <u>[Business](#i68c4e1d46e8b478fb5bd56210bcd1bf5_13)</u> | <u>[1](#i68c4e1d46e8b478fb5bd56210bcd1bf5_13)</u> |
| Item 1A. | <u>[Risk Factors](#i68c4e1d46e8b478fb5bd56210bcd1bf5_49)</u> | <u>[9](#i68c4e1d46e8b478fb5bd56210bcd1bf5_49)</u> |
| Item 1B. | <u>[Unresolved Staff Comments](#i68c4e1d46e8b478fb5bd56210bcd1bf5_52)</u> | <u>[20](#i68c4e1d46e8b478fb5bd56210bcd1bf5_52)</u> |
| Item 1C. | <u>[Cybersecurity](#i68c4e1d46e8b478fb5bd56210bcd1bf5_55)</u> | <u>[20](#i68c4e1d46e8b478fb5bd56210bcd1bf5_55)</u> |
| Item 2. | <u>[Properties](#i68c4e1d46e8b478fb5bd56210bcd1bf5_58)</u> | <u>[21](#i68c4e1d46e8b478fb5bd56210bcd1bf5_58)</u> |
| Item 3. | <u>[Legal Proceedings](#i68c4e1d46e8b478fb5bd56210bcd1bf5_61)</u> | <u>[21](#i68c4e1d46e8b478fb5bd56210bcd1bf5_61)</u> |
| Item 4. | <u>[Mine Safety Disclosures](#i68c4e1d46e8b478fb5bd56210bcd1bf5_64)</u> | <u>[21](#i68c4e1d46e8b478fb5bd56210bcd1bf5_64)</u> |
| **Part II** | | |
| Item 5. | <u>[Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](#i68c4e1d46e8b478fb5bd56210bcd1bf5_70)</u> | <u>[22](#i68c4e1d46e8b478fb5bd56210bcd1bf5_70)</u> |
| Item 6. | <u>[\[Reserved\]](#i68c4e1d46e8b478fb5bd56210bcd1bf5_73)</u> | <u>[23](#i68c4e1d46e8b478fb5bd56210bcd1bf5_73)</u> |
| Item 7. | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i68c4e1d46e8b478fb5bd56210bcd1bf5_76)</u> | <u>[24](#i68c4e1d46e8b478fb5bd56210bcd1bf5_76)</u> |
| Item 7A. | <u>[Quantitative and Qualitative Disclosures About Market Risk](#i68c4e1d46e8b478fb5bd56210bcd1bf5_124)</u> | <u>[38](#i68c4e1d46e8b478fb5bd56210bcd1bf5_124)</u> |
| Item 8. | <u>[Financial Statements and Supplementary Data](#i68c4e1d46e8b478fb5bd56210bcd1bf5_127)</u> | <u>[39](#i68c4e1d46e8b478fb5bd56210bcd1bf5_127)</u> |
| Item 9. | <u>[Changes in and Disagreements With Accountants on Accounting and Financial Disclosure](#i68c4e1d46e8b478fb5bd56210bcd1bf5_130)</u> | <u>[39](#i68c4e1d46e8b478fb5bd56210bcd1bf5_130)</u> |
| Item 9A. | <u>[Controls and Procedures](#i68c4e1d46e8b478fb5bd56210bcd1bf5_133)</u> | <u>[39](#i68c4e1d46e8b478fb5bd56210bcd1bf5_133)</u> |
| Item 9B. | <u>[Other Information](#i68c4e1d46e8b478fb5bd56210bcd1bf5_139)</u> | <u>[42](#i68c4e1d46e8b478fb5bd56210bcd1bf5_139)</u> |
| Item 9C. | <u>[Disclosure Regarding Foreign Jurisdictions that Prevent Inspections](#i68c4e1d46e8b478fb5bd56210bcd1bf5_142)</u> | <u>[42](#i68c4e1d46e8b478fb5bd56210bcd1bf5_142)</u> |
| **Part III** | | |
| Item 10. | <u>[Directors, Executive Officers and Corporate Governance](#i68c4e1d46e8b478fb5bd56210bcd1bf5_148)</u> | <u>[43](#i68c4e1d46e8b478fb5bd56210bcd1bf5_148)</u> |
| Item 11. | <u>[Executive Compensation](#i68c4e1d46e8b478fb5bd56210bcd1bf5_151)</u> | <u>[44](#i68c4e1d46e8b478fb5bd56210bcd1bf5_151)</u> |
| Item 12. | <u>[Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters](#i68c4e1d46e8b478fb5bd56210bcd1bf5_154)</u> | <u>[44](#i68c4e1d46e8b478fb5bd56210bcd1bf5_154)</u> |
| Item 13. | <u>[Certain Relationships and Related Transactions, and Director Independence](#i68c4e1d46e8b478fb5bd56210bcd1bf5_157)</u> | <u>[45](#i68c4e1d46e8b478fb5bd56210bcd1bf5_157)</u> |
| Item 14. | <u>[Principal Account](#i68c4e1d46e8b478fb5bd56210bcd1bf5_160)[ant](#i68c4e1d46e8b478fb5bd56210bcd1bf5_160)[Fees and Services](#i68c4e1d46e8b478fb5bd56210bcd1bf5_160)</u> | <u>[45](#i68c4e1d46e8b478fb5bd56210bcd1bf5_160)</u> |
| **Part IV** | | |
| Item 15. | <u>[Exhibits](#i68c4e1d46e8b478fb5bd56210bcd1bf5_166)[and](#i68c4e1d46e8b478fb5bd56210bcd1bf5_166)[Financial Statement Schedules](#i68c4e1d46e8b478fb5bd56210bcd1bf5_166)</u> | <u>[46](#i68c4e1d46e8b478fb5bd56210bcd1bf5_166)</u> |
| Item 16. | <u>[Form 10-K Summary](#i68c4e1d46e8b478fb5bd56210bcd1bf5_172)</u> | <u>[50](#i68c4e1d46e8b478fb5bd56210bcd1bf5_172)</u> |
| <u>[Signatures](#i68c4e1d46e8b478fb5bd56210bcd1bf5_175)</u> | <u>[Signatures](#i68c4e1d46e8b478fb5bd56210bcd1bf5_175)</u> | <u>[51](#i68c4e1d46e8b478fb5bd56210bcd1bf5_175)</u> |
| <u>[Index to Consolidated Financial Statements](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u> | <u>[Index to Consolidated Financial Statements](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u> | <u>F-[1](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u> |

---

i

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**Part I**

**Item 1. *Business***

**The Company**

Science Applications International Corporation (herein referred to as "SAIC," the "Company," "we," "us," or "our") is a leading provider of technical, engineering and mission and enterprise information technology ("IT") services primarily to the U.S. government. The Company provides these services for large, complex projects with a targeted emphasis on higher-end, differentiated technology services and solutions that accelerate and transform secure and resilient digital environments through systems design, development, modernization, integration, and sustainment to drive enterprise and mission outcomes. Our end-to-end IT offerings span the entire spectrum of our customers' IT infrastructure.

Our business has a long and successful history of over 50 years serving all military forces (Army, Air Force, Navy, Marines, Coast Guard, and Space Force) and agencies of the Department of War ("DoW", formerly referred to as the Department of Defense), National Aeronautics and Space Administration ("NASA"), U.S. Department of State, Department of Justice, Department of Homeland Security and members of the Intelligence Community. We serve our customers through approximately 1,700 active contracts and task orders. We have approximately 23,000 employees that are led by an experienced executive team of proven industry leaders.

Effective February 3, 2024, the first day of fiscal 2025, we completed a business reorganization which replaced our previous two operating sectors with five customer facing business groups supported by the enterprise organizations, including the Innovation Factory. The five business groups, which are also our operating segments, are aggregated into two reportable segments for financial reporting purposes given the similarity in economic and qualitative characteristics, and based on the nature of the customers they serve. Our two reportable segments are the Defense and Intelligence segment and the Civilian segment.

The Defense and Intelligence segment provides a diverse portfolio of national security solutions to the DoW and the Intelligence Community of the United States Government.

The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments, in order to deliver services for citizen well-being, border security, and protecting lives. This includes integrating solutions into a spectrum of public service missions that impact travel, trade, health and the economy.

The offerings of both reportable segments entail the integration of emerging technologies into mission critical operations that modernize and enable national imperatives, including IT modernization, digital engineering, artificial intelligence ("AI"), mission systems support and advisory, training and simulation, and ground vehicles support. These services include end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment and security of the customers' entire IT infrastructure.

Effective January 31, 2026, the first day of fiscal 2027, we completed a business reorganization that consolidated our five business groups into three. The reorganization is designed to simplify our structure and optimize operations and customer focus for growth. The consolidated business groups will continue to report directly to our Chief Executive Officer ("CEO") who will continue to be the chief operating decision maker ("CODM"). We do not expect the reorganization to have an impact on our reportable segments.

Our long-standing customer relationships have enabled us to achieve an in-depth understanding of our customers' missions and provide differentiated service offerings to meet our customers' most complex requirements. Through our offerings, we provide end-to-end services spanning the design, development, integration, deployment, management and operations, sustainment and security of our customers' entire IT infrastructure. Our offerings include:

*IT Modernization:* We help defense, intelligence, and civilian agencies reimagine the way they accomplish their objectives through digital transformation by providing next-generation cloud computing, cybersecurity, and software capabilities. We modernize IT environments for government customers and then operate and maintain them via their preferred service delivery methods.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

*Digital Engineering:* Our digital engineering integrates industry-leading tools and processes for design; engineering; analytics; modeling, simulation and visualization; and manufacturing execution, all within a secure and collaborative ecosystem to ensure faster systems outcomes for our customers.

*Artificial Intelligence ("AI"):* We deploy and integrate AI solutions for customers, including AI solutions that assist with the design, deployment, and management of AI applications and allow customers to work with their complex and sensitive data to power the most demanding analytics, data science, and AI use cases.

*Mission Systems Support:* We design, build, modify, integrate, and sustain weapon systems across all branches of the U.S. military, ensuring mission readiness on land, at sea, and in the air.

*Training and Simulation:* We are invested in accelerating the adoption and application of immersive technologies that solve pressing human performance and operational efficiency challenges.

*Ground Vehicles Support:* We integrate, modify, upgrade, and sustain ground vehicles for our nation's armed forces, leveraging commercial products and in-house solutions to address some of the toughest challenges facing warfighters. Our experts in cybersecurity, enhanced surveillance, secure communications, mobility, and more apply core as well as emerging capabilities to address evolving mission needs.

Our Innovation Factory supports the operating segments by developing enterprise-class solutions which are delivered to our customers as stand-alone solutions or integrated with and aligned to our product offerings through the operations of the business to meet complex customer needs and accelerate digital transformation. The Innovation Factory includes designated teams focused on AI, application development, network services, platforms and cloud, engineering, and cybersecurity. It uses a highly automated, cloud-hosted tool set to rapidly build, test and deploy solutions and works with customers to enhance solutions going forward.

We integrate emerging technology securely and in real-time into mission critical operations that modernize and enable national imperatives:

*Undersea Dominance:* We deliver systems to ensure the U.S. maintains proactive control over every threat in the undersea domain.

*Border of the Future:* We support integrated systems across all ports of entry (i.e., land, sea, air) for all U.S. travel, trade, contraband detection, and immigration functions.

*Citizen Experience:* We drive commercial-quality U.S. government service delivery through scalable solutions that innovate mission outcomes of legacy systems.

*All Domain Warfighting:* We develop integrated conflict deterrence, combat preparedness, and data connectivity capabilities for the U.S. Military and Intelligence Community.

*Next Generation Space:* We integrate advanced solutions to enable the rapid deployment of future space missions.

Our core strengths have supported our successful performance on programs of national importance. Those strengths include:

*Enduring Customer Relationships and Mission-Orientation.* We have strong and long-lasting customer relationships throughout the U.S. government. Our track record of serving the missions of our government customers spans decades, including several enduring customer relationships that have lasted 20 years or more. Our employees, many of whom are deployed at customer sites, work closely with our customers in fulfilling their missions. Our strong customer relationships enable us to develop deep customer knowledge and translate our mission understanding into successful program execution that fosters continued demand for our services.

*Full Life Cycle Offerings.* We integrate technologies and deliver services that provide our customers with seamless end-to-end solutions. Our expertise includes initial requirements definition, development and integration services, training, logistics and sustainment. These full life cycle offerings, combined with deep customer knowledge, allow us to more effectively support our customers' missions.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

*Significant Scale and Diversified Contract Base.* We are one of the largest pure-play technology service providers to the U.S. government. Our significant scale advantage enables us to serve as a prime systems integrator on large, complex programs and to allocate resources toward further developing and expanding our repeatable, proven solutions and differentiated technical capabilities. Our diversified revenue base consists of programs ranging from research and development to operations and maintenance.

*Technical Experts Led by Experienced Management.* The quality, training and knowledge of our employees are important competitive assets. Our skilled workforce ranges from entry-level technicians to expert-level, highly cleared professionals in network engineering, software design and development, IT modernization, logistics, technology integration and systems engineering. Additionally, the majority of our workforce holds an active security clearance, which is required on many of our existing programs and future program opportunities.

Our workforce is led by a talented and experienced senior leadership team with a long history of solving our customers' most difficult challenges. Our executive team consists of members who have served as senior leaders in public companies and are recognized as leaders in their respective markets by customers and partners.

*Repeatable Methodologies and Certified Processes.* Our technical excellence is driven by our proven, repeatable, disciplined processes for management, engineering, technical support and services. We deploy our tools and processes enterprise-wide and emphasize a consistent approach to planning, designing and delivering solutions and services to our customers. We hold certifications from the International Organization for Standardization ("ISO") (including ISO 9001, ISO/IEC 27001, and AS9100D), and from the Capability Maturity Model Integration Institute as a CMMI®-DEV Maturity Level 3 organization.

**Acquisitions and Divestitures**

On October 15, 2025, we acquired SilverEdge Government Solutions, an innovative provider of mission-driven technology solutions and products. The acquisition advances our strategy to provide mission focused solutions and commercial products to our customers.

On May 6, 2023, we closed the sale of our logistics and supply chain management business to ASRC Federal Holding Company, LLC. The sale enables the us to focus our resources on long-term strategic growth areas.

On February 4, 2023, we sold 0.1% of our 50.1% majority ownership interest in Forfeiture Support Associates J.V. to its sole joint venture partner for a nominal amount. As a result of the sale and amendment to the joint venture operating agreement of FSA, we no longer control the joint venture and accounts for its retained interest as an equity method investment as of the date of the transaction.

For additional discussion and analysis related to recent business developments, see "Economic Opportunities, Challenges, and Risks" in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 of this report.

**Key Customers**

In fiscal 2026, 2025 and 2024, 98% of our total revenues were attributable to prime contracts with the U.S. government or to subcontracts with other contractors engaged in work for the U.S. government.

In fiscal 2026, 2025 and 2024, approximately 52% of our total revenues were attributable to the "Department of War", while 46% were attributable to "Intelligence and other federal government agencies" and the remainder attributable to "Commercial, state and local governments and international" customers.

Substantially all of our revenues were earned by entities located in the United States.

**Regulation**

As a government contractor, we operate in a heavily regulated environment and are subject to various laws, regulations, and policies at the federal, state, and local levels. The Federal Acquisition Regulation ("FAR") is the primary regulation governing the procurement process for U.S. government contracts. Together with various agency-specific supplements, the FAR governs the terms and conditions of government contracts, including bidding, performance, and pricing, and imposes specific compliance obligations related to security, intellectual property, data

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

privacy, and environmental regulations. For contracts with the DoW, we are subject to the Defense Federal Acquisition Regulation Supplement ("DFARS"), which imposes additional requirements on defense contractors, including specific cybersecurity measures, contractor security clearances, and compliance with the Defense Contract Audit Agency ("DCAA") and Defense Contract Management Agency ("DCMA") audit and oversight processes. The DFARS also includes clauses related to the protection of classified and sensitive information, with which we must comply when handling such materials. The regulations govern contract pricing and reimbursable costs by, among other things, requiring government contractors to provide cost or pricing data when negotiating certain government contracts, defining allowable and unallowable costs, and otherwise governing the right to reimbursement under various flexibly priced contracts.

The U.S. government may revise its procurement practices or adopt new contract rules and regulations at any time. In some cases, such changes could have an adverse impact on our profitability and ability to win new business. The DoW is increasingly using procedures like "other transaction authority" agreements ("OTAs") to accelerate the procurement process for emerging technologies. OTAs bypass many of the formal and time-consuming requirements found in the typical government contracting process, reducing the barriers to entry and consequently increasing competition from companies that previously did not compete for public sector work. In addition, modifications to cost-reimbursement contract structures could limit our ability to seek reimbursement of certain costs and overhead expenses and therefore erode our profit margins.

Most of our contracts are subject to the Cost Accounting Standards ("CAS"), which are a set of rules and guidelines that govern how companies account for costs on government contracts. We must ensure that our cost accounting practices comply with CAS requirements, which include specific methods for handling indirect costs, overhead rates, and labor allocation.

The U.S. government may terminate our contracts and subcontracts at any time either at its convenience or for default, based on our failure to meet specified performance requirements. If a contract is terminated for convenience, we generally are entitled to the costs already incurred on the contract and profit on those costs. If a contract is terminated for default, we should be entitled to payment for our work that the government customer has accepted.

Some of our operations and service offerings require us to access personally identifiable information and protected health information. These activities are regulated by extensive federal and state privacy and data security laws requiring rigorous privacy protections and security safeguards.

Our business and operations are subject to both U.S. and non-U.S. laws, regulations, and procurement policies and practices, including regulations relating to lobbying, conflicts of interest, import-export controls, foreign investment, tariffs, taxation, exchange controls, repatriation of earnings, and the Foreign Corrupt Practices Act and other anti-corruption laws. Violations of these laws could result in financial penalties, suspension or debarment, and/or the loss of government contracts. We have policies and procedures designed to ensure compliance with these laws and regulations, and a robust ethics and compliance program to maintain a compliance-oriented workforce. We are also susceptible to varying political and economic risks.

The regulations and risks affecting our business are described in more detail under "Risk Factors" in Part I, Item 1A of this report.

**Contracts**

We must comply with and are affected by laws and regulations relating to the formation, administration and performance of U.S. government and other contracts. The U.S. government procurement environment has evolved due to statutory and regulatory procurement reform initiatives. Budgetary pressures and reforms in the procurement process have increasingly caused many U.S. government agencies to purchase services and solutions using contracting processes that give them the ability to select multiple winners or pre-qualify certain contractors to provide various services or solutions on established general terms and conditions rather than through single award contracts. The predominant contracting methods through which U.S. government agencies procure services and solutions include the following:

*Single Award Contracts.* U.S. government agencies may procure services and solutions through single award contracts, which specify the scope of work that will be delivered and identify the contractor that will provide the specified services. When an agency has a requirement, interested contractors are solicited, qualified and then provided with a request for proposal. The process of qualifying prospective bidders, soliciting proposals and

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

evaluating contractor bids and selection process can take a year or more to complete. This method of contracting may provide the contractor with greater certainty of the timing and amounts to be received at the time of contract award because it generally results in the customer contracting for a specific scope of work from the single successful awardee.

*Sole Source Award Contracts.* U.S. government agencies may procure services and solutions through sole source award contracts in situations where only one contractor is deemed to qualify to provide the specified services due to proprietary technology, unique capabilities, or specialized expertise. This method bypasses the competitive bidding process, and a detailed justification must be approved by the U.S. government agency to ensure that no other contractor can meet the specified requirements. Similar to single award contracts, this method provides the contractor with greater certainty regarding the timing and amounts to be received at the time of contract award.

*Indefinite Delivery, Indefinite Quantity ("IDIQ") Contracts.* The U.S. government uses IDIQ contracts to obtain commitments from contractors to provide certain services or solutions on pre-established terms and conditions. The U.S. government then issues task orders under the IDIQ contracts to purchase the specific services or solutions it needs. IDIQ contracts are awarded to one or more contractors following a competitive procurement process. Under a single award IDIQ contract, all task orders under that contract are awarded to one pre-selected contractor. Under a multi-award IDIQ contract, task orders can be awarded to any of the pre-selected contractors, which can result in further limited competition for the award of task orders. Multi-award IDIQ contracts that are open for any government agency to use for the procurement of services are commonly referred to as "government-wide acquisition contracts." IDIQ contracts often have multi-year terms and unfunded ceiling amounts that enable, but not commit, the U.S. government to purchase substantial amounts of services or solutions from one or more contractors. At the time an IDIQ contract is awarded (prior to the issuance of any task orders), a contractor may have limited or no visibility as to the ultimate amount of services or solutions that the U.S. government will purchase under the contract, and, in the case of a multi-award IDIQ, the contractor from which such purchases may be made.

*U.S. General Services Administration ("GSA") Schedule Contracts.* The GSA maintains listings of approved suppliers of services and solutions with pre-negotiated prices for use throughout the U.S. government. In order for a company to provide services under a GSA Schedule contract, a company must be pre-qualified and awarded a contract by the GSA. When an agency uses a GSA Schedule to meet its requirements, the agency (or the GSA on behalf of the agency) conducts the procurement and bidders are limited to GSA Schedule-qualified contractors. GSA Schedule contracts are designed to provide the user agency with reduced procurement time and lower procurement costs. Similar to IDIQ contracts, at the time a GSA Schedule contract is awarded, a contractor may have limited or no visibility as to the ultimate amount of services or solutions that customers will ultimately purchase under the contract.

*Other Transaction Authority ("OTA") Agreements.* The U.S. government may procure and enter into OTA agreements, which are used for research projects, prototype development or follow-on production to encourage rapid innovation and technological advancement. The OTA process includes submitting proposals, being selected as a partner and negotiating terms which bypasses the traditional FAR contracts procurement processes.

**Contract Types**

Generally, the type of contract used for the acquisition of our services and solutions is determined by or negotiated with the U.S. government and may depend on certain factors, including: the type and complexity of the work to be performed; degree and timing of the responsibility to be assumed by the contractor for the costs of performance; the extent of price competition; and the amount and nature of the profit incentive offered to the contractor for achieving or exceeding specified standards or goals. We generate revenues under several types of contracts, including the following:

&nbsp;&nbsp;&nbsp;&nbsp;• Cost-reimbursement contracts include cost-plus-fixed-fee, award-fee and incentive-fee contracts. These contracts provide for reimbursement of our direct contract costs and allocable indirect costs, plus a fee (contract profit). These types of contracts are generally used when uncertainties involved in contract performance do not permit costs to be estimated with sufficient accuracy to use a fixed-price contract. Cost-reimbursement contracts usually subject us to lower risk and generally require us to use our best efforts to

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

accomplish the scope of the work within a specified time and amount of costs. Award and incentive fee contracts generally are based on certain performance criteria including technical performance and quality.

&nbsp;&nbsp;&nbsp;&nbsp;• Time-and-materials ("T&M") contracts typically provide for negotiated fixed hourly rates for specified categories of direct labor plus reimbursement of other direct costs. This type of contract is generally used when there is uncertainty of the extent or duration of the work to be performed by the contractor at the time of contract award or it is not possible to anticipate costs with any reasonable degree of confidence. On T&M contracts, we assume the risk of providing appropriately qualified staff to perform these contracts at the hourly rates set forth in the contracts over their period of performance. Fixed-price-level-of-effort contracts are similar except they require a specified level of effort over a specified period of time and payment is based on effort expended.

&nbsp;&nbsp;&nbsp;&nbsp;• Firm-fixed price ("FFP") contracts provide for a predetermined price for specific solutions. These contracts offer us potential increased profits if we can complete the work at lower costs than planned. While FFP contracts allow us to benefit from cost savings, these contracts also increase our exposure to reduced profits or losses from increased or unexpected costs.

Our earnings and profitability may vary materially depending on changes in the proportionate amount of revenues derived from each type of contract, the nature of services or solutions provided, as well as the achievement of performance objectives and the stage of performance at which the right to receive fees is finally determined. Given the relative amount of risk assumed by the contractor, cost-reimbursement and T&M contracts generally have lower profitability than FFP contracts. For the proportionate amount of revenues derived from each type of contract for the last three fiscal years, see "Other Key Performance Measures—Contract Types" in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 of this report.

**Competition**

Competition for contracts is intense, and we often compete against a large number of established multinational companies, which may have greater name recognition, financial resources and larger technical staffs than we do. We also compete against smaller, more specialized companies that concentrate their resources on particular areas, as well as the U.S. government's own capabilities. As a result of the diverse requirements of the U.S. government, we frequently collaborate with other companies to compete for large contracts and bid against these same companies in other situations. Our principal competitors include the following:

&nbsp;&nbsp;&nbsp;&nbsp;• the engineering and technical services divisions of large defense contractors that provide IT services in addition to other hardware systems and products, which include companies such as General Dynamics Corporation, Lockheed Martin Corporation, Northrop Grumman Corporation, and RTX Corporation;

&nbsp;&nbsp;&nbsp;&nbsp;• contractors focused principally on technical and IT services for the U.S. government, such as Booz Allen Hamilton Inc., CACI International, Inc., Leidos Holdings, Inc., ManTech International Corporation, Parsons Corporation, Peraton, and Serco Group plc; and

&nbsp;&nbsp;&nbsp;&nbsp;• diversified commercial providers that also provide U.S. government IT services, such as Accenture plc, AECOM, Amentum Holdings, Inc., Deloitte, and International Business Machines Corporation.

We compete on various factors, which include: our technical expertise and qualified and/or security-cleared personnel; our ability to deliver innovative cost-effective solutions in a timely manner; successful program execution on previous programs; our reputation and standing with customers; pricing; and the size and geographic presence of our Company.

Competition within the government services industry has intensified, which has led to fewer sole-source awards and an increased emphasis on cost competitiveness and affordability. In addition, procurement initiatives to improve efficiency, refocus priorities, increase small business awards and enhance best practices could result in fewer new opportunities for our industry as a whole, which would intensify competition within the industry as companies compete for a more limited set of new programs.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**Patents and Proprietary Information**

Our technical services and solutions are not generally dependent on patent protection, although we do selectively seek patent protection. We claim a proprietary interest in certain of our solutions, software programs, methodologies and know-how. This proprietary information is protected by copyrights, trade secrets, licenses, contracts and other means. We selectively pursue opportunities to license or transfer our technologies to third parties.

In connection with the performance of services, the U.S. government has certain rights to inventions, data, software codes and related material that we develop under U.S. government-funded contracts and subcontracts. Generally, the U.S. government may disclose or license such information to third parties, including, in some instances, our competitors. In the case of some subcontracts that we perform, the prime contractor may also have certain rights to the programs and solutions that we develop under the subcontract.

**People and Culture**

As our business focuses on high-end innovation and solutions in mission IT, enterprise IT, engineering services, and professional services, our ability to attract, hire, develop, and retain highly skilled talent is core to our operations and success. As of January 30, 2026, we employed approximately 23,000 individuals, including more than 5,800 active military or veterans, which represents 25% of our workforce.

Our corporate values of innovation, inclusion and integrity underpin our culture, which is key to advancing long-term shareholder interests. We strive for innovative solutions and positive business results by expecting our people to drive execution excellence and to understand our customers intimately. We empower our people to take strategic risks and leverage emerging technology to solve our customers' and country's most complex problems. Our employees excel because they are invested in our Company, our mission, and our customers' success. We work to create an environment where engaged employees can perform meaningful work with purpose and develop their careers in a flexible and healthy work environment. Our commitment to our employees, and their commitment to our Company, are reflected in our fiscal 2026 culture survey results, where we exceeded the national benchmark for overall survey results by 4%.

Our customers and the business community recognize and appreciate our innovative workforce. In fiscal 2026, we received several noteworthy accolades, including Forbes Americas' Dream Employers and its Best Employers for Veterans, and Glassdoor Best Places to Work.

***Talent Development***

In fiscal 2026, we continued to invest in our workforce through various talent development and retention initiatives, such as upskilling, rotational assignments, and leadership development programs accounting for nearly 4,000 hours. We have more than 20 third-party strategic partners that help us deliver a wide range of job-specific training. In addition to technical and professional skills training, we offer higher education and tuition assistance programs for continuing education and industry certifications. Our employees completed more than 175,000 training hours, or just over 7.5 hours per employee.

We seek to build our leadership team from within our workforce, with merit-based promotions for the most qualified candidates. We invest in tomorrow's leaders by providing leadership development programs for aspiring, frontline, and mid-level leaders, as well as executive coaching and executive education. More than 320 employees participated in leadership development programs for just over 3,200 hours of training. We also had more than 200 early career professionals who joined us for internships.

When hiring externally, we focus on identifying and attracting highly skilled, exceptional talent. Employee referrals often result in our best-performing new hires. In fiscal 2026, nearly 34% of new employees came from employee

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

referrals. With a voluntary attrition rate of just under 12% in fiscal 2026, we continue to be an industry leader in employee retention.

***Supporting Well-being***

We are committed to the health and well-being of our workforce. Our employees' safety is paramount, and we actively work to prevent workplace hazards. We encourage our employees to participate in health and wellness initiatives, including mental health offerings. Our wellness program helps employees incorporate healthy actions into everyday life through useful resources and incentives. We offer a suite of convenient, easily accessible tools to support wellness, whether an employee works at an SAIC facility, at a customer site, or remotely. Our Employee Assistance Program provides confidential counseling, personal financial guidance and resources, legal support, and work-life assistance. We are committed to providing accommodations to employees with disabilities that enable them to perform the essential functions of their job and access to equal employment opportunities.

**Research and Development**

For information related to our research and development activities, see Note 1—Business Overview and Summary of Significant Accounting Policies to the consolidated financial statements contained within this report.

**Seasonality**

The U.S. government's fiscal year ends on September 30. It is not uncommon for U.S. government agencies to award extra tasks or complete other contract actions leading up to the end of its fiscal year in order to avoid the loss of unexpended fiscal year funds, which may favorably impact our third fiscal quarter. In addition, revenues may be unfavorably impacted during our fourth fiscal quarter due to a greater number of holidays and higher utilization of vacation time.

**Environmental Matters**

Our operations are subject to various foreign, federal, state, and local environmental protection and health and safety laws and regulations. Although we do not currently anticipate that compliance costs or the liabilities associated with environmental laws will adversely affect our business, financial position, and results of operations and/or cash flows, it is possible that we may incur material costs or liabilities in the future. These regulations and risks are described in more detail under "Risk Factors" in Part I, Item 1A of this report.

**Executive Officers**

For information about our executive officers, see "Directors, Executive Officers and Corporate Governance" in Part III, Item 10 of this report.

**Company Website and Available Information**

Our corporate headquarters is located at 12010 Sunset Hills Road, Reston, VA 20190. Our phone number is (703) 676-4300 and our homepage is *www.saic.com*, which contains information about our Company and operations. Through a link on the Investor Relations section of our website, copies of each of our filings with the Securities and Exchange Commission ("SEC") can be viewed and downloaded free of charge as soon as reasonably practicable after the reports and amendments are electronically filed with or furnished to the SEC. The information on our website is not incorporated by reference into and is not a part of this report.

You may also request hard copies of the materials referenced in the preceding paragraph, at no cost, by emailing investor relations at InvestorRelations@saic.com.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**Item 1A. *Risk Factors***

*In your evaluation of our Company and business, you should carefully consider the risks and uncertainties described below, together with information included elsewhere within this report and other documents we file with the SEC. These risks, as well as additional risks and uncertainties not currently known to us or that we currently believe are immaterial also may materially harm our business, financial condition or operating results and thus result in a decline in the price of our stock.*

**Industry and Economic Risks**

***We depend on U.S. government agencies as our primary customers and, if our reputation or relationships with these agencies were to be harmed, it could adversely impact our financial performance.***

We generated 98% of our total revenues during each of the last three fiscal years from contracts with the U.S. government, either as a prime contractor or as a subcontractor to other companies performing prime contracts for the U.S. government. We expect to continue to derive substantially all of our revenues from work performed under U.S. government contracts. Our relationship with the U.S. government – particularly with DoW agencies – is key to maintaining these contracts, winning new work, and growing our revenues. Negative press reports or publicity, regardless of accuracy, could harm our reputation and jeopardize our business with our customers, potentially adversely affecting our revenues, cash flows, and financial results.

***Reduced U.S. government defense spending, changes in acquisition priorities, significant delays in U.S. government appropriations, and delays in contract awards, program starts, and other procurement activity, could adversely affect our future revenues, cash flow, and financial results.***

Because we generate substantially all of our revenues from contracts with U.S. government agencies, our operating results could be adversely affected by spending caps, changes in budgetary priorities, or delays in the government budget process, program starts, or the award of contracts or task orders under contracts. Current U.S. government spending levels for defense-related and other programs may not be sustained through government fiscal year ("GFY") 2026. Future spending and program authorizations may be stagnant or decrease, or spending priorities may shift to programs in areas in which we do not provide services or are less likely to be awarded contracts. A change in administration or changing national priorities may reduce defense-related and other programs due to competing demands for federal funds and the number and intensity of military conflicts or other factors.

The DoW has released a new Acquisition Transformation Strategy to rebuild the defense industrial base, which prioritizes speed and execution in the acquisition process, and may restructure contract requirements, reorganize the DoW workforce, shift its acquisition strategy toward longer-term contract structures, and require increased upfront investment on R&D-based concepts and solutions. We will remain engaged and responsive to these new requirements and assess impacts on our procurement, contracting and program execution.

When Congress fails to pass a budget before the end of the fiscal year, government operations typically are funded through one or more continuing resolutions ("CRs"), which enable government agencies to continue operating but do not allow new spending initiatives. CRs can lead to contract awards being delayed, canceled, or funded at lower levels, which could adversely impact our operations, cash flows, and financial results.

In addition, it is possible that an impasse on policy issues could impact continuous government funding for the Department of Homeland Security through September 30, 2026, which could cause us to incur labor or other costs without reimbursement under customer contracts or the delay or cancellation of key programs, and could adversely affect our operations, cash flows, and financial results.

The U.S. government also conducts periodic reviews of U.S. defense strategies and priorities, which may shift DoW budgetary priorities, reduce overall spending or delay contract or task order awards for defense-related programs from which we would otherwise expect to derive a significant portion of our future revenues. A significant decline in overall U.S. government spending, a significant shift in spending priorities, the substantial reduction or elimination of defense-related programs or significant budget-related delays in contract or task order awards for large programs could adversely affect our future revenues and limit our growth prospects.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

***We face aggressive competition that can impact our ability to obtain contracts and may affect our future revenues, profitability, and growth prospects.***

We expect that most of the contracts we pursue in the foreseeable future will be awarded through a competitive bidding process as the U.S. government increasingly relies on IDIQ, GSA Schedule, and other multi-award contracts, which has led to greater competition and increased pricing pressure. The competitive bidding process involves substantial resources and a number of risks, including significant cost and managerial time to prepare bids and proposals for contracts that may not be awarded to us, or that may be awarded but for which we do not receive meaningful task orders. Following contract award, we may encounter significant expense, delay, contract modifications, or even contract loss in the event our competitors protest the award of contracts to us in competitive bidding. Any resulting loss or delay of startup and funding of work under protested contract awards may adversely affect our revenues and/or profitability. In addition, multi-award contracts require that we make sustained post-award efforts to obtain task orders under the contract, failure of which may result in us not recognizing revenues under these multi-award contracts. Our failure to compete effectively in this procurement environment could adversely affect our revenues and profitability.

We compete with larger companies that have more name recognition, greater financial resources, and larger technical staffs, and we also compete with smaller, more specialized companies that concentrate their resources on particular areas. Additionally, we may compete with the U.S. government's own capabilities. To remain competitive, we must consistently provide superior service, technology, and performance on a cost-effective basis to our customers.

***Our earnings and profitability may vary based on the mix of our contracts and may be adversely impacted if we fail to estimate and manage costs, time, and resources accurately.***

Our profitability and cash flow may vary materially depending on the types of government contracts we are awarded, the nature of services performed under those contracts, the costs incurred in performing the work, the achievement of performance objectives, and the stage of performance at which the right to receive fees is determined, particularly under incentive and award fee contracts. Failure to perform to customer expectations and contract requirements may result in reduced fees or losses and may adversely affect our financial performance.

We generate revenues under several contract types, including cost-reimbursable, T&M, and FFP contracts. Under cost-reimbursable contracts, the government pays allowable costs incurred during performance of the contract plus a fee up to a ceiling based on the amount that has been funded. Cost, schedule, or technical performance issues on cost-reimbursable contracts could result in reduced fees, decreased profit, or program cancellation. Under T&M contracts, the government pays for the exact cost of all materials, plus a predetermined hourly rate for the labor involved. Under FFP contracts, the government pays a fixed price regardless of the actual costs of performance, meaning that we bear the risk of cost overruns, but we also have the opportunity for profit if we manage the program efficiently. Cost-reimbursable and T&M contracts are generally less profitable than FFP contracts. In fiscal 2026, approximately 62%, 22% and 16% of our total revenues came from cost-reimbursable contracts, T&M contracts and FFP contracts, respectively.

To varying degrees, there is financial risk with each of these contract types if we underestimate the costs of performance or fail to manage the program efficiently and cost-effectively. Unexpected expenses and/or unanticipated delays (including those caused by contract disputes or other factors outside our control, such as poor performance by our subcontractors, rising inflation, natural disasters, or other force majeure events) could result in reduced profits or losses.

***We use estimates in recognizing revenues, and our profitability may be adversely affected if we make changes to those estimates.***

A significant portion of our revenues are recognized on contracts using a cost input measure, which requires estimates of total costs at completion, fees earned, or both. Due to the technical nature of our services and the length of certain contracts, this estimation process is complex and involves significant judgment. Adjustments to original estimates are often required as work progresses, experience is gained, and additional information becomes known, even though the scope of the work required under the performance obligation may not have changed. Changes in the underlying assumptions, circumstances, or estimates could necessitate adjustments that may adversely affect future financial results.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**Legal and Regulatory Risks**

***Our failure to comply with the laws and regulations governing organizational conflicts of interest ("OCIs") could lead to penalties including, potentially, termination of one or more of our U.S. government contracts.***

Many of our U.S. government contracts contain OCI clauses that may limit our ability to compete for or perform certain other contracts or other types of services for particular customers. OCI arises when we engage in activities that may make us unable to render impartial assistance or advice to the U.S. government, impair our objectivity in performing contract work, or provide us with an unfair competitive advantage. Existing OCI, and any OCI that may develop, could preclude our competition for or performance on a significant project or contract, which could limit our opportunities.

***The U.S. government may issue or revise existing rules, regulations, and directives at any time, creating uncertainty and requiring unanticipated investments in related compliance efforts.***

In recent quarters, the U.S. government customer has increasingly focused on affordability, efficiencies, and cost recovery when contracting with private companies. The U.S. government performs ongoing evaluations of federal agencies and existing government contracts, grants, and programs for affordability, efficiency, and alignment with U.S. government objectives. These efforts to reduce federal spending create uncertainty and risk for government contractors, including potentially resulting in change in budgetary priorities and timing on issuing awards. Decreases in, or delays in contract awards and in government spending on the types of programs that we support, and terminations or stop-work-orders on government contracts on which we are currently performing could adversely affect our future revenues and profitability. At the same time, given the nature of our business, the administration's focus on efficiency, along with the potential for certain traditionally government functions to be transferred to private entities, may present business opportunities for us.

Federal legislation, regulations, executive orders, and other initiatives dealing with, among other things, procurement reform, the mitigation of potential OCIs, the deterrence of fraud, the U.S. government taking ownership stakes in certain competitors, the threat of contract cancellation if timely performance is not met, the elimination of diversity, equity, and inclusion ("DEI"), and changes in corporate environmental obligations, could affect our business. A recent executive order was issued to limit stock buy-backs, dividends or other forms of corporate distribution if certain contractors underperform on critical defense supply contracts. We will continue to monitor to determine if this ultimately affects our future revenues, cash flows and profitability. Additionally, we are subject to the laws and regulations of the states in which we operate, which, at times, may conflict with federal laws and regulations, introducing ambiguity.

Recent executive orders relating to DEI, other social issues and "return-to-office" requirements, along with pending legal challenges, create uncertainty and may be temporarily unsettling for portions of our workforce. As always, we are committed to complying with all applicable laws and regulations, and we do not anticipate an adverse impact on our future operations and revenues related to these executive orders.

The ongoing reforms to the U.S. government acquisition process, including changes to procurement rules and regulations, could transform how contracts are awarded, negotiated, and managed, which could lead to delays in contract awards and/or modifications to the scope or terms of contracts we hold. We could face increased competition, greater scrutiny, a more complex regulatory environment, heightened compliance requirements, and additional administrative burdens, all of which have the potential to affect our profitability.

An executive order was issued to overhaul the FAR, including simplifying the procurement process and potentially changing the criteria for cost allowability and compliance, which could negatively impact our profitability. In addition, the FAR Council recently proposed significant revisions to the FAR related to OCIs, which, if adopted, could limit our ability to bid on certain contracts and/or require us to modify or restructure some business relationships. They could also impose additional compliance burdens and constraints on our business operations. Increased costs related to identifying, assessing, and mitigating OCI's could negatively impact our profitability.

Similarly, recent executive orders related to energy and the environment suggest a shift towards deregulation at the federal level. Although deregulation initiatives could provide short-term relief from regulatory obligations, the executive orders introduce uncertainty and risk, including the potential for legal challenges and the possibility of new environmental policies at the state or local levels that may impose stricter regulations. We are actively monitoring and adapting to changes in environmental laws, assessing the physical risks posed by climate change, and

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

implementing sustainability initiatives aimed at reducing the environmental impact of our operations. However, the full extent of these risks and their potential impact on our business remains uncertain and could materially affect its financial performance.

***We are subject to government audits, cost adjustments, reviews, and investigations that could adversely affect our profitability, cash flows, or growth prospects.***

The DCAA, the DCMA, and others routinely audit a contractor's performance on government contracts, indirect cost rates and pricing practices, and compliance with applicable government contracting and procurement laws, regulations, and standards. They also review the adequacy of the contractor's compliance with government standards for its business systems, including its accounting, earned value management, estimating, materials management, property management, and purchasing systems. A finding of significant control deficiencies in a contractor's business systems or a finding of noncompliance with the CAS can result in decremented billing rates until the control deficiencies are corrected and DCMA approves their remediation. Government audits and reviews have become more rigorous as the agencies that conduct them have come under increased scrutiny, leading to stricter interpretations of the standards to which government contractors are held and the increased likelihood of adverse outcomes.

Government audits may conclude that our practices are not consistent with applicable laws and regulations, leading to adjustments to contract costs and mandatory customer refunds. Such adjustments can be applied retroactively. Adverse audit findings or the failure to obtain an "approved" determination on our systems could adversely affect our business by, among other things, restricting our ability to bid on new contracts and diminishing our competitive position for proposals under evaluation. A determination of noncompliance could also result in the U.S. government imposing penalties and sanctions against us, including withholding of payments, suspension of payments, and increased government scrutiny. Increased scrutiny could adversely impact contract performance, impede our invoicing for work performed, delay our receipt of timely payment, and weaken our ability to compete for new contracts.

As is typical in our industry, DCAA's indirect cost audits of our business remain open for certain prior years and the current year. We have recorded contract revenues based on an estimate of costs that we believe will be approved. However, we cannot guarantee the outcome of any ongoing or future audits or that any required adjustments will not exceed our reserves.

We are also subject to government reviews and investigations relating to all aspects of our business, including our contracts and operations. If a review or investigation identifies improper or illegal activities, we may be subject to civil or criminal penalties or administrative sanctions, which could include the termination of contracts, forfeiture of profits, triggering of price reduction clauses, suspension of payments, imposition of fines, and/or suspension or debarment from doing business with the U.S. government. Allegations of impropriety, even if untrue, may cause us reputational harm and impede our ability to win new contract awards or receive contract renewals. Fines, penalties, and other sanctions are not uncommon in our industry and could negatively impact our profitability, cash position, and future opportunities.

***Our business is subject to governmental review and investigation, which could adversely affect our profitability, cash position and growth prospects.***

We are routinely subject to governmental investigations relating to all aspects of our business including our contracts and operations. If a review or investigation identifies improper or illegal activities, we may be subject to civil or criminal penalties or administrative sanctions, which could include the termination of contracts, forfeiture of profits, the triggering of price reduction clauses, suspension of payments, fines, and suspension or debarment from doing business with governmental agencies. We may suffer harm to our reputation if allegations of impropriety are made against us, which would impair our ability to win new contract awards or receive contract renewals. Penalties and sanctions are not uncommon in our industry. If we incur a material penalty or administrative sanction or otherwise suffer harm to our reputation, our profitability, cash position and future prospects could be adversely affected.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

***The U.S. government may terminate, cancel, modify, or curtail our contracts at any time and, if we do not replace them, we may be unable to achieve or sustain revenue growth and may suffer a decline in revenues and profitability.***

Many of the U.S. government programs for which we are a prime contractor or subcontractor may extend for several years, and may include one or more base years and one or more option years. The U.S. government generally has the right not to exercise options to extend or expand our contracts, and may otherwise terminate, cancel, modify, or curtail our contracts at its convenience. Any decision by the U.S. government not to exercise contract options or to terminate, cancel, modify, or curtail our major programs or contracts would adversely affect our revenues, revenue growth, and profitability.

We have experienced, and will continue to experience in the normal course of business, periodic performance issues under certain of our contracts. If a government customer terminates a contract for default, we may be exposed to liability, including for excess costs incurred by the customer in procuring undelivered services and solutions from another source. Depending on the nature and value of the contract, a performance issue or termination for default could cause our actual results to differ from those anticipated and could harm our reputation.

***Our use of net operating loss carryforwards and other tax attributes to offset future taxable income may become limited if we or the IRS determine that we have experienced an ownership change.***

As of January 30, 2026, we have estimated $656 million of gross net operating loss carryforwards and gross tax basis in our acquired amortizable goodwill, as well as other intangible assets of approximately $1.1 billion. Net operating loss carryforwards and other tax attributes are subject to various annual limitations under Sections 382 and 383 of the Internal Revenue Code, which restricts a corporation's ability to use such carryforwards and attributes following an ownership change.

***Changes in tax laws and regulations or exposure to additional tax liabilities could adversely affect our financial results.***

We are subject to income and other taxes in the U.S. and various foreign jurisdictions. Our future effective tax rates, profitability, cash flows, and financial position could be adversely affected by changes in applicable domestic or foreign tax laws, regulations, treaties, or policies (including those with retroactive effect), or their interpretation and application. This includes unanticipated changes in our tax provisions, increases in tax liabilities from final determinations of tax audits, disputes, litigation, or agreements, reevaluation of uncertain tax positions, or other factors requiring significant judgment.

In July 2025, the One Big Beautiful Bill Act (the "Act") was enacted, making permanent or extending many provisions from the prior Tax Cuts and Jobs Act ("TCJA") while introducing key changes such as the repeal of mandatory capitalization of research and development expenditures, restoration of 100% depreciation for qualified property placed in service after January 19, 2025, and other modifications to deductions, credits, and incentives. These provisions have favorably affected our fiscal year 2026 results, including lower tax payments, improved cash flows from accelerated deductions on R&D, and an overall reduction in near-term cash tax liabilities compared to prior years impacted by TCJA amortization requirements.

***Legal disputes could require us to pay potentially large damage awards and could be costly to defend, which could adversely affect our cash balances and profitability, and could damage our reputation.***

We are subject to several lawsuits and claims described under "Legal Proceedings" in Part I, Item 3 of this report. We are also subject to, and may become a party to, a variety of other immaterial litigation or claims arising from time to time in the ordinary course of our business. The Department of Justice and other U.S. or foreign enforcement agencies may bring claims or lawsuits in connection with our performance of government contracts or our billing or record-keeping relating to those contracts. Although rare, government agencies can seek to suspend or debar government contractors they believe have engaged in misconduct. The government has considerably more resources at its disposal to pursue these matters than we do to defend ourselves against them, and certain statutes under which the Department of Justice may bring claims (like the False Claims Act) provide for treble damages and penalties on a per invoice basis. Consequently, the government generally has more leverage against us than a commercial plaintiff or other private party would have. Settlements or adverse judgments may result in significant monetary damages or injunctions, and litigation and claims could be costly to defend. Even if we are successful, fully indemnified, or insured, we could suffer damage to our reputation that impedes our ability to compete for work

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

or obtain adequate insurance in the future. The outcome of litigation and other claims, including those described under "Legal Proceedings" in Part I, Item 3 of this report, is inherently uncertain, and management's view of these matters may change in the future.

***Our business is subject to numerous legal and regulatory requirements, and any violation of these requirements, or any misconduct by our employees, subcontractors, agents, or business partners, could harm our business and reputation.***

In addition to government contract procurement laws and regulations, we are subject to numerous other federal, state, and foreign legal requirements related to, among other things, fraud (including but not limited to falsifying time and other records), data privacy and protection, employment and labor relations, immigration, taxation, anticorruption, import/export controls, trade restrictions, internal and disclosure control obligations, securities regulations, and antitrust. Compliance with diverse and changing legal requirements is costly, time-consuming, and requires significant resources. Violations can result in fines, penalties, restitution, or other damages (which can be significant), criminal sanctions against our Company and/or our officers, the loss of security clearances, the cancellation of current contracts and the ineligibility for future contracts, and suspension or debarment from federal, state, or local contracting – any of which could adversely affect our business and financial results. Additionally, depending on the circumstances, our Company can be held liable for the misconduct of its employees, subcontractors, agents, or business partners.

**Business and Operational Risks**

***A failure to attract, train, retain, and utilize skilled employees and our senior management team would adversely affect our ability to execute our strategy and may disrupt our operations.***

Our business relies heavily on the expertise and skills of our employees. Many government programs require our personnel to have security clearances. Our continued success depends on the ability to recruit and retain highly trained, skilled and, at times, cleared engineering, technical, and professional personnel. Competition for talent is intense, and competitors aggressively recruit key employees. Security clearances can be difficult and time-consuming to obtain, and cleared talent is in demand. Particularly in highly specialized areas, it has become more difficult to recruit and retain qualified employees, which could affect our growth in the current and future fiscal years. We will continue to devote significant resources to recruiting, training, and retaining top talent, but we cannot guarantee the outcome of these efforts. The failure to timely secure qualified employees could impair our ability to win new business or meet existing contractual obligations, which could adversely affect our future financial performance. In addition, salaries and related expenses are a significant portion of the cost of our services and, accordingly, our ability to utilize our workforce efficiently can impact our profitability. If our employees are under-utilized, our profitability could suffer.

Our success also depends on the continued employment of a highly qualified and experienced senior management team that focuses on retaining existing business and generating new business. Although we have succession plans in place, the loss of key personnel in critical functions could temporarily impair our ability to win new contracts or perform existing work.

***We may make acquisitions, divestitures, investments, or enter into joint ventures in the future that involve numerous risks, which, if realized, may adversely affect our business and financial performance.***

Subject to the limitations of our credit facility (as further described in "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 of this report), we may make strategic acquisitions or investments, engage in joint ventures, or divest existing businesses, which could cause unforeseen expenses, disrupt our business, fail to yield the anticipated benefits, or pose other risks that could adversely affect our reputation, operations, or financial results, including:

&nbsp;&nbsp;&nbsp;&nbsp;• we may not retain key employees (including those with needed security clearances), customers, and business partners of an acquired business in the future;

&nbsp;&nbsp;&nbsp;&nbsp;• we may fail to successfully integrate acquired businesses, such as failing to successfully implement IT and other control systems relating to the operations of any acquired business;

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

&nbsp;&nbsp;&nbsp;&nbsp;• we may not generate sufficient earnings to meet the required Leverage Ratio under the Credit Facility, which would give lenders the right to, among other things, foreclose on our assets;

&nbsp;&nbsp;&nbsp;&nbsp;• acquisitions normally require a significant investment of time and resources, which may disrupt our business and distract our management from other important responsibilities;

&nbsp;&nbsp;&nbsp;&nbsp;• we may not be able to accurately estimate the financial effect of any acquisitions and investments on our business and we may not realize anticipated revenue opportunities, cost savings, or other synergies or benefits, or acquisitions may not result in improved operating performance; and

&nbsp;&nbsp;&nbsp;&nbsp;• we may assume known and unknown material liabilities, including legal or regulatory risks that were not identified as part of our due diligence or for which we are unable to receive a purchase price adjustment or reimbursement through indemnification.

If any acquisitions, investments, or joint ventures fail, perform poorly, or their value is otherwise impaired for any reason, including contractions in credit markets and global economic conditions, our business and financial results could be adversely affected.

In addition, we may periodically divest businesses, including businesses that are no longer a part of our ongoing strategic plan. These divestitures similarly require significant investment of time and resources. They may disrupt our business, distract management from other responsibilities, and create losses on disposal or continued financial involvement in the divested business, including through indemnification, guarantee, or other financial arrangements, for a period of time following the transaction, which could adversely affect our financial results.

***We use and deploy AI solutions for our customers that could harm our reputation, create liability if they do not function as predicted, or we are required to discontinue their use.***

We deploy and integrate AI solutions for our business operations and for customers, including AI solutions that assist with the design, deployment, and management of AI applications that allow customers to work with their complex and sensitive data to power the most demanding analytics, data science, and AI use cases. These AI solutions may be vulnerable to misuse or cyberattack. Additionally, because this technology is developing so rapidly, we may be unable to keep up with new AI developments. We use some AI solutions that we develop and other AI solutions that we obtain from third parties. The development methods and algorithms of these solutions could be flawed, and the datasets could contain incorrect or biased information, which may require us to discontinue use of certain AI technology immediately or within short timelines. Content or code generated by AI systems may be vulnerable to cyberattack, require human review, be unreliable, illegal, or offensive, and could result in the AI solution not working as intended. If we deploy AI solutions that have unintended consequences or are more controversial than we anticipate, our customers may seek redress, and we may experience reputational harm that could affect our business or financial results, including increased costs, schedule delays, or operational disruptions. Our use and deployment of AI solutions and capabilities could be limited by, or subject to regulatory action, supply chain risk, or legal liability under, proposed rules or legislation regarding privacy, intellectual property, and other laws, which could ultimately affect our competitiveness in bids or impair our performance on existing contracts.

***We face various risks related to health epidemics, pandemics, and similar outbreaks, which may have material adverse effects on our business, financial position, results of operations, and/or cash flows.***

We face various risks related to health epidemics, pandemics, and similar outbreaks such as the global outbreak of COVID-19. If significant portions of our workforce cannot work effectively due to illness, quarantines, government actions, facility closures, or for other reasons in connection with an epidemic, our operations will be impacted. We may be unable to perform fully on our contracts and some of our costs may not be fully recoverable or adequately covered by insurance. Another epidemic could cause disruption in our supply chain, could delay or limit the operations of the U.S. government and other customers to perform (including making timely payments to us), could impact investment performance, and could cause other negative events.

In addition, the resulting volatility in the global capital markets could restrict our access to capital and/or increase our cost of capital.

***Customer systems failures could damage our reputation and adversely affect our revenues and profitability.***

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

Many of the systems and networks that we develop, install, and maintain for our customers involve managing and protecting personal information and information relating to national security and other sensitive government functions. While we have programs designed to comply with relevant privacy and security laws and restrictions, if a system or network that we develop, install, or maintain were to fail or experience a security breach or service interruption (whether caused by us, third-party service providers, cybersecurity threats, or other events), we may experience loss of revenue, remediation costs, claims for damages, or contract termination. This could cause serious harm to our reputation and prevent us from having access to, or being eligible for, further work involving these systems and networks. Our errors and omissions liability insurance may not adequately compensate us for the damages that we incur, and our results could be adversely affected.

***We depend on our teaming arrangements and relationships with other contractors and subcontractors. If we are not able to maintain these relationships, or if these parties fail to satisfy their obligations to us or the customer, our revenues, profitability, and growth prospects could be adversely affected.***

We rely on teaming relationships with other prime contractors and subcontractors to bids on large procurements and other opportunities when we believe the combination of services, products, and solutions we can offer with teammates will help us win and perform the contract. Our future revenues and growth could be adversely affected if our partners reduce or end their contract relationships with us, or if the U.S. government terminates or reduces programs of prime contractors to which we subcontract, does not award them new contracts, or refuses to pay under a contract. We may contract with subcontractors that do not have experience on U.S. government contracts or with our customers, providing them with the experience, relationships, and past performance to compete with us on future contracts, which could potentially result in contract losses. If subcontractors fail to timely meet their contractual obligations or have regulatory compliance or other problems, our ability to fulfill our obligations as a prime contractor or higher tier subcontractor may be jeopardized.

***We have only a limited ability to protect our intellectual property rights, which are important to our success. Our failure to adequately protect our proprietary information and intellectual property rights could adversely affect our competitive position.***

We rely principally on trade secrets to protect much of our intellectual property in cases where we do not believe that patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Although our employees are subject to confidentiality obligations, this protection may be inadequate to deter or prevent misappropriation of our confidential information. We may be unable to detect unauthorized use of our intellectual property or otherwise take appropriate steps to enforce our rights. Failure to obtain or maintain trade secret protection could adversely affect our competitive business position. If we are unable to prevent third parties from infringing or misappropriating our copyrights, trademarks, or other proprietary information, our competitive position could be adversely affected. In addition, in connection with the performance of services, the U.S. government has certain rights to inventions, data, software codes, and related material that we develop under government-funded contracts and subcontracts, which may permit the U.S. government to disclose or license this information to third parties, including, in some instances, our competitors.

In the course of conducting our business, we may inadvertently infringe the intellectual property rights of others, resulting in claims against us or our customers. Our contracts generally indemnify our customers for third-party claims for intellectual property infringement by the services and solutions we provide. The expense of defending these claims may adversely affect our financial results.

***We face risks related to climate change if extreme weather events adversely affect our ability to work or our customers' requirements or priorities.***

Severe storms, increased precipitation and flooding, heat waves, forest fires, and other natural disasters tied to climate change could adversely affect our ability to execute our strategy and may disrupt our operations. Any climate event limiting our employees' ability to work could potentially impair our capability to perform and meet our contractual obligations, address our customers' needs, and ultimately win new business, all of which could adversely affect our business, financial position, results of operations, and/or cash flows. While we have a distributed workforce with employees working remotely across the U.S., we do have employees who, because of client requirements or contractual obligations, must work at specified locations. In these instances, if there were a severe weather event that impacted such a location, we might not be able to meet the client's requirements or our contractual obligations. In the shorter term, a climate-related event could temporarily impede our ability to do the

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

required work in person, produce operational or other unforeseen challenges, and in the longer term, threaten our performance of contracts, any of which could harm our business and its results.

Although we have business continuity plans and other safeguards in place, there is no assurance that such plans and safeguards will be effective in preventing adverse impacts on our operations or long-term plans. Local conditions and regulations may delay the return of employees to business sites, which could undermine our efforts to meet our contractual obligations. Climate-related limitations on individual employees may also create obstacles to meeting customer requirements or our contractual obligations.

Additionally, our customers could change priorities or direction due to a direct climate-change impact, concerns about long-term sustainability, legislative or regulatory pressure, or market factors such as investor, consumer, or societal requests or demands. Such changes and responses by our customers have the potential to adversely impact our future revenues, profitability, and prospects.

***We could incur significant liabilities and suffer negative publicity if our detection systems fail to operate as intended or our assessment reports prove to be inaccurate.***

We have developed and sold tsunami buoys and related services that are designed to assist in the detection of tsunamis or large waves that may have catastrophic consequences to coastal communities. Our buoys have been deployed by the U.S. National Oceanic and Atmospheric Administration and non-U.S. governments in other areas around the world. There are many factors, some of which are beyond our control, that could result in the failure of these buoys. We may develop other products or provide services for the detection of catastrophic natural or man-made threats.

Some of our contracts involve evaluating and/or assessing the likelihood or potential consequences of natural disasters and other threats. The failure of our products and services to help detect the threats for which they were designed, or the failure of our reports to accurately assess the consequences of certain threats could contribute to injury, death, or extensive property damage, potentially leading to product liability, professional liability, or other claims against us. Further, if our products, services, or reports fail to (or are perceived to have failed to) help detect or adequately assess a threat, the negative publicity could have a material adverse effect on our business.

***Our services and operations sometimes involve using, handling, or disposing of hazardous substances or dangerous materials, which could expose us to potentially significant liabilities.***

Some of our services and operations involve the use, handling, or disposal of hazardous substances or dangerous materials, including explosive, chemical, biological, radiological, or nuclear materials. These activities generally subject us to extensive foreign, federal, state, and local environmental protection and health and safety laws and regulations, which, among other things, require us to incur compliance costs and the risk of liability. Failure to comply with these environmental protection and health and safety laws and regulations could result in civil, criminal, regulatory, administrative, or contractual sanctions, including but not limited to fines, penalties, and/or suspension or debarment actions. We could be required to incur costs to change, upgrade, remediate, and/or close some of our operations or properties. Although we do not have extensive real estate holdings, our ownership and operation of real property also subjects us to environmental protection laws, some of which create liability for current or previous owners or operators of businesses and real property liable for hazardous substance releases, even if they did not know of and were not responsible for the releases. If we have any violations of, or incur liabilities pursuant to, these laws or regulations, our financial condition and operating results could be adversely affected.

***We face risks associated with our international business.***

Our international operations, which have historically generated a small portion of our revenues, may be subject to additional and different risks than our domestic operations. Failure to comply with U.S. government laws and regulations applicable to international business, such as the Foreign Corrupt Practices Act and U.S. export control regulations, could have an adverse impact on our business with the U.S. government and could expose us to administrative, civil, or criminal penalties, and potentially significant contract losses.

We provide services and solutions in support of U.S. government customers in countries that are politically unstable, active conflict zones, or subject to high-risk intelligence operations. Operating in these environments may increase the risk of an incident resulting in injury or loss of life, property damage or destruction, or the inability to

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

meet our contractual obligations. It is impossible to predict the impact that these regulatory, geopolitical, and other factors may have on our business in the future.

***Pension funding and costs are dependent upon several economic assumptions, which, if changed, may cause our future earnings and cash flow to fluctuate significantly.***

Through our acquisition of Engility Holdings, Inc. ("Engility") in fiscal 2019, we assumed obligations under Engility's defined benefit pension plan (the "Pension Plan"). The impact of the Pension Plan on our generally accepted accounting principles ("GAAP") earnings may be volatile. Because our calculations are sensitive to funding levels and rely on several key economic assumptions, including interest rates, rates of return on plan assets, and participant mortality estimates, the expenses we record for the Pension Plan may materially change from year to year. Changes in these factors also affect our plan funding, cash flow, and stockholders' equity. In addition, the Pension Plan funding may be subject to changes caused by legislative or regulatory actions.

We will make contributions to fund the Pension Plan when considered necessary or advantageous to do so. The macro-economic factors discussed above, including the return on assets and the minimum funding requirements established by government funding or taxing authorities, or established by other agreement, may influence future funding requirements. A significant decline in the fair value of the assets in the Pension Plan, or other adverse changes to the Pension Plan, could require us to make significant funding contributions and affect cash flows in future periods.

We also, in the acquisition of Engility, assumed obligations under a Retiree Health Reimbursement Account plan ("RHRA"). The impact of Engility's RHRA on our GAAP earnings may be volatile in that the amount of expense we record for the plan may materially change from year to year because those calculations are sensitive to several key economic assumptions, including interest rates and actuarial assumptions related to participant mortality, retirement, and termination.

CAS govern the extent to which postretirement costs and plan contributions are allocable to and recoverable under contracts with the U.S. government. On December 27, 2011, the CAS Board published a final rule that harmonizes CAS pension cost reimbursement rules with the Pension Protection Act of 2006 ("PPA") funding requirements. The rule is expected to mitigate the mismatch between CAS costs and minimum funding requirements under PPA-amended Employee Retirement Income Security Act of 1974 ("ERISA"), which should accelerate allowable CAS pension costs as compared to prior rules. We anticipate that government contractors will be entitled to an equitable adjustment for any additional CAS contract costs resulting from the final rule. We have sought, and expect to continue seeking, reimbursement from the U.S. government for a portion of our postretirement costs and plan contributions. For additional information related to our pension funding and costs, see Note 9—Retirement Plans to the consolidated financial statements contained within this report.

***Goodwill and intangible assets represent a significant amount of our total assets and any impairment of these assets would negatively affect our results of operations.***

Goodwill is tested for impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. This includes, for example, significant adverse changes in the legal or regulatory landscape or in the business climate, adverse actions or assessments by regulators, unanticipated competition, the loss of key contracts, significant decreases in our stock price, or disruptions in customer relationships that affect current and future operating cash flows of the reporting unit. We assess intangible assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable at the asset group level. Any future impairment of goodwill or other intangible assets would have a negative impact on our profitability and financial results.

***We maintain our cash at financial institutions, often in balances that exceed federally insured limits.***

Most of our cash is held in accounts at U.S. banking institutions that we believe are of high quality. Cash held in depository accounts may exceed the $250,000 Federal Deposit Insurance Corporation ("FDIC") insurance limits. If these banking institutions were to fail, we could lose part or all of the amounts in excess of the insurance limits. A material loss related to a bank failure could have a material adverse effect on our financial position and could impact our ability to pay operational expenses or make other payments. Additionally, if our customers, suppliers, insurers, joint venture partners, sureties, or other parties with which we partner are materially impacted by a bank failure or

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

other issues in the banking industry, including changes in legislation and regulation, it may have an adverse impact on our operational and financial performance.

**Cybersecurity Risks**

***Our business and financial results could be negatively affected by cyber or other security threats.***

We encounter cybersecurity and physical security threats as part of the work we do for our customers and our internal business. Our IT systems contain a variety of sensitive and classified information which attract adversaries including nation-state threat actors. We face cybersecurity threats including attempts to disrupt our critical systems, gain unauthorized access to data, release or corrupt sensitive information, and interfere with operations. Adversaries that acquire unauthorized access to customer accounts can use that information to compromise data. Inadequate account security practices could result in malicious activity affecting customer use of our solutions. We work cooperatively with our customers to address cybersecurity threats and we are subject to extensive regulations related to cybersecurity.

Actual or perceived cybersecurity vulnerabilities may lead to claims against us. Our customers, their employees, or third parties may seek to hold us liable for any costs or other damages associated with unauthorized access to sensitive information for which we are responsible under customer contracts.

We develop custom software code and our products may utilize or include open source or AI-generated code, which may make our products susceptible to cyberattacks. We also rely on our supply chain to deliver products and services to our customers. Threat actors have and may continue to seek and gain access to our systems through our business partners and suppliers. A cybersecurity incident affecting our business partners and suppliers could materially adverse impact on our business.

Our information security staff manage cybersecurity risks by implementing security controls in accordance with industry standards and conducting regular employee cybersecurity training. Our cybersecurity policies, procedures and maturity are subject to review and audit by third parties. Although we have implemented and regularly update cybersecurity controls, there can be no assurance that these measures will successfully prevent or mitigate cybersecurity incidents.

We have been subject to cybersecurity incidents, disruptions and data loss targeting our data and systems of the data and systems of our customers. None of these incidents has had a material impact on us or, to our knowledge, our customers. We report cybersecurity incidents, as appropriate, to affected customers and the cognizant regulatory, law enforcement, and national security authorities. Future cybersecurity incidents could damage our reputation, expose us to liability, or prevent us from winning future work, and could have a material adverse impact on our business.

Because of the rapidly evolving nature of these threats, there can be no assurance that our policies, procedures and security controls will detect or prevent them, mitigate their affects and we cannot predict their full impact.

In addition, government agencies investigate and may bring actions against us for noncompliance with legal, contractual, or regulatory requirements regarding cybersecurity controls and disclosure of cybersecurity incidents to customers, regulators, law enforcement, or the public. Any remediation costs, damages or other liabilities related to cybersecurity incidents may not be fully insured or indemnified by other means.

**Forward-Looking Statement Risks**

This report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "may," "will," "should," "expects," "projects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "continue," "outlook," and similar words or phrases. The forward-looking statements in this report relate to anticipated events and future operating results and financial performance. These statements are not guarantees of future performance and are subject to risks and uncertainties, including but not limited to changes in market conditions, regulatory and legal developments, governmental and political conditions, competitive pressures, technological advancements, economic conditions, supply chain disruptions, and the risk factors discussed above that could cause actual results to differ materially from those expressed or implied in this report.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

Except where required by law, we expressly disclaim a duty to update or revise any forward-looking statements after the date of this Form 10-K to reflect subsequent events, changed circumstances or expectations, or revised estimates and assumptions. The forward-looking statements in this Form 10-K are intended to be subject to the safe harbor protections in the federal securities laws.

**Item 1B. *Unresolved Staff Comments***

No information is required in response to this item.

**Item 1C. *Cybersecurity***

**Risk Management and Strategy**

We are subject to various cybersecurity risks and continuously monitor and assess our cybersecurity measures to protect against a multitude of cyber threats from adversaries, including nation state actors, that target critical infrastructure sectors such as the defense industrial base. A cybersecurity incident involving us or our subcontractors or suppliers could materially affect our operations, performance, and results.

We expend considerable resources on our cybersecurity management and oversight program designed to identify, manage, and mitigate cybersecurity risks. This program is integrated into our overall risk management systems and processes and includes continuous monitoring of cybersecurity threats, regular assessments of information systems, vulnerability management, penetration testing, employee training on cybersecurity best practices, and ongoing assessments of risk.

We have established an incident response plan to promptly and effectively address cybersecurity incidents. The incident response plan provides steps to identify, mitigate, and recover from incidents, and procedures to escalate issues to senior management, legal, and, when appropriate, our Board of Directors. The plan includes procedures for investigating and containing incidents, notifying affected parties, as appropriate, and implementing corrective actions.

As a defense contractor, we must comply with DoW cybersecurity requirements for handling Controlled Unclassified Information ("CUI") and requirements in the Defense Federal Acquisition Regulation Supplement ("DFARS") regarding reporting cybersecurity incidents to the DoW, including the DoW's Cybersecurity Maturity Model Certification ("CMMC") program. We are participating in this program and plan to obtain the appropriate CMMC certification. We also adhere to the standards set forth by the National Institute of Standards and Technology ("NIST") and the International Organization for Standardization ("ISO") to ensure the highest level of security and operational excellence. Our commitment to compliance with these rigorous frameworks is integral to maintaining the confidentiality, integrity, and availability of our services and products.

We rely on various third-party providers, such as vendors, suppliers and other business partners for certain aspects of our operations. These third parties are also susceptible to cybersecurity risks. We conduct due diligence on the cybersecurity practices and controls on these providers and include provisions in our contracts requiring appropriate cybersecurity measures. In addition, in the case of a third-party cybersecurity incident, we identify and mitigate risks to minimize the effects to us from third-party incidents.

We share and receive threat intelligence with our peers in the defense industrial base, government agencies, information sharing and analysis centers, and cybersecurity associations. We have relationships with third-party service providers who also assess our security controls through penetration testing, independent audits, and consulting on best practices to address emerging challenges. These assessments evaluate the effectiveness of our security controls.

**Governance**

***Management's Responsibilities***

Our information security program is led by our corporate Chief Information Security Officer ("CISO"), who works closely in a cross-functional capacity with key corporate and operational business stakeholders, including our Chief Information Officer. They and the other individuals supporting our information security program demonstrate their cybersecurity expertise through qualifications such as prior work experience, possession of a cybersecurity certification, degree, or other cybersecurity experience. The CISO collaborates with these functions for the purpose

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

of establishing processes and procedures to monitor potential cybersecurity risks, identifying cybersecurity incidents, implementing appropriate mitigation measures, reporting cybersecurity breaches, assessing materiality, maintaining our cybersecurity program, and other information security incidents. The CISO provides regular updates and written reports on our cybersecurity posture and preparedness to senior management, the Audit Committee, the Nominating and Corporate Governance Committee and the Board.

***Board of Directors' Roles and Responsibilities***

Our cybersecurity risks and associated mitigations, as part of our enterprise risk management ("ERM"), are continually monitored by senior leadership. The Nominating and Corporate Governance Committee of our Board of Directors oversees the ERM process. The Chief Risk Officer reports to the Nominating and Corporate Governance Committee on a quarterly basis regarding the ERM program.

These risks and mitigations are also subject to oversight by the Audit Committee of our Board of Directors. The Audit Committee is the primary committee that oversees enterprise cybersecurity risks and reviews cybersecurity matters, including our policies and procedures for protecting our cybersecurity infrastructure and for compliance with data protection and security regulations, and related risks. The Audit Committee receives information regarding such risks from management, including our CISO, and reports to the Board on a quarterly basis. The Audit Committee also oversees the Board's response to any significant cybersecurity incidents.

***Cybersecurity Threats***

While we have taken significant steps to manage cybersecurity risks, there can be no assurance that these measures will prevent all potential incidents. A material cybersecurity incident could have material adverse effect on our financial condition, results of operations, or cash flows. We are committed to addressing cybersecurity risks in an ever-evolving technological landscape. Management will continue to evaluate and enhance its cybersecurity measures to adapt to emerging threats and comply with evolving regulatory requirements.

We describe whether and how risks from identified cybersecurity threats have materially affected or are reasonably likely to materially affect us, including our organizational strategy, results of operations, or financial condition as part of our risk factor disclosures in Part I, Item 1A of this report.

**Item 2. *Properties***

We occupy approximately 3 million square feet of floor space, substantially all of which is leased. Our corporate headquarters is located in Reston, Virginia. Our principal locations outside of Reston, Virginia include Chantilly, Virginia; Arlington, Virginia; Huntsville, Alabama; El Segundo, California; Bedford, Indiana; and Charleston, South Carolina. As of January 30, 2026, we conducted our operations at approximately 106 properties located in 20 states, the District of Columbia, and various foreign countries. We consider our facilities suitable and adequate for our present needs, which are generally limited to office, integration, warehouse and computer laboratory spaces.

**Item 3. *Legal Proceedings***

We have provided information about legal proceedings in which we are involved in Note 17—Legal Proceedings and Other Commitments and Contingencies to the consolidated financial statements contained within this report.

We are also routinely subject to investigations and reviews relating to compliance with various laws and regulations. Additional information regarding such investigations and reviews is described under the heading "Government Investigations, Audits and Reviews" in Note 17—Legal Proceedings and Other Commitments and Contingencies to the consolidated financial statements contained within this report.

**Item 4. *Mine Safety Disclosures***

No information is required in response to this item.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**Part II**

**Item 5. *Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities***

Through closing of trading on March 4, 2024, our common stock was listed on the New York Stock Exchange under the ticker symbol "SAIC." Effective as of the opening of trading on March 5, 2024, we voluntarily transferred the listing of our shares of common stock to The Nasdaq Stock Market LLC. Our common stock continues to be traded under the symbol "SAIC." As of March 6, 2026, there were approximately 17,000 holders of record of our common stock. The number of holders of record of our common stock may not be representative of the number of beneficial owners due to shares that may be held by depositories, brokers or nominees.

We declared and paid cash dividends on our common stock of $0.37 per share each quarterly period of fiscal 2026, 2025 and 2024. Total dividends declared and paid during fiscal 2026, 2025 and 2024 were $1.48 per share. Quarterly cash dividends are typically paid in April, July, October and January, for the first, second, third and fourth quarters, respectively. We currently intend to continue paying quarterly cash dividends in the near future, although the declaration of any future dividends and the amount thereof will be determined by our Board of Directors and will depend on many factors, including our financial condition, capital requirements, available cash, results of operations, and other factors our Board of Directors may deem relevant.

**Stock Performance Graph**

The following graph compares the total cumulative return on our common stock, from the beginning of fiscal year 2020 through fiscal year 2026, to two indices: (i) the Russell 1000 Index and (ii) the Dow Jones US Computer Services Index. The graph assumes an initial investment of $100 on January 29, 2021 and that dividends have been reinvested. The comparisons in the graph are required by the U.S. Securities and Exchange Commission ("SEC"), based upon historical data and are not intended to forecast or be indicative of possible future performance of our common stock.

![2069](saic-20260130_g1.jpg)

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**Purchases of Equity Securities**

We may repurchase shares on the open market in accordance with established repurchase plans. Whether repurchases are made and the timing and amount of repurchases depend on a variety of factors including market conditions, our capital position, internal cash generation and other factors.

The following table presents repurchases of our common stock during the three months ended January 30, 2026:

---

| | | | | |
|:---|:---|:---|:---|:---|
| Period<sup>(1)</sup> | Total Number of Shares (or Units) Purchased<sup>(2)</sup> | Average Price Paid per Share (or Unit) | Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs | Maximum Number of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs<sup>(3)(4)</sup> |
| November 1, 2025 - December 5, 2025 | 397524 | $89.30 | 397524 | 7677112 |
| December 6, 2025 - January 2, 2026 | 299156 | 101.28 | 299156 | 7331505 |
| January 3, 2026 - January 30, 2026 | 285117 | 107.87 | 282337 | 6992885 |
| Total | 981797 | $98.34 | 979017 |  |

---

(1)Date ranges represent our fiscal periods during the current quarter. Our fiscal quarters typically consist of one five-week period and two four-week periods.

(2)Includes shares purchased on surrender by stockholders of previously owned shares to satisfy minimum statutory tax withholding obligations related to vesting of stock awards in addition to shares purchased under our publicly announced plans or programs.

(3)In December 2024, our Board of Directors authorized the repurchase of up to $1.2 billion of our outstanding common stock under our existing share repurchase plan. As of January 30, 2026, we have repurchased approximately 28.5 million shares of our common stock under the plan for approximately $2.5 billion, which included amounts previously authorized under the plan prior to December 2024.

(4)The maximum number of shares that may yet be purchased under our publicly announced plans or programs is calculated by taking the total remaining dollars authorized at the end of each period and dividing it by the closing stock price as of the period end date.

**Item 6. *[Reserved]***

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**Item 7. *Management's Discussion and Analysis of Financial Condition and Results of Operations***

*The following discussion and analysis of our financial condition and results of operations, and quantitative and qualitative disclosures about market risk should be read in conjunction with our consolidated financial statements and the related notes included in this Form 10-K, as well as Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our Form 10-K for the year ended January 31, 2025, which provides additional information on comparisons of fiscal 2025 and 2024. It contains forward-looking statements (which may be identified by words such as those described in "Risk Factors—Forward-Looking Statement Risks" in Part I, Item 1A of this report), including statements regarding our intent, belief, or current expectations with respect to, among other things, trends affecting our financial condition or results of operations; backlog; our industry; government budgets and spending; market opportunities; the impact of competition; and the impact of acquisitions and divestitures. Such statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ materially from those in the forward-looking statements as a result of various factors. Risks, uncertainties and assumptions that could cause or contribute to these differences include those discussed below and elsewhere in this report, particularly in "Risk Factors" in Part I, Item 1A of this report. Due to such risks, uncertainties and assumptions, you are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to update these factors or to publicly announce the results of any changes to our forward-looking statements due to future results or developments.*

*We use the terms "SAIC," the "Company," "we," "us" and "our" to refer to Science Applications International Corporation and its consolidated subsidiaries.*

*We utilize a 52/53 week fiscal year ending on the Friday closest to January 31, with fiscal quarters typically consisting of 13 weeks. Fiscal 2026 began on February 1, 2025 and ended on January 30, 2026, fiscal 2025 began on February 3, 2024 and ended on January 31, 2025, and fiscal 2024 began on February 4, 2023 and ended on February 2, 2024.*

**Business Overview**

We are a leading technology integrator providing full life cycle services and solutions in the technical, engineering and mission and enterprise information technology ("IT") markets. We developed our brand by addressing our customers' mission critical needs and solving their most complex problems for over 50 years. As one of the largest pure-play technology service providers to the U.S. government, we serve markets of significant scale and opportunity. Our primary customers are the departments and agencies of the U.S. government. We serve our customers through approximately 1,700 active contracts and task orders and employ approximately 23,000 individuals who are led by an experienced executive team of proven industry leaders. Our long history of serving the U.S. government has afforded us the ability to develop strong and longstanding relationships with some of the largest customers in the markets we serve. Substantially all of our revenues and tangible long-lived assets are generated and located in the United States.

Effective February 3, 2024, the first day of fiscal 2025, we completed a business reorganization which replaced our previous two operating sectors with five customer facing business groups supported by the enterprise organizations, including the Innovation Factory. The five business groups, which are also our operating segments, are aggregated into two reportable segments for financial reporting purposes given the similarity in economic and qualitative characteristics, and based on the nature of the customers they serve. Our two reportable segments are the Defense and Intelligence segment and the Civilian segment.

The Defense and Intelligence segment provides a diverse portfolio of national security solutions to the DoW and the Intelligence Community of the United States Government.

The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments, in order to deliver services for citizen well-being, border security, and protecting lives. This includes integrating solutions into a spectrum of public service missions that impact travel, trade, health and the economy.

The offerings of both reportable segments entail the integration of emerging technologies into mission critical operations that modernize and enable national imperatives, including IT modernization, digital engineering, artificial intelligence ("AI"), mission systems support and advisory, training and simulation, and ground vehicles support. These services include end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment and security of the customers' entire IT infrastructure.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

Our Innovation Factory supports the operating segments by developing enterprise-class solutions which are delivered to our customers as stand-alone solutions or integrated with and aligned to our product offerings through the operations of the business to meet complex customer needs and accelerate digital transformation. The Innovation Factory includes designated teams focused on AI, application development, network services, platforms and cloud, engineering, and cybersecurity. It uses a highly automated, cloud-hosted tool set to rapidly build, test and deploy solutions and works with customers to enhance solutions going forward.

Costs associated with corporate functions that are not allocable to the reportable segments are presented as Corporate. See Note 16—Business Segments Information to the consolidated financial statements contained within this report for additional information.

Effective January 31, 2026, the first day of fiscal 2027, we completed a business reorganization that consolidated our five business groups into three. The reorganization is designed to simplify our structure and optimize operations and customer focus for growth. The consolidated business groups will continue to report directly to our Chief Executive Officer ("CEO") who will continue to be the chief operating decision maker ("CODM"). We do not expect the reorganization to have an impact on our reportable segments.

**Economic Opportunities, Challenges, and Risks**

In fiscal 2026, we generated 98% of our revenues from contracts with the U.S. government, including subcontracts on which we perform. Our business performance is affected by the overall level of U.S. government spending and the alignment of our offerings and capabilities with the budget priorities of the U.S. government. In March 2025, the President signed a continuing resolution ("CR") that extends government funding through the close of government fiscal year ("GFY") 2025. The measure provides budget certainty for agencies through September 30, 2025. The CR also provides flexibility for new starts on programs at the DoW, which are typically not allowed under CRs.

In July 2025, Congress passed a budget reconciliation package that will add approximately $150 billion in new non-border defense spending, and $175 billion in new border security and enforcement spending, among other provisions. This funding is available to agencies immediately, and can be used through GFY 2029. Portions of this new funding will increase spending in areas addressable to us, including new investments in Naval operations and border surveillance. The measure also extended and expanded key tax provisions that will positively impact our Company.

On October 1, 2025, the federal government shut down following the expiration of the March 2025 CR. On November 12, 2025, the President signed a spending agreement that officially reopened the government after 43 days. The agreement includes three full-year appropriations bills, including the Agriculture-FDA, Military Construction-Veterans Affairs, and Legislative Branch packages.

In February 2026, the President signed an appropriations package that finalized full-year funding for most government agencies. All agencies and functions funded by those bills will now be covered in full through September 30, 2026, the close of GFY 2026. The Department of Homeland Security is currently the only remaining agency with a delay in approved appropriations for GFY 2026 and is currently shut down. If the shutdown continues for an extended period of time, it could have an adverse impact on our financial outlook.

As part of the budget reconciliation package signed into law in July 2025, the federal debt limit was increased by $5 trillion. This is expected to extend protection from a potential government default until at least the end of calendar year 2026.

The U.S. government administration has put in place a number of executive orders and actions which could affect our business. In addition, the U.S government performs an ongoing evaluation of the structure and priorities of Federal agencies. Agencies are conducting comprehensive reviews of existing and new contracting activity to identify potential efficiencies or nonalignment with new Administration priorities. Our contracts have been, and will continue to be, subject to these reviews. We have not experienced a material financial statement impact from recent executive orders or program cancellations across the government. However, ongoing reductions in personnel, changes in agency alignment, required reviews of new contracting activity, decreases or delays in new or existing contract awards and in government spending on the types of programs that we support, and terminations or stop-work-orders and delay in funding on government contracts on which we are currently performing could adversely affect our future revenues, cash flows and profitability.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

Adverse changes in fiscal and economic conditions could materially impact our business. Some changes that could have an adverse impact on our business include the implementation of future spending reductions (including sequestration), delayed passage of appropriations bills resulting in temporary or full-year continuing resolutions, inflationary increases adversely impacting fixed-price contracts, and potential government shutdowns.

Spending packages, including the infrastructure bill, Inflation Reduction Act, and CHIPS and Science Act, as well as future potential spending packages, may provide additional opportunity in areas of SAIC focus such as digital modernization, cyber, microelectronics support, and climate resiliency.

The U.S. government has increasingly relied on contracts that are subject to a competitive bidding process (including indefinite delivery, indefinite quantity ("IDIQ"), U.S. General Services Administration ("GSA") schedules, and other multi-award contracts), which has resulted in greater competition and increased pricing pressure. Additionally, the U.S. government has put renewed emphasis on increasing the number of small business prime set aside contracts that further reduce the addressable market in some areas.

Despite the budget and competitive pressures affecting the industry, we believe we are well-positioned to protect and expand existing customer relationships and benefit from opportunities that we have not previously pursued. Our scale, size, and prime contractor leadership position are expected to help differentiate us from our competitors, especially on large contract opportunities. We believe our long-term, trusted customer relationships and deep technical expertise provide us with the sophistication to handle highly complex, mission-critical contracts. Our value proposition is found in the proven ability to serve as a trusted adviser to our customers. In doing so, we leverage our expertise and scale to help them execute their mission.

We succeed as a business based on the solutions we deliver, our past performance, and our ability to compete on price. Our solutions are inspired through innovation based on adoption of best practices and technology integration of the best capabilities available. Our Innovation Factory develops superior enterprise-class solutions which are delivered to our customers as stand-alone solutions or integrated with and aligned to our product offerings to meet complex customer needs and accelerate digital transformation. Our past performance was achieved by employees dedicated to supporting our customers' most challenging missions. Our current cost structure and ongoing efforts to reduce costs by strategic sourcing and developing repeatable offerings sold "as a service" and as managed services in a more commercial business model are expected to allow us to compete effectively on price in an evolving environment. Our ability to be competitive in the future will continue to be driven by our reputation for successful program execution, competitive cost structure, development of new pricing and business models, and efficiencies in assigning the right people, at the right time, in support of our contracts.

On October 15, 2025, we acquired SilverEdge Government Solutions ("SilverEdge"), an innovative provider of mission-driven technology solutions and products. The acquisition advances our strategy to provide mission focused solutions and commercial products to our customers. See Note 4—Acquisitions and Divestitures to the consolidated financial statements contained within this report for additional information.

On May 6, 2023, SAIC closed the sale of its logistics and supply chain management business ("Supply Chain Business") to ASRC Federal Holding Company, LLC ("ASRC Federal"). The sale enables us to focus its resources on long-term strategic growth areas.

On February 4, 2023, we sold 0.1% of our 50.1% majority ownership interest in Forfeiture Support Associates J.V. ("FSA") to its sole joint venture partner for a nominal amount. As a result of the sale and amendment to the joint venture operating agreement of FSA, we no longer control the joint venture and accounts for its retained interest as an equity method investment as of the date of the transaction.

See "Risk Factors" in Part I, Item 1A of this report for additional discussion of our industry and regulatory environment.

**Management of Operating Performance and Reporting**

Our business and program management process is directed by professionals focused on serving our customers by providing high quality services in achieving program requirements. These professionals carefully monitor contract margin performance by constantly evaluating contract risks and opportunities. Throughout each contract's life cycle, program managers review performance and update contract performance estimates to reflect their understanding of the best information available.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

The primary financial measures used to evaluate our consolidated results of operations include revenues, operating income, adjusted operating income<sup>(1)</sup>, adjusted EBITDA<sup>(1)</sup>, and operating cash flows. Given that revenues fluctuate on our contract portfolio over time due to contract awards and completions, changes in customer requirements, and increases or decreases in ordering volume of materials, we evaluate significant trends and fluctuations resulting from these factors. Whether performed by our employees or by our subcontractors, we primarily provide services and, as a result, our cost of revenues are predominantly variable. We also analyze our cost mix (labor, subcontractor and materials) in order to understand operating margin because programs with a higher proportion of SAIC labor are generally more profitable. Changes in cost of revenues as a percentage of revenues other than from revenue volume or cost mix are normally driven by fluctuations in shared or corporate costs, or cumulative revenue adjustments due to changes in estimates.

Changes in operating cash flows are described with regard to changes in cash generated through the provision of services, significant drivers of fluctuations in assets or liabilities and the impacts of changes in timing of cash receipts or disbursements.

(1)&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP measure, see "Non-GAAP Measures" section below for additional information about this measure.

**Consolidated Results of Operations**

The following table summarizes our results of operations:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended | Year Ended | Year Ended |
| | **January 30, 2026** | Percent change | January 31, 2025 | Percent change | February 2, 2024 |
| | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| Revenues | $**7262** | *(3) %* | $7479 | *— %* | $7444 |
| Cost of revenues | **6390** | *(3) %* | 6587 | *— %* | 6572 |
| &nbsp;&nbsp;&nbsp;&nbsp;*As a percentage of revenues* | ***88.0*** *%*** |  | *88.1 %* |  | *88.3 %* |
| Selling, general and administrative expenses | **350** | *3 %* | 339 | *(9) %* | 373 |
| (Gain) loss on divestitures, net of transaction costs | **—** | *— %* |  | *(100) %* | (240) |
| Other operating (income) expense | **1** | *(110) %* | (10) | *400 %* | (2) |
| Operating income | **521** | *(7) %* | 563 | *(24) %* | 741 |
| &nbsp;&nbsp;&nbsp;&nbsp;*As a percentage of revenues* | ***7.2*** *%*** |  | *7.5 %* |  | *10.0 %* |
| Provision for income taxes | **(29)** | *(56) %* | (66) | *(54) %* | (143) |
| Net income | $**358** | *(1) %* | $362 | *(24) %* | $477 |

---

*Revenues.* Revenues decreased $217 million from fiscal 2025 to fiscal 2026 primarily due to contract completions and ramp down in volume on existing contracts, including approximately $26 million attributable to the government shutdown, partially offset by new contracts. Revenues attributed to SilverEdge for the year ended January 30, 2026 were $27 million. Adjusting for the acquisition of SilverEdge, revenues contracted by approximately 3.3%.

*Cost of Revenues.* Cost of revenues decreased $197 million from fiscal 2025 to fiscal 2026 primarily due to contract completions and ramp down in volume on existing contracts, partially offset by new contracts.

*Selling, General and Administrative Expenses.* Selling, general and administrative expenses increased $11 million from fiscal 2025 to fiscal 2026 primarily due to executive transition costs, net of recoveries and costs related to the settlement of federal tax audits, partially offset by a recovery of costs from the settlement of a patent infringement matter (see Note 17—Legal Proceedings and Other Commitments and Contingencies for additional information).

*Operating Income.* Operating income as a percentage of revenues decreased from fiscal 2025 to fiscal 2026 primarily due to executive transition costs, net of recoveries, the favorable resolution of the Assault Amphibious Vehicle ("AAV") contract termination in the prior year ($13 million), costs related to the settlement of federal tax audits, and timing and volume mix in our contract portfolio, partially offset by a recovery of costs from the settlement of a patent infringement matter.

*Income Taxes.* Our effective income tax rate for fiscal 2026 was 7.5%, compared to 15.5% for fiscal 2025. This decrease was primarily driven by a $47 million tax benefit related to an IRS audit settlement, pending final

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

administrative approvals, covering fiscal years 2016 through 2019, and adjustments in liabilities for uncertain tax positions related to other open tax years.

On July 4, 2025, the One Big Beautiful Bill Act (the "Act") was enacted, introducing significant changes to U.S. corporate income tax laws. One key provision of the Act permanently reinstates the immediate expensing of U.S. research and development expenditures, resulting in a cash tax benefit in the current year. Based on our interpretation, the Act results in an increase to our income taxes receivable with an offsetting decrease to our deferred tax assets and an increase to our effective tax rate for the year. These impacts are reflected in our current period effective tax rate but may change as we await further interpretive guidance from the IRS.

In December 2021, the Organisation for Economic Co-operation and Development (OECD) enacted a 15% global minimum tax framework ("Pillar Two") which became effective in certain jurisdictions beginning in fiscal 2024. While U.S. adoption is uncertain, several countries where we operate have implemented it, and others are in the process of adopting. We do not anticipate Pillar Two to have a significant impact on our effective tax rate or our consolidated results of operations, financial position, and cash flows.

**Segment and Corporate Results**

The primary financial performance measures we use to manage our reportable segments and monitor results of operations are revenues and adjusted operating income. Adjusted operating income is calculated by taking operating income and excluding depreciation and amortization, acquisition, integration, restructuring, and impairment costs, and any other material non-recurring costs.

The following tables summarize our results of operations by reportable segment:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ***Defense and Intelligence*** | Year Ended | Year Ended | Year Ended | Year Ended | Year Ended |
|  | **January 30, 2026** | Percent change | January 31, 2025 | Percent change | February 2, 2024 |
|  | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| Revenues | $**5581** | *(3) %* | $5726 | *(2) %* | $5817 |
| Adjusted operating income | $**478** | *(6) %* | $509 | *1 %* | $504 |
| &nbsp;&nbsp;&nbsp;&nbsp;As a percentage of revenues | ***8.6*** *%*** |  | *8.9 %* |  | *8.7 %* |

---

*Revenues.* Revenues decreased $145 million from fiscal 2025 to fiscal 2026 primarily due to contract completions and ramp down in volume on existing contracts, partially offset by new contracts. Revenues attributed to SilverEdge for the year ended January 30, 2026 were $27 million.

*Adjusted operating income.* Adjusted operating income as a percentage of revenues decreased from fiscal 2025 to fiscal 2026 primarily due to contract completions and ramp down in volume on existing contracts and the favorable resolution of the AAV contract termination in the prior year ($13 million), partially offset by new contracts.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ***Civilian*** | Year Ended | Year Ended | Year Ended | Year Ended | Year Ended |
|  | **January 30, 2026** | Percent change | January 31, 2025 | Percent change | February 2, 2024 |
|  | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| Revenues | $**1681** | *(4) %* | $1753 | *8 %* | $1627 |
| Adjusted operating income | $**228** | *6 %* | $216 | *5 %* | $206 |
| &nbsp;&nbsp;&nbsp;&nbsp;As a percentage of revenues | ***13.6*** *%*** |  | *12.3 %* |  | *12.7 %* |

---

*Revenues.* Revenues decreased $72 million from fiscal 2025 to fiscal 2026 primarily due to ramp down in volume on existing contracts and contract completions, partially offset by new contracts.

*Adjusted operating income.* Adjusted operating income as a percentage of revenues increased from fiscal 2025 to fiscal 2026 primarily due to improved profitability across the contract portfolio.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ***Corporate*** | Year Ended | Year Ended | Year Ended | Year Ended | Year Ended |
|  | **January 30, 2026** | Percent change | January 31, 2025 | Percent change | February 2, 2024 |
|  | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| Adjusted operating loss | $**(4)** | *(80) %* | $(20) | *(61) %* | $(51) |

---

*Adjusted operating loss.* Adjusted operating loss decreased from fiscal 2025 to fiscal 2026 primarily due to recovery of costs from the settlement of a patent infringement matter and lower other selling, general and administrative expenses.

**Non-GAAP Measures**

Consolidated adjusted operating income, earnings before interest, taxes, depreciation and amortization ("EBITDA"), and adjusted EBITDA are non-GAAP financial measures. While we believe that these non-GAAP financial measures are also useful for management and investors in evaluating our financial information, they should be considered as supplemental in nature and not as a substitute for financial information prepared in accordance with GAAP. Reconciliations, definitions, and how we believe these measures are useful to management and investors are provided below. Other companies may define similar measures differently.

*Adjusted operating income.* Adjusted operating income is a performance measure that primarily excludes the impact of non-recurring transactions and activities that we do not consider to be indicative of our ongoing operating performance. Adjusted operating income is calculated by taking operating income and excluding depreciation and amortization, acquisition, integration, restructuring, and impairment costs, and any other material non-recurring costs. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, reorganizations, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards. Depreciation of property, plant, and equipment relates to property, plant, and equipment specifically identifiable for each segment and Corporate. Adjusted operating income also excludes amortization of intangible assets because we do not have a history of significant acquisition activity, and therefore consider acquisitions to be a non-recurring activity, and the amount of an acquisition's purchase price allocated to intangible assets and the related amortization term are unique to each acquisition. Executive transition costs, net of recoveries, represent costs associated with the departure of our CEO and other executives in the third quarter of the fiscal year 2026, net of the portion recovered through our indirect rates in accordance with Cost Accounting Standards. Costs related to the settlement of federal tax audits represent costs related to the IRS audit settlement for fiscal years 2016 through 2019. The (Gain) loss on divestitures, net of transaction costs includes gains associated with the deconsolidation of FSA and the sale of the Supply Chain Business.

We believe that adjusted operating income provides management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding our long-term financial performance.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

Adjusted operating income for the periods presented were calculated as follows:

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30, 2026** | January 31, 2025 | February 2, 2024 |
| | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| **Revenues** | $**7262** | $7479 | $7444 |
| **Operating income** | $**521** | $563 | $741 |
| &nbsp;&nbsp;&nbsp;*Operating income as a percentage of revenues* | ***7.2*** *%*** | *7.5 %* | *10.0 %* |
| Depreciation of property, plant, and equipment | **30** | 25 | 26 |
| Amortization of intangible assets | **119** | 115 | 115 |
| Acquisition, integration, restructuring and impairment costs | **16** | 6 | 24 |
| Depreciation included in restructuring and impairment costs | **(1)** | (1) | (1) |
| Recovery of acquisition, integration, restructuring and impairment costs<sup>(1)</sup> | **(6)** | (3) | (6) |
| Executive transition costs, net of recoveries | **16** |  |  |
| Costs related to the settlement of federal tax audits | **7** |  |  |
| (Gain) loss on divestitures, net of transaction costs | **—** |  | (240) |
| **Adjusted operating income** | $**702** | $705 | $659 |
| &nbsp;&nbsp;*Adjusted operating income as a percentage of revenues* | ***9.7*** *%*** | *9.4 %* | *8.9 %* |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Adjustment reflects the portion of acquisition, integration, restructuring and impairment costs recovered through our indirect rates in accordance with U.S. government Cost Accounting Standards.

*EBITDA and Adjusted EBITDA.* The performance measure EBITDA is calculated by taking net income and excluding interest and loss on sale of receivables, provision for income taxes, and depreciation and amortization. Adjusted EBITDA is a performance measure that excludes the impact of non-recurring transactions and activities that we do not consider to be indicative of our ongoing operating performance. Adjusted EBITDA is calculated by taking EBITDA and excluding acquisition, integration, restructuring and impairment costs, and any other material non-recurring costs. Acquisition, integration, restructuring and impairment costs represent costs incurred related to acquisitions, reorganizations, facilities optimization efforts, and impairments of long-lived assets, along with associated depreciation. Recovery of acquisition, integration, restructuring and impairment costs represents costs recovered through our indirect rates in accordance with Cost Accounting Standards. Executive transition costs, net of recoveries, represent costs associated with the departure of our CEO and other executives in the third quarter of the fiscal year 2026, net of the portion recovered through our indirect rates in accordance with Cost Accounting Standards. Costs related to the settlement of federal tax audits represent costs related to the IRS audit settlement for fiscal years 2016 through 2019. The (Gain) loss on divestitures, net of transaction costs includes gains associated with the deconsolidation of FSA and the sale of the Supply Chain Business.

We believe that EBITDA and adjusted EBITDA provide management and investors with useful information in assessing trends in our ongoing operating performance and may provide greater visibility in understanding the long-term financial performance of our Company.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

EBITDA and adjusted EBITDA for the periods presented were calculated as follows:

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30, 2026** | January 31, 2025 | February 2, 2024 |
| | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| **Revenues** | $**7262** | $7479 | $7444 |
| **Net income** | $**358** | $362 | $477 |
| Interest expense, net and loss on sale of receivables | **140** | 140 | 129 |
| Provision for income taxes | **29** | 66 | 143 |
| Depreciation and amortization | **149** | 140 | 142 |
| **EBITDA** | **676** | 708 | 891 |
| &nbsp;&nbsp;&nbsp;*EBITDA as a percentage of revenues* | ***9.3*** *%*** | *9.5 %* | *12.0 %* |
| Acquisition, integration, restructuring and impairment costs | **16** | 6 | 24 |
| Depreciation included in restructuring and impairment costs | **(1)** | (1) | (1) |
| Recovery of acquisition, integration, restructuring and impairment costs<sup>(1)</sup> | **(6)** | (3) | (6) |
| Executive transition costs, net of recoveries | **16** |  |  |
| Costs related to the settlement of federal tax audits | **7** |  |  |
| (Gain) loss on divestitures, net of transaction costs | **—** |  | (240) |
| **Adjusted EBITDA** | $**708** | $710 | $668 |
| &nbsp;&nbsp;&nbsp;*Adjusted EBITDA as a percentage of revenues* | ***9.7*** *%*** | *9.5 %* | *9.0 %* |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Adjustment reflects the portion of acquisition, integration, restructuring and impairment costs recovered through our indirect rates in accordance with U.S. government Cost Accounting Standards.

Adjusted operating income and adjusted EBITDA as a percentage of revenues increased from fiscal 2025 to fiscal 2026 primarily due to a recovery of costs from the settlement of a patent infringement matter and lower other selling, general and administrative expenses, partially offset by the favorable resolution of the AAV contract termination in the prior year ($13 million), and timing and volume mix in our contract portfolio.

**Other Key Performance Measures**

In addition to the financial measures described above, we believe that bookings and backlog are useful measures for management and investors to evaluate our potential future revenues. We also consider measures such as contract types and cost of revenues mix to be useful for management and investors to evaluate our operating income and performance.

*Net Bookings and Backlog.* Net bookings represent the estimated amount of revenues to be earned in the future from funded and negotiated unfunded contract awards that were received during the period, net of adjustments to estimates on previously awarded contracts. We calculate net bookings as the period's ending backlog plus the period's revenues less the prior period's ending backlog and initial backlog obtained through acquisitions.

Backlog represents the estimated amount of future revenues to be recognized under negotiated contracts as work is performed. We do not include in backlog estimates of revenues to be derived from IDIQ contracts, but rather record backlog and bookings when task orders are awarded on these contracts. Given that much of our revenue is derived from IDIQ contract task orders that renew annually, bookings on these contracts tend to refresh annually as the task orders are renewed. Additionally, we do not include in backlog contract awards that are under protest until the protest is resolved in our favor.

We segregate our backlog into two categories as follows:

&nbsp;&nbsp;&nbsp;&nbsp;• *Funded Backlog.* Funded backlog for contracts with government agencies primarily represents estimated amounts of revenue to be earned in the future from contracts for which funding is appropriated less revenues previously recognized on these contracts. It does not include the unfunded portion of contracts in which funding is incrementally appropriated or authorized on a quarterly or annual basis by the U.S. government and other customers even though the contract may call for performance over a number of years. Funded backlog for contracts with non-government customers represents the estimated value on

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

contracts, which may cover multiple future years, under which we are obligated to perform, less revenues previously recognized on these contracts.

&nbsp;&nbsp;&nbsp;&nbsp;• *Negotiated Unfunded Backlog.* Negotiated unfunded backlog represents estimated amounts of revenue to be earned in the future from negotiated contracts for which funding has not been appropriated or otherwise authorized and from unexercised priced contract options. Negotiated unfunded backlog does not include any estimate of future potential task orders expected to be awarded under IDIQ, GSA Schedules or other master agreement contract vehicles, with the exception of certain IDIQ contracts where task orders are not competitively awarded and separately priced but instead are used as a funding mechanism, and where there is a basis for estimating future revenues and funding on future anticipated task orders.

We expect to recognize revenue from a substantial portion of our funded backlog within the next twelve months. However, the U.S. government can adjust the scope of services of or cancel contracts at any time. Similarly, certain contracts with commercial customers include provisions that allow the customer to cancel prior to contract completion. Most of our contracts have cancellation terms that would permit us to recover all or a portion of our incurred costs and fees (contract profit) for work performed.

The estimated value of our total backlog as of the dates presented was:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **January 30, 2026** | **January 30, 2026** | **January 30, 2026** | January 31, 2025 | January 31, 2025 | January 31, 2025 |
| | Defense and Intelligence | Civilian | Total SAIC | Defense and Intelligence | Civilian | Total SAIC |
| | (in millions) | (in millions) | (in millions) | (in millions) | (in millions) | (in millions) |
| Funded backlog | $**2511** | $**1061** | $**3572** | $2599 | $845 | $3444 |
| Negotiated unfunded backlog | **15869** | **3181** | **19050** | 15341 | 3072 | 18413 |
| Total backlog | $**18380** | $**4242** | $**22622** | $17940 | $3917 | $21857 |

---

We had net bookings worth an estimated $7.8 billion and $6.6 billion during fiscal 2026 and 2025, respectively.

*Contract Types.* Our earnings and profitability may vary materially depending on changes in the proportionate amount of revenues derived from each type of contract. For a discussion of the types of contracts under which we generate revenues, see "Business—Contract Types" in Part I, Item 1 of this report. The following tables summarize revenues by contract type as a percentage of each reportable segment and total SAIC revenues for the periods presented:

---

| | | | |
|:---|:---|:---|:---|
|  | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** |
| | **Defense and Intelligence** | **Civilian** | **Total SAIC** |
| Cost reimbursement | **79%** | **3%** | **62%** |
| Time and materials ("T&M") | **9%** | **67%** | **22%** |
| Firm-fixed price ("FFP") | **12%** | **30%** | **16%** |
| Total | **100%** | **100%** | **100%** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | Year Ended January 31, 2025 | Year Ended January 31, 2025 | Year Ended January 31, 2025 |
| | Defense and Intelligence | Civilian | Total SAIC |
| Cost reimbursement | 79% | 5% | 62% |
| Time and materials ("T&M") | 10% | 62% | 22% |
| Firm-fixed price ("FFP") | 11% | 33% | 16% |
| Total | 100% | 100% | 100% |

---

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

---

| | | | |
|:---|:---|:---|:---|
|  | Year Ended February 2, 2024 | Year Ended February 2, 2024 | Year Ended February 2, 2024 |
| | Defense and Intelligence | Civilian | Total SAIC |
| Cost reimbursement | 76% | 5% | 61% |
| Time and materials ("T&M") | 9% | 60% | 20% |
| Firm-fixed price ("FFP") | 15% | 35% | 19% |
| Total | 100% | 100% | 100% |

---

*Cost of Revenues Mix.* We generate revenues by providing a customized mix of services to our customers. The profit generated from our service contracts is affected by the proportion of cost of revenues incurred from the efforts of our employees (which we refer to below as labor-related cost of revenues), the efforts of our subcontractors and the cost of materials used in the performance of our service obligations under our contracts. Contracts performed with a higher proportion of SAIC labor are generally more profitable. The following tables present cost mix as a percentage of each reportable segment and total SAIC revenues for the periods presented:

---

| | | | |
|:---|:---|:---|:---|
|  | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** |
| | **Defense and Intelligence** | **Civilian** | **Total SAIC** |
| Labor-related cost of revenues<sup>(1)</sup> | **58%** | **58%** | **58%** |
| Subcontractor-related cost of revenues | **28%** | **31%** | **29%** |
| Other materials-related cost of revenues | **14%** | **11%** | **13%** |
| Total | **100%** | **100%** | **100%** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | Year Ended January 31, 2025 | Year Ended January 31, 2025 | Year Ended January 31, 2025 |
| | Defense and Intelligence | Civilian | Total SAIC |
| Labor-related cost of revenues<sup>(1)</sup> | 56% | 56% | 56% |
| Subcontractor-related cost of revenues | 29% | 30% | 29% |
| Other materials-related cost of revenues | 15% | 14% | 15% |
| Total | 100% | 100% | 100% |

---

---

| | | | |
|:---|:---|:---|:---|
|  | Year Ended February 2, 2024 | Year Ended February 2, 2024 | Year Ended February 2, 2024 |
| | Defense and Intelligence | Civilian | Total SAIC |
| Labor-related cost of revenues<sup>(1)</sup> | 54% | 59% | 55% |
| Subcontractor-related cost of revenues | 29% | 35% | 31% |
| Supply chain materials-related cost of revenues | 3% | —% | 2% |
| Other materials-related cost of revenues | 14% | 6% | 12% |
| Total | 100% | 100% | 100% |

---

<sup>(1)</sup> Labor-related cost of revenues includes direct labor on customer contracts, direct fringe, and other direct costs.

**Liquidity and Capital Resources**

As a services provider, our business currently requires minimal infrastructure investment. We expect to fund our ongoing working capital, commitments and any other discretionary investments with cash on hand, future operating cash flows and, if needed, borrowings under our $1.0 billion Revolving Credit Facility and $300 million Master Accounts Receivable Purchase Agreement ("MARPA Facility") (see Note 14—Sale of Receivables to the consolidated financial statements contained within this report for additional information).

We anticipate that our future cash needs will be for working capital, capital expenditures, and contractual and other commitments. We consider various financial measures when we develop and update our capital deployment strategy, which include evaluating cash provided by operating activities, free cash flow and financial leverage.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

Our ability to fund these needs will depend, in part, on our ability to generate cash in the future, which depends on our future financial results. Our future results are subject to general economic, financial, competitive, legislative and regulatory factors that may be outside of our direct control. Although we believe that the financing arrangements in place will permit us to finance our operations on acceptable terms and conditions for at least the next year, our future access to, and the availability of financing on acceptable terms and conditions will be impacted by many factors (including our credit rating, capital market liquidity and overall economic conditions). Therefore, we cannot ensure that such financing will be available to us on acceptable terms or that such financing will be available at all. Nevertheless, we believe that our existing cash on hand, generation of future operating cash flows, and access to bank financing and capital markets will provide adequate resources to meet our short-term liquidity and long-term capital needs.

Borrowings under our Term Loan Facilities and our Revolving Credit Facility ("Credit Facility") incur interest at a variable rate.

During fiscal 2026, we issued unsecured senior notes through a private offering and amended our Credit Facility. See Note 11—Debt Obligations to the consolidated financial statements contained within this report for additional information.

Our Credit Facility contains customary terms and conditions including financial covenants and covenants restricting our ability to merge or consolidate with another entity or undertake other fundamental changes, enter into property sale and leaseback transactions, and incur liens. Our dividends and share repurchases may be limited under certain leverage ratios, and we may be required to make an annual debt prepayment based on our cash flows from operating activities. See Note 11—Debt Obligations to the consolidated financial statements contained within this report for a more complete understanding of our Credit Facility.

We currently maintain credit ratings from major U.S. rating agencies. Failure to maintain acceptable ratings could have an adverse effect on our future cost of capital and any significant increase in the level of our borrowings could negatively impact these ratings.

We may repurchase shares in accordance with established repurchase plans. We retire our common stock upon repurchase with the excess over par value allocated to additional paid-in capital. When repurchases for the period exceed total additional-paid-in-capital, the excess repurchases are recorded as a reduction to retained earnings. We have not made any material purchases of common stock other than in connection with established share repurchase plans.

During fiscal 2026, we repurchased approximately 4.0 million shares of our common stock from the open market under our existing share repurchase plan for approximately $422 million. In December 2024, our Board of Directors authorized the repurchase of up to $1.2 billion of our outstanding common stock under our existing share repurchase plan. As of January 30, 2026, we have repurchased approximately 28.5 million shares of our common stock under the plan for approximately $2.5 billion, which included amounts previously authorized under the plan prior to December 2024.

The following table summarizes our principal contractual commitments as of January 30, 2026:

---

| | | |
|:---|:---|:---|
| | Total | Due in Fiscal 2027 |
| | (in millions) | (in millions) |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt, including current portion | $2501 | $19 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest payments on debt<sup>(1)</sup> | 666 | 135 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease obligations | 277 | 33 |
| &nbsp;&nbsp;&nbsp;&nbsp;Estimated purchase obligations<sup>(2)</sup> | 72 | 50 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other liabilities<sup>(3)</sup> | 90 | 21 |
| Total contractual obligations | $3606 | $258 |

---

(1)Amounts include an estimate of future variable interest payments on the Term Loan Facilities based on scheduled outstanding principal amounts, current applicable margin and projected 1-month and 3-month Term SOFR as of January 30, 2026.

(2)Excludes purchase orders for services or products to be delivered pursuant to U.S. government contracts in which we have full recourse under normal contract termination clauses.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

(3)Other liabilities primarily consist of liabilities associated with deferred compensation plan obligations and liabilities for unrecognized tax benefits. Deferred compensation plan obligations due in fiscal 2027 are based on participants' payment elections on retirement and estimated retirement ages. Liabilities for unrecognized tax benefits due in fiscal 2027 are based on the fiscal year in which the reversals of timing positions are likely to occur. This amount excludes estimated future minimum commitments related to our Defined Benefit Plans (see Note 9—Retirement Plans).

See respective notes to the consolidated financial statements contained within this report for further information about our long-term debt (Note 11—Debt Obligations), lease payment obligations (Note 15—Operating Leases), liabilities for unrecognized tax benefits (Note 10—Income Taxes), and letters of credit and surety bonds (Note 17—Legal Proceedings and Other Commitments and Contingencies).

**Historical Cash Flow Trends**

The following table summarizes our cash flows:

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30, 2026** | January 31, 2025 | February 2, 2024 |
| | (in millions) | (in millions) | (in millions) |
| Net cash provided by operating activities | $**609** | $494 | $396 |
| Net cash (used in) provided by investing activities | **(248)** | (35) | 314 |
| Net cash used in financing activities | **(235)** | (498) | (725) |
| Total increase (decrease) in cash, cash equivalents and restricted cash | $**126** | $(39) | $(15) |

---

*Cash Flows Provided by Operating Activities.* Cash flows provided by operating activities were $609 million for fiscal 2026, which represented an increase of $115 million from fiscal 2025. The increase was primarily due to timing of customer collections, lower cash outflows from the usage of the MARPA Facility, lower cash taxes paid, net of tax refunds received in the current year, and other changes in working capital, partially offset by timing of vendor payments.

*Cash (Used in) Provided by Investing Activities.* Cash used in investing activities increased by $213 million in fiscal 2026 compared to the prior year period primarily due to $203 million of cash paid in the current year for the acquisition of SilverEdge, net of cash acquired and proceeds from the sale of equity method investments in the prior year.

*Cash Used in Financing Activities.* Cash used in financing activities decreased by $263 million in fiscal 2026 compared to the prior year period primarily due to higher proceeds from borrowings, net of principal payments and debt issuance costs, and a decrease in stock repurchases in the current year.

**Commitments and Contingencies**

We are subject to a number of reviews, investigations, claims, lawsuits and other uncertainties related to our business. For a discussion of these items, see Note 17—Legal Proceedings and Other Commitments and Contingencies to the consolidated financial statements contained within this report.

**Critical Accounting Policies and Estimates**

Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which are prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies, as well as the reported amounts of revenues, expenses, gains and losses during the reporting periods. Management evaluates these estimates and assumptions on an ongoing basis. Our estimates and assumptions have been prepared on the basis of the most current reasonably available information and, in some cases, are our basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Estimates and assumptions may change in the future as more current information is available.

Management believes that our critical accounting policies and estimates are those that are both material to the presentation of our financial condition and results of operations and require management's most difficult, subjective

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

and complex judgments. Typically, the circumstances that make these judgments difficult, subjective and complex have to do with making estimates about the effect of matters that are inherently uncertain. These policies are described below.

*Revenue Recognition.* We generate our revenues primarily from long-term contracts in which we provide technical, engineering and mission and enterprise IT services directly for the U.S. government and as a subcontractor with other contractors engaged in work for the U.S. government. We evaluate the nature of the contract and the services provided when determining the accounting method utilized for each contract. We recognize a significant portion of our revenues using a cost input measure of progress that requires us to rely on the skill and expertise of our engineers, program managers and business management professionals in the many areas of cost estimation. These estimates of costs can span several years and take into account many factors including the availability, productivity and cost of labor, potential delays in our performance and the level of future indirect cost allocations.

Many of our contracts include forms of variable consideration such as reimbursable costs, award and incentive fees, usage-based pricing, service-level penalties, performance bonuses, and other provisions that can either increase or decrease the transaction price. Variable amounts are generally determined upon our achievement of certain performance metrics, program milestones or cost targets and may be based upon customer discretion. At contract inception, we estimate the transaction price and may include variable consideration in the transaction price only to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. When developing these estimates, we consider the customer, contract terms, the complexity of the work and related risks, the extent of customer discretion, historical experience and the potential of a significant reversal of revenue.

*Changes in Estimates on Contracts.* Changes in estimates of revenues, cost of revenues or profits related to performance obligations satisfied over time are recognized in operating income in the period in which such changes are made for the inception-to-date effect of the changes. Changes in these estimates can occur routinely over the performance period for a variety of reasons, which include: changes in scope; changes in cost estimates due to unanticipated cost growth or reassessments of risks impacting costs; changes in the estimated transaction price, such as variable amounts for incentive or award fees; and performance being better or worse than previously estimated.

A significant portion of our contracts recognize revenue using a cost input measure (cost-to-cost), which requires estimates of total costs at completion. Estimating costs at completion is complex due to the nature of the services being performed and the length of certain contracts. Contract costs generally include direct costs, such as labor, subcontract costs and materials, and indirect costs identifiable with or allocable to a specific contract. Management must make assumptions regarding the complexity of the work to be performed, the schedule and associated tasks, labor productivity and availability, increases in wages and prices of materials, execution by our subcontractors, overhead cost rates, and other variables. For contracts using a cost input measure, when total expected contract costs exceed total estimated contract revenues, we recognize the total estimated loss in the quarter identified. Total estimated losses are inclusive of any unexercised options that are probable of award, only if they increase the amount of the loss. Aggregate net changes in contract estimates increased operating income by $1 million and $15 million for fiscal 2026 and 2025, respectively. Aggregate net changes in contract estimates were immaterial in fiscal 2024. For additional information related to changes in estimates on contracts, including gross favorable and unfavorable adjustments as well as the impact to earnings per share, see Note 3—Revenues to the consolidated financial statements contained within this report.

*Business Combinations.* We record substantially all assets acquired and liabilities assumed in a business combination at fair value as of the acquisition date. The excess amount of the aggregated purchase consideration paid over the fair value of the net of assets acquired and liabilities assumed is recorded as goodwill.

The fair values of assets acquired and liabilities assumed are determined using either an income, cost or market approach. Each of these valuation methods requires significant judgment, including analysis of historical performance and estimates of future performance. Estimates can be affected by contract performance and other factors that may cause final amounts to differ materially from original estimates.

Under the income approach, fair value is based on the present value of future cash flows to be generated over the remaining economic life of an asset or liability being measured. This method includes estimates for projections of revenues and expenses, royalty rates, tax rates, contributory asset charges, discount rates, and tax amortization

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

benefits. Under the cost approach, fair value is measured by determining the replacement cost of an asset. Under the market approach, the fair value reflects the price and other relevant information of market transactions for comparable assets, liabilities or groups of assets and liabilities. Valuation techniques consistent with the market approach often use market multiples derived from a set of comparables.

The valuations are based on information that existed as of the acquisition date. During the measurement period that shall not exceed one year from the acquisition date, we may adjust provisional amounts recorded for assets acquired and liabilities assumed to reflect new information that we have subsequently obtained regarding facts and circumstances that existed as of the acquisition date.

*Goodwill and Intangible Assets.* Goodwill is recorded as the difference between the aggregate consideration paid for an acquisition and the fair value of the assets acquired and liabilities assumed. Goodwill is not amortized, but rather tested for potential impairment annually at the beginning of the fourth quarter, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.

The goodwill impairment test is performed at the reporting unit level. In our qualitative assessment, an evaluation is performed to determine whether it is more likely than not that an impairment exists based on qualitative factors. Qualitative factors include macroeconomic, industry and market conditions, cost factors, overall financial performance, relevant entity-specific events, factors affecting the reporting unit, and share price.

We may additionally perform a quantitative assessment in which the estimated fair value of each reporting unit is compared to its respective carrying value including goodwill. If the fair value is less than the carrying value, the amount of impairment expense is equal to the difference between the reporting unit's fair value and the reporting unit's carrying value.

Determining the fair value of each reporting unit involves judgment and the use of estimates and assumptions. We estimate the fair value of our reporting units using either a market approach, income approach, or a combination of both. When performing a quantitative assessment for our annual impairment analysis, we reconcile the aggregate fair value of all of our reporting units to our market capitalization as of the measurement date.

Under the income approach, we estimate the fair value of a reporting unit using a multi-year discounted cash flow model that involves assumptions about projected future revenue growth, operating margins, income tax rates, capital expenditures, discount rate and terminal value. The discount rate is an estimate of the cost of capital that a market participant would expect for the respective reporting unit. The terminal value represents the present value in the last year of the projection period of all subsequent cash flows into perpetuity.

Under the market approach, we estimate the fair value of a reporting unit based on multiples of earnings derived from observable market data of comparable public companies. We evaluate companies within our industry that have operations with observable and comparable economic characteristics and are similar in nature, scope and size to the reporting unit being compared. We analyze historical acquisitions in our industry to estimate a control premium that we incorporate into the fair value estimate of a reporting unit under the market approach.

Determining the carrying value of each reporting unit requires judgment and involves the assignment of assets and liabilities to the reporting units based on a systematic and rational allocation methodology. Certain assets and liabilities may be specifically identified and assigned to a reporting unit based on the information contained within our financial systems; whereas, other assets and liabilities may be allocated using measurable relationships or other basis for allocation.

As a result of the internal reorganization on February 3, 2024, we reallocated goodwill to the five new goodwill reporting units. We performed a goodwill impairment test immediately before and after the reorganization, both of which resulted in no impairment. For the goodwill impairment test immediately after the reorganization, we performed a quantitative assessment of our goodwill as of February 3, 2024 for the five new goodwill reporting units. We estimated the fair value of each reporting unit using a 50:50 weighting of fair values derived from an income approach and market approach.

During the fourth quarter of fiscal 2026, we completed our annual goodwill impairment testing using a qualitative assessment and determined that it was more likely than not that an impairment did not exist and that a quantitative analysis was not necessary.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

Intangible assets with finite lives are amortized using the method that best reflects how their economic benefits are utilized or, if a pattern of economic benefits cannot be reliably determined, on a straight-line basis over their estimated useful lives. Intangible assets with finite lives are assessed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable.

*Income Taxes.* Our income tax expense, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits reflect our best estimate of current and future taxes to be paid and includes judgments related to matters for which ultimate resolution may not become known until the final resolution of an examination by taxing authorities or the statute of limitations lapses.

We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making this determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent operating results. If we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount or would no longer be able to realize our deferred income tax assets in the future as currently recorded, we would make an adjustment to the valuation allowance, which would either decrease or increase, respectively, the provision for income taxes.

**Recently Issued But Not Yet Adopted Accounting Pronouncements**

For information on recently issued but not yet adopted accounting pronouncements, see Note 1—Business Overview and Summary of Significant Accounting Policies to the consolidated financial statements contained within this report.

**Item 7A. *Quantitative and Qualitative Disclosures About Market Risk***

We are exposed to certain market risks in the normal course of business. The following information about our market sensitive financial instruments contains forward-looking statements.

**Foreign Currency Risk**

Most of our contracts are paid in U.S. dollars and our cost to perform on these contracts are generally paid in U.S. dollars. Since the substantial majority of our business is conducted in U.S. dollars, a 10% change in any foreign currency exchange rates would not have a material impact to our financial condition or results of operations.

**Interest Rate Risk**

Debt obligations. Our financial risk management objective is to reduce the negative impact to earnings from changes in interest rates, which we may manage through operational means or the use of financial instruments, such as interest rate swaps. As of January 30, 2026, we have approximately $1.6 billion of variable rate debt. The fair value of our outstanding long-term debt obligations approximates their carrying value. We regularly evaluate our outstanding debt agreements to meet our risk management objective. A hypothetical 50 basis points ("bps") change to interest rates would have a net impact of $8 million on our results of operations and cash flows. For additional information related to our debt agreements, see Note 11—Debt Obligations to the consolidated financial statements contained in this report.

*Cash equivalents.* A 10% unfavorable interest rate movement for interest earned on our cash and cash equivalents would not materially impact the value of our cash holdings and would have a negligible impact on interest income at current market interest rates.

**Inflation Risk**

For each of the most recent three fiscal years ended January 30, 2026, inflation has not had a significant impact on our revenues or costs. Approximately 62% of our revenues for fiscal 2026 were derived from cost-reimbursement type contracts, which have limited inflation risk because our contracts generally entail the provision of labor on a reimbursable basis, and, when materials are acquired, they provide for billing to the customer during the period in which the materials were received. Bids for longer-term FFP and T&M contracts typically include sufficient provisions for labor and other cost escalations to cover anticipated cost increases over the period of performance. As a result, if we were to experience significant levels of inflation, our revenues and costs for cost-type contracts would generally both increase commensurate with inflation and operating income as a percentage of total revenues

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

would not be significantly affected. Operating income as a percentage of total revenues would not be significantly affected for longer-term FFP and T&M contracts to the extent that bid contract cost escalations are sufficient to cover heightened inflation levels.

**Item 8. *Financial Statements and Supplementary Data***

See our consolidated financial statements attached hereto and listed on the index found on page <u>[F-1](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u> of this report.

**Item 9. *Changes in and Disagreements With Accountants on Accounting and Financial Disclosure***

No information is required in response to this item.

**Item 9A. *Controls and Procedures***

**Evaluation of Disclosure Controls and Procedures**

Our management, with the participation of our principal executive officer (our Chief Executive Officer) and principal financial officer (our Chief Financial Officer), has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of January 30, 2026, and our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated to our management, including our principal executive officer and our principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

**Changes in Internal Control Over Financial Reporting**

There have been no changes in our internal control over financial reporting during the fourth quarter of fiscal 2026 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**Management's Report On Internal Control Over Financial Reporting**

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP.

Internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, completely, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with GAAP; (iii) provide reasonable assurance that our receipts and expenditures are made only in accordance with the authorization of our management and directors; and (iv) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on the consolidated financial statements. Internal control over financial reporting includes the controls themselves, monitoring and internal auditing practices and actions taken to correct deficiencies as identified.

Our management, with the participation of the Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our internal control over financial reporting as of January 30, 2026 based on the framework established in the 2013 Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Our management has assessed in its evaluation the effectiveness of our internal control over financial reporting as of January 30, 2026 and has concluded that our internal control over financial reporting was effective.

Ernst & Young LLP, an independent registered public accounting firm, audited our consolidated financial statements included in this report and our internal control over financial reporting, and the firm's report on our internal control over financial reporting are set forth below this report.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

Although our management, including the Chief Executive Officer and the Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting, because of inherent limitations, our management does not expect that our internal controls over financial reporting will prevent or detect all errors and all fraud. Also, projections of any evaluation of effectiveness in such assessment to future periods are subject to the risk that controls may be inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Stockholders and the Board of Directors of

Science Applications International Corporation

**Opinion on Internal Control Over Financial Reporting** 

We have audited Science Applications International Corporation's internal control over financial reporting as of January 30, 2026, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Science Applications International Corporation (the Company) maintained, in all material respects, effective internal control over financial reporting as of January 30, 2026, based on the COSO criteria.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of January 30, 2026 and January 31, 2025, the related consolidated statements of income, comprehensive income, equity and cash flows for each of the three years in the period ended January 30, 2026, and the related notes and our report dated March 16, 2026 expressed an unqualified opinion thereon.

**Basis for Opinion**

The Company's management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management's Report On Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company's internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.

Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

**Definition and Limitations of Internal Control Over Financial Reporting** 

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ Ernst & Young LLP

Tysons, Virginia

March 16, 2026

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**Item 9B. *Other Information***

During the three months ended January 30, 2026, no director or officer of the Company adopted, modified or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," as such terms are defined in Item 408 of Regulation S-K.

**Item 9C. *Disclosure Regarding Foreign Jurisdictions that Prevent Inspections***

No information is required in response to this item.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**Part III**

**Item 10. *Directors, Executive Officers and Corporate Governance***

Our executive officers as of March 16, 2026, are listed below, along with their ages on that date, positions and offices held and business experience during at least the past five years. All such persons have been elected to serve until their successors are elected and qualified or until their earlier resignation or removal.

---

| | | |
|:---|:---|:---|
| Name of officer | Age | Position(s) with the Company and prior business experience |
| James C. Reagan | 67 | Chief Executive Officer since February 2026. Mr. Reagan previously served as Interim Chief Executive Officer for the Company from October 2025 to February 2026 and served as Executive Vice President and Chief Financial Officer of Leidos Holdings, Inc. from July 2015 until July 2021. Prior to joining Leidos, Mr. Reagan served as Chief Financial Officer for several organizations including Vencore, Inc., a defense contractor serving the Intelligence Community and Department of Defense, and at PAE, Inc., a defense and government services engineering contractor. Mr. Reagan was also Chief Financial Officer of Aspect Communications and held several senior roles at MCI Telecommunications, Nextel and AMS. Mr. Reagan has served as an independent member of the Board from January 2023 to October 2025, and has continued to serve on the Board since October 2025 in an Employee Director capacity. |
| Prabu Natarajan | 55 | Executive Vice President and Chief Financial Officer since January 2021. Prior to joining SAIC, Mr. Natarajan was Vice President of Financial Planning and Merger and Acquisition for Northrop Grumman from January 2016 to December 2020. Mr. Natarajan joined Northrop Grumman in August 2011 and was also Vice President of Business Management and CFO for the Information Systems Sector from August 2014 to January 2016 and Vice President, Treasurer and Taxes from August 2011 to August 2014. Mr. Natarajan has held positions at The AES Corporation and PricewaterhouseCoopers LLP. |
| Hilary L. Hageman | 57 | Executive Vice President, General Counsel and Corporate Secretary since July 2022. Ms. Hageman previously served as Senior Vice President and Deputy General Counsel at SAIC until 2019 when she became the General Counsel and Corporate Secretary of Cubic Corporation. Immediately prior to her return to SAIC, Ms. Hageman served as Executive Vice President, General Counsel and Corporate Secretary for a public satellite company primarily supporting the defense and aerospace industries. Ms. Hageman has also held other senior legal roles at CACI and at the U.S. Department of War. |
| Kathleen T. McCarthy | 61 | Executive Vice President and Chief Human Resources Officer since May 2025. Prior to joining SAIC, Ms. McCarthy served as Chief Human Resources Officer for the Defense & Systems and GE Aviation businesses of GE Aerospace from February 2021 to May 2025. Prior to that, she was Chief Human Resources Officer of GE Digital from January 2019 to February 2021. Ms. McCarthy also held HR leadership roles across American Express and Thomson Reuters. |
| Srinivas Attili | 48 | Executive Vice President of the Civilian Business Group since May 2024. Mr. Attili joined SAIC from McKinsey & Company, where he served as a partner from March 2021 to May 2024 and led digital transformation initiatives for healthcare organizations. Prior to McKinsey, Mr. Attili was a principal at Deloitte from July 2017 to February 2021, was at IBM for over 14 years from October 2002 to June 2017, and served as a consultant at PwC from November 2000 to October 2002. |
| Vincent P. DiFronzo | 67 | Executive Vice President of the Air Force, Space and Intelligence Business Group since January 2026 and Executive Vice President of the Air Force and Combatant Commands Business Group from February 2024 until January 2026. Previously, Mr. DiFronzo served as Vice President and Senior Vice President of Operations, Air Force, Space Force, and Combatant Commands from March 2020 until October 2020 and as an SAIC Vice President from June 2015 until March 2020. Mr. DiFronzo served as Assistant Vice President at Alion Science and Technology Corporation from December 2013 to May 2015 and as Senior Program Manager at Scientific Research Corporation from November 2008 through December 2010. |

---

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

---

| | | |
|:---|:---|:---|
| Barbara M. Supplee | 56 | Executive Vice President of the Army Navy Business Group since January 2026, Executive Vice President of the Navy Business Group from February 2024 until January 2026, and SAIC Senior Vice President from March 2023 until February 2024. Before joining SAIC, Ms. Supplee served as Vice President and General Manager for Navy and Marine Corps at GDIT from November 2022 until March 2023. She previously held several positions at CACI International, including Senior Vice President, August 2021 until November 2022; Vice President of Business Development, February 2021 until August 2021; and Vice President, April 2019 until February 2021. Before joining GDIT, she was Senior Capture Director and Executive Director at BAE Systems from June 2014 until February 2021. |

---

For additional information required by Item 10 with respect to executive officers and directors, including audit committee and audit committee financial experts, procedures by which stockholders may recommend nominees to the Board of Directors, and compliance with Section 16(a) of the Securities Exchange Act of 1934, see the information set forth under the captions "Proposal 1—Election of Directors," "Corporate Governance" and "Other Information" in the 2026 Definitive Proxy Statement, which information is incorporated by reference into this report.

We have adopted a Code of Conduct, which describes our standards for protecting SAIC and customer assets, fostering a safe and healthy work environment, dealing fairly with customers and others, conducting business properly, reporting misconduct and protecting employees from retaliation. This Code applies to all directors, executive officers and employees and forms the foundation of our corporate policies and procedures designed to promote ethical behavior in all aspects of our business. To obtain copies of the Code of Conduct, visit our website at *investors.saic.com* and click on the links titled "Governance" then "Governance Documents" and then "Code of Conduct." We intend to post on our website any material changes to or waivers from our Code of Conduct. The information on our website is not incorporated by reference into and is not a part of this report.

We have adopted an insider trading policy that governs the purchase, sale, and/or other transactions of our securities by our directors, officers and employees. A copy of our insider trading policy is filed as Exhibit 19 to this report. We comply with the federal securities laws and the applicable exchange listing requirements, including those that govern trading by a company in its own securities.

**Item 11. *Executive Compensation***

For information required by Item 11 with respect to executive compensation, see the information set forth under the captions "Compensation Discussion and Analysis," "Executive Compensation" and "Corporate Governance" in the 2026 Definitive Proxy Statement, which information is incorporated by reference into this report.

For information required by Item 11 with respect to compensation committee interlocks, insider participation, and the compensation committee report, see the information set forth under the captions "Corporate Governance" and "Compensation Discussion and Analysis" in the 2026 Definitive Proxy Statement, which information is incorporated by reference into this report.

**Item 12. *Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters***

For information required by Item 12 with respect to the security ownership of certain beneficial owners and management, see the information set forth under the caption "Other Information" in the 2026 Definitive Proxy Statement, which information is incorporated by reference into this report.

We currently maintain three shareholder-approved equity compensation plans that issue stock-based awards including the 2023 Equity Incentive Plan ("2023 EIP"), the Management Stock Compensation Plan, and the Amended and Restated 2013 Employee Stock Purchase Plan ("ESPP"). For summaries of these plans, see Note 8—Stock-Based Compensation to the consolidated financial statements contained within this report.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

The following table provides the number of shares of our common stock to be issued, the weighted-average exercise price of the outstanding stock options and the number of shares remaining for future award grants as of January 30, 2026:

---

| | | | |
|:---|:---|:---|:---|
| Equity Compensation Plan Information | Equity Compensation Plan Information | Equity Compensation Plan Information | Equity Compensation Plan Information |
| Plan Category | Number of securities to be issued upon exercise of outstanding options, warrants and rights<sup>(1)</sup> | Weighted-average exercise price of outstanding<br>options, warrants<br>and rights<sup>(2)</sup> | Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))<sup>(3)</sup> |
|  | (a) | (b) | (c) |
| Equity compensation plans approved by security holders | 1500615 | $— | 3017798 |
| Equity compensation plans not approved by security holders |  |  |  |
| Total | 1500615 | $— | 3017798 |

---

(1)This amount includes 41,675 stock options outstanding and 203,748 shares subject to other stock-based awards previously granted but not yet issued under the 2013 Equity Incentive Plan ("2013 EIP"), and 1,255,192 shares issuable for other stock-based awards under the 2023 EIP. This amount does not include shares to be issued pursuant to purchase rights under the ESPP. Performance share awards under the 2013 EIP and 2023 EIP assume the maximum payout at the end of the three-year performance period.

(2)Does not include shares to be issued for stock-based awards, other than stock options, which will not require any payment upon issuance of those shares.

(3)Includes 1,514,796 shares of our common stock available for issuance under the ESPP and 1,503,002 shares under the 2023 EIP. On June 7, 2023, the Company's stockholders approved an amended and restated ESPP which limits the total number of shares reserved for issuance to 2.0 million and extends the ESPP expiration date from September 26, 2023 to the earlier of its termination by the Board or the issuance of all shares available for issuance. On June 7, 2023, the Company's stockholders approved the 2023 EIP. The 2023 EIP authorized 2.2 million new shares of the Company's common stock to be issued as various types of stock-based compensation and cash awards. After June 7, 2023, no new awards may be issued under the 2013 EIP and any awards that subsequently expire, are forfeited or canceled, are settled in cash, or are used to cover recipient tax obligations, will become available for issuance under the 2023 Plan. Awards previously issued and outstanding under the 2013 EIP will continue to remain outstanding and be subject to the terms of the 2013 EIP. We expect that the number of shares actually issued under the 2023 EIP will be significantly less than the number of total awards outstanding under the plan because (a) a net option exercise results in a smaller portion of the number of award shares being issued when a participant uses award shares, rather than cash, to pay the exercise price, which historically most participants have elected to do, (b) most participants historically have elected to let the Company retain award shares to pay for taxes due on the exercise of options and all participants are required to use award shares to pay for taxes upon the vesting of restricted stock or restricted stock units, (c) some participants may terminate employment with the Company before the vesting of awards resulting in awards being forfeited and (d) some participants may not exercise stock options before the expiration date for a variety of reasons, including if the exercise price exceeds the then current market price of shares.

**Item 13. *Certain Relationships and Related Transactions, and Director Independence***

For information required by Item 13 with respect to certain relationships and related transactions and the independence of directors and nominees, see the information set forth under the caption "Corporate Governance" in the 2026 Definitive Proxy Statement, which information is incorporated by reference into this report.

**Item 14. *Principal Accountant Fees and Services***

For information required by Item 14 with respect to principal accountant fees and services, see the information set forth under the caption "Audit Matters" in the 2026 Definitive Proxy Statement, which information is incorporated by reference into this report.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**Part IV**

**Item 15. *Exhibits and Financial Statement Schedules***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Documents filed as part of the report:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. *Financial Statements*

Our consolidated financial statements are attached hereto and listed on the Index to Consolidated Financial Statements set forth on page F-1 of this report.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. *Financial Statement Schedules*

Financial statement schedules are omitted because they are not applicable or the required information is shown in our consolidated financial statements or the notes thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. *Exhibits*

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description of Exhibit** |
| <u>[2.1](https://www.sec.gov/Archives/edgar/data/1571123/000119312513387316/d605504dex21.htm)</u> | <u>[Distribution Agreement dated September 25, 2013, between the Company (formerly SAIC Gemini, Inc.) and Leidos Holdings, Inc. (formerly SAIC, Inc.). Incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K as filed with the SEC on October 1, 2013.](https://www.sec.gov/Archives/edgar/data/1571123/000119312513387316/d605504dex21.htm)</u> |
| <u>[2.2](https://www.sec.gov/Archives/edgar/data/1571123/000157112318000036/saic-ex21_20180909.htm)</u> | <u>[Agreement and Plan of Merger, dated September 9, 2018, by and among Science Applications International Corporation, Inc., a Delaware corporation, Engility, a Delaware corporation, and Raptors Merger Sub, Inc., a Delaware corporation. (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the Securities and Exchange Commission upon request any omitted schedule or exhibit to the Agreement and Plan of Merger.) Incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K as filed with the SEC on September 10, 2018.](https://www.sec.gov/Archives/edgar/data/1571123/000157112318000036/saic-ex21_20180909.htm)</u> |
| <u>[2.3](https://www.sec.gov/Archives/edgar/data/1571123/000114036120002437/ex2_1.htm)</u> | <u>[Asset Purchase Agreement, dated February 5, 2020, by and among Science Applications International Corporation, Inc., a Delaware corporation and Unisys Corporation, a Delaware corporation. Incorporated by reference to Exhibit 2.1 to the Company's Current Report on Form 8-K as filed with the SEC on February 6, 2020.](https://www.sec.gov/Archives/edgar/data/1571123/000114036120002437/ex2_1.htm)</u> |
| <u>[3.1](https://www.sec.gov/Archives/edgar/data/1571123/000119312513387316/d605504dex31.htm)</u> | <u>[Amended and Restated Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K as filed with the SEC on October 1, 2013.](https://www.sec.gov/Archives/edgar/data/1571123/000119312513387316/d605504dex31.htm)</u> |
| <u>[3.2](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000128/saic8k09052024-exhibit31.htm)</u> | <u>[Amended and Restated Bylaws. Incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K as filed with the SEC on September 5, 2024.](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000128/saic8k09052024-exhibit31.htm)</u> |
| <u>[4.1](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000176/saic8k09252025exhibit41.htm)</u> | <u>[Indenture, dated September 25, 2025, by and among Science Applications International Corporation, the guarantors party thereto and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the SEC on September 25, 2025.](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000176/saic8k09252025exhibit41.htm)</u> |
| <u>[4.2](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000045/saicexhibit410202202410k.htm)</u> | <u>[Description of Securities. Incorporated by reference to Exhibit 4.1 to the Company's Annual Report on Form 10-K as filed with the SEC on March 20, 2024.](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000045/saicexhibit410202202410k.htm)</u> |
| <u>[4.3](https://www.sec.gov/Archives/edgar/data/1571123/000119312520073944/d859105dex41.htm)</u> | <u>[Indenture, dated March 13, 2020, by and among Science Applications International Corporation, the guarantors party thereto and U.S. Bank National Association, as trustee. Incorporated by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K filed with the SEC on March 16, 2020.](https://www.sec.gov/Archives/edgar/data/1571123/000119312520073944/d859105dex41.htm)</u> |
| <u>[10.1\*](saicfy2610-kex101.htm)</u> | <u>[Offer Letter, dated](saicfy2610-kex101.htm)[February](saicfy2610-kex101.htm)[18](saicfy2610-kex101.htm)[, 202](saicfy2610-kex101.htm)[6](saicfy2610-kex101.htm)[.](saicfy2610-kex101.htm)</u> |
| <u>[10.2\*](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)</u> | <u>[Offer Letter](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)[, date](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)[d](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)[October 23, 2025.](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)[Incorporated by reference to Exhibit 10.](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)[3](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)[to the Company's Current Report on Form](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)[10](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)[-](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)[Q](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)[filed with the SEC on](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)[December](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)[5](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)[, 2025.](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex103.htm)</u> |
| <u>[10.](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex102.htm)[3](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex102.htm)[\*](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex102.htm)</u> | <u>SAIC Executive Severance, Change in Control and Retirement Policy, effective September 5, 2023. [Incorporated by reference to Exhibit 10.](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex102.htm)[2](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex102.htm)[to the Company's Current Report on Form](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex102.htm)[10](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex102.htm)[-](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex102.htm)[Q](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex102.htm)[filed with the SEC on](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex102.htm)[December](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex102.htm)[5](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex102.htm)[, 2025.](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000189/saic1031202510-qex102.htm)</u> |
| <u>[10.4](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000178/saic8k09302025exhibit101.htm)</u> | <u>[Eighth Amendment to the Third Amended and Restated Credit Agreement, dated September 30, 2025, by and among SAIC, Citibank N.A., as administrative agent and collateral agent, and certain other lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on October 1, 2025.](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000178/saic8k09302025exhibit101.htm)</u> |
| <u>[10.5](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000140/saic8k10182024exhibit101.htm)</u> | <u>[Seventh Amendment to the Third Amended and Restated Credit Agreement, dated October 18, 2024, by and among SAIC, Citibank N.A., as administrative agent and collateral agent, and certain other lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on October 22, 2024.](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000140/saic8k10182024exhibit101.htm)</u> |
| <u>[10.6](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000022/saic8k02082024exhibit101.htm)</u> | <u>[Sixth Amendment to the Third Amended and Restated Credit Agreement, dated February 8, 2024, by and among SAIC, Citibank N.A., as administrative agent and collateral agent, and certain other lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on February 12, 2024.](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000022/saic8k02082024exhibit101.htm)</u> |
| <u>[10.7](https://www.sec.gov/Archives/edgar/data/1571123/000157112322000049/exhibit10120220630.htm)</u> | <u>[Fifth Amendment to the Third Amended and Restated Credit Agreement, dated June 30, 2022, by and among SAIC, Citibank N.A., as administrative agent and collateral agent, and certain other lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on June 30, 2022.](https://www.sec.gov/Archives/edgar/data/1571123/000157112322000049/exhibit10120220630.htm)</u> |

---

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description of Exhibit** |
| <u>[10.8](https://www.sec.gov/Archives/edgar/data/1571123/000157112321000032/exhibit1011.htm)</u> | <u>[Fourth Amendment to the Third Amended and Restated Credit Agreement, dated July 2, 2021, by](https://www.sec.gov/Archives/edgar/data/1571123/000157112321000032/exhibit1011.htm)[and among SAIC, Citibank N.A., as administrative agent and collateral agent, and certain other lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current](https://www.sec.gov/Archives/edgar/data/1571123/000157112321000032/exhibit1011.htm)[Report on Form 8-K filed with the SEC on July 7, 2021.](https://www.sec.gov/Archives/edgar/data/1571123/000157112321000032/exhibit1011.htm)</u> |
| <u>[10.9](https://www.sec.gov/Archives/edgar/data/1571123/000157112321000008/exhibit101.htm)</u> | <u>[Third Amendment to the Third Amended and Restated Credit Agreement, dated March 1, 2021, by and among SAIC, Citibank N.A., as administrative agent and collateral agent, and certain other lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on March 5, 2021.](https://www.sec.gov/Archives/edgar/data/1571123/000157112321000008/exhibit101.htm)</u> |
| <u>[10.10](https://www.sec.gov/Archives/edgar/data/1571123/000119312520073944/d859105dex101.htm)</u> | <u>[Second Amendment to the Third Amended and Restated Credit Agreement, dated March 13, 2020, by and among Science Applications International Corporation, Citibank, N.A., as administrative agent and collateral agent, and certain other agents and lenders party thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on March 16, 2020.](https://www.sec.gov/Archives/edgar/data/1571123/000119312520073944/d859105dex101.htm)</u> |
| <u>[10.11](https://www.sec.gov/Archives/edgar/data/1571123/000157112320000006/exhibit101.htm)</u> | <u>[First Amendment to the Third Amended and Restated Credit Agreement, dated February 19, 2020, by and among SAIC, Citibank, as administrative agent and collateral agent, and certain other agents and lenders party thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on February 24, 2020.](https://www.sec.gov/Archives/edgar/data/1571123/000157112320000006/exhibit101.htm)</u> |
| <u>[10.12](https://www.sec.gov/Archives/edgar/data/1571123/000157112318000063/exhibit101.htm)</u> | <u>[Third Amended and Restated Credit Agreement, dated October 31, 2018, by and among SAIC, Citibank, as administrative agent and collateral agent, and certain other agents and lenders party thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K as filed with the SEC on November 5, 2018.](https://www.sec.gov/Archives/edgar/data/1571123/000157112318000063/exhibit101.htm)</u> |
| <u>[10.13](https://www.sec.gov/Archives/edgar/data/1571123/000157112318000004/exhibit101.htm)</u> | <u>[Second Amendment to the Second Amended and Restated Credit Agreement, dated February 7, 2018 by and among the Company, Citibank N.A. as administrative agent and collateral agent, and certain other lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K as filed with the SEC on February 9, 2018.](https://www.sec.gov/Archives/edgar/data/1571123/000157112318000004/exhibit101.htm)</u> |
| <u>[10.14](https://www.sec.gov/Archives/edgar/data/1571123/000156459016024727/saic-ex101_7.htm)</u> | <u>[First Amendment to the Second Amended and Restated Credit Agreement, dated August 23, 2016 by and among the Company, Citibank N.A. as administrative agent and collateral agent, and certain other lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K as filed with the SEC on August 25, 2016.](https://www.sec.gov/Archives/edgar/data/1571123/000156459016024727/saic-ex101_7.htm)</u> |
| <u>[10.15](https://www.sec.gov/Archives/edgar/data/1571123/000156459015003242/saic-ex101_201505047.htm)</u> | <u>[Second Amended and Restated Credit Agreement, dated May 4, 2015 by and among the Company, Citibank N.A. as administrative agent and collateral agent, and Bank of America, N.A., as a syndication agent, and certain other lenders and parties thereto. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K as filed with the SEC on May 4, 2015.](https://www.sec.gov/Archives/edgar/data/1571123/000156459015003242/saic-ex101_201505047.htm)</u> |
| <u>[10.16](https://www.sec.gov/Archives/edgar/data/1571123/000157112320000003/exhibit101.htm)</u> | <u>[Master Accounts Receivable Purchase Agreement, dated January 21, 2020, among Science Applications International Corporation, Engility Services, LLC, and MUFG Bank, Ltd. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K as filed with the SEC on February 12, 2020.](https://www.sec.gov/Archives/edgar/data/1571123/000157112320000003/exhibit101.htm)</u> |
| <u>[10.17](https://www.sec.gov/Archives/edgar/data/1571123/000157112320000003/exhibit102.htm)</u> | <u>[Performance Undertaking, January 21, 2020, made by Science Applications International Corporation in favor of MUFG Bank, Ltd. Incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K as filed with the SEC on February 12, 2020.](https://www.sec.gov/Archives/edgar/data/1571123/000157112320000003/exhibit102.htm)</u> |
| <u>[10.1](https://www.sec.gov/Archives/edgar/data/1571123/000157112320000011/exhibit101.htm)[8](https://www.sec.gov/Archives/edgar/data/1571123/000157112320000011/exhibit101.htm)</u> | <u>[Amendment No.1 to Master Accounts Receivable Purchase Agreement, dated March 17, 2020, among Science Applications International Corporation, Engility Services, LLC, and MUFG Bank, Ltd. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K as filed with the SEC on March 26, 2020.](https://www.sec.gov/Archives/edgar/data/1571123/000157112320000011/exhibit101.htm)</u> |
| <u>[10.1](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex44.htm)[9](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex44.htm)[\*](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex44.htm)</u> | <u>[Science Applications International Corporation Management Stock Compensation Plan, effective September 27, 2013. Incorporated by reference to Exhibit 4.4 to the Company's Registration Statement on Form S-8 as filed with the SEC on September 27, 2013.](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex44.htm)</u> |
| <u>[10.](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex45.htm)[20](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex45.htm)[\*](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex45.htm)</u> | <u>[Science Applications International Corporation Key Executive Stock Deferral Plan, effective September 27, 2013. Incorporated by reference to Exhibit 4.5 to the Company's Registration Statement on Form S-8 as filed with the SEC on September 27, 2013.](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex45.htm)</u> |

---

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description of Exhibit** |
| <u>[10.2](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex48.htm)[1](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex48.htm)[\*](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex48.htm)</u> | <u>[Science Applications International Corporation 401(k) Excess Deferral Plan, effective September 27, 2013. Incorporated by reference to Exhibit 4.8 to the Company's Registration Statement on Form S-8 as filed with the SEC on September 27, 2013.](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex48.htm)</u> |
| <u>[10.2](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex49.htm)[2](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex49.htm)[\*](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex49.htm)</u> | <u>[Science Applications International Corporation Retirement Plan, effective September 27, 2013. Incorporated by reference to Exhibit 4.9 to the Company's Registration Statement on Form S-8 as filed with the SEC on September 27, 2013.](https://www.sec.gov/Archives/edgar/data/1571123/000119312513382523/d603674dex49.htm)</u> |
| <u>[10.2](https://www.sec.gov/Archives/edgar/data/1571123/000119312514155706/d673471ddef14a.htm)[3](https://www.sec.gov/Archives/edgar/data/1571123/000119312514155706/d673471ddef14a.htm)[\*](https://www.sec.gov/Archives/edgar/data/1571123/000119312514155706/d673471ddef14a.htm)</u> | <u>[Science Applications International Corporation Amended and Restated 2013 Equity Incentive Plan, effective June 4, 2014. Incorporated by reference to Appendix A to the Company's Definitive Proxy Statement on Schedule 14A as filed with the SEC on April 24, 2014.](https://www.sec.gov/Archives/edgar/data/1571123/000119312514155706/d673471ddef14a.htm)</u> |
| <u>[10.24\*](https://www.sec.gov/Archives/edgar/data/1571123/000119312514135913/d648713dex1014.htm)</u> | <u>[Form of Nonstatutory Stock Option Agreement of the Science Applications International Corporation 2013 Equity Incentive Plan. Incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K as filed with the SEC on April 9, 2014.](https://www.sec.gov/Archives/edgar/data/1571123/000119312514135913/d648713dex1014.htm)</u> |
| <u>[10.2](https://www.sec.gov/Archives/edgar/data/1571123/000157112322000007/saicexhibit102101282022.htm)[5](https://www.sec.gov/Archives/edgar/data/1571123/000157112322000007/saicexhibit102101282022.htm)[\*](https://www.sec.gov/Archives/edgar/data/1571123/000157112322000007/saicexhibit102101282022.htm)</u> | <u>[Form of Restricted Stock Unit Award Agreement of the Science Applications International Corporation 2013 Amended and Restated Equity Incentive Plan. Incorporated by reference to Exhibit 10.21 to the Company's Annual Report on Form 10-K as filed with the SEC on March 28, 2022.](https://www.sec.gov/Archives/edgar/data/1571123/000157112322000007/saicexhibit102101282022.htm)</u> |
| <u>[10.2](https://www.sec.gov/Archives/edgar/data/1571123/000157112322000007/saicexhibit102201282022.htm)[6](https://www.sec.gov/Archives/edgar/data/1571123/000157112322000007/saicexhibit102201282022.htm)[\*](https://www.sec.gov/Archives/edgar/data/1571123/000157112322000007/saicexhibit102201282022.htm)</u> | <u>[Form of Performance Share Award Agreement of the Science Applications International Corporation 2013 Amended and Restated Equity Incentive Plan. Incorporated by reference to Exhibit 10.22 to the Company's Annual Report on Form 10-K as filed with the SEC on March 28, 2022.](https://www.sec.gov/Archives/edgar/data/1571123/000157112322000007/saicexhibit102201282022.htm)</u> |
| <u>[10.2](https://www.sec.gov/Archives/edgar/data/1571123/000156459015002280/saic-ex1017_201501301152.htm)[7](https://www.sec.gov/Archives/edgar/data/1571123/000156459015002280/saic-ex1017_201501301152.htm)[\*](https://www.sec.gov/Archives/edgar/data/1571123/000156459015002280/saic-ex1017_201501301152.htm)</u> | <u>[Deferred Compensation Plan, effective January 1, 2015. Incorporated by reference to Exhibit 10.17 of the Company's Annual Report on Form 10-K as filed with the SEC on March 31, 2015.](https://www.sec.gov/Archives/edgar/data/1571123/000156459015002280/saic-ex1017_201501301152.htm)</u> |
| <u>[10.28](https://www.sec.gov/Archives/edgar/data/1571123/000119312513472090/d614152dex101.htm)</u> | <u>[Master Transitional Contracting Agreement between the Company (formerly SAIC Gemini, Inc.) and Leidos Holdings, Inc. (formerly SAIC, Inc.) dated September 25, 2013. Incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q as filed with the SEC on December 13, 2013.](https://www.sec.gov/Archives/edgar/data/1571123/000119312513472090/d614152dex101.htm)</u> |
| <u>[10.](https://www.sec.gov/Archives/edgar/data/1571123/000119312523148120/d498908dex101.htm)[29](https://www.sec.gov/Archives/edgar/data/1571123/000119312523148120/d498908dex101.htm)[\*](https://www.sec.gov/Archives/edgar/data/1571123/000119312523148120/d498908dex101.htm)</u> | <u>[Transition Letter, dated May 15, 2023. Incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed with the SEC on May 18, 2023.](https://www.sec.gov/Archives/edgar/data/1571123/000119312523148120/d498908dex101.htm)</u> |
| <u>[10.3](https://www.sec.gov/Archives/edgar/data/1571123/000119312523162526/d506184dex43.htm)[0](https://www.sec.gov/Archives/edgar/data/1571123/000119312523162526/d506184dex43.htm)[\*](https://www.sec.gov/Archives/edgar/data/1571123/000119312523162526/d506184dex43.htm)</u> | <u>[Science Applications International Corporation 2023 Equity Incentive Plan, effective June 7, 2023. Incorporated by reference to Exhibit 4.3 to the Company's Registration Statement on Form S-8 (File No. 333-272484) as filed with the Securities and Exchange Commission (SEC) on June 7, 2023.](https://www.sec.gov/Archives/edgar/data/1571123/000119312523162526/d506184dex43.htm)</u> |
| <u>[10.3](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000086/saicexhibit1010503202410q.htm)[1](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000086/saicexhibit1010503202410q.htm)[\*](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000086/saicexhibit1010503202410q.htm)</u> | <u>[First Amendment to the Science Applications International Corporation 2023 Equity Incentive Plan, effective March 5, 2024, incorporated by reference as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q as filed with the SEC on June 3, 2024.](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000086/saicexhibit1010503202410q.htm)</u> |
| <u>[10.3](https://www.sec.gov/Archives/edgar/data/1571123/000157112323000102/saicexhibit10220230607.htm)[2](https://www.sec.gov/Archives/edgar/data/1571123/000157112323000102/saicexhibit10220230607.htm)[\*](https://www.sec.gov/Archives/edgar/data/1571123/000157112323000102/saicexhibit10220230607.htm)</u> | <u>[Form of Restricted Stock Unit Award Agreement of the Science Applications International Corporation 2023 Equity Incentive Plan. Incorporated by reference to Exhibit 10.2 to the Company's Current Report on Form 8-K filed with the SEC on June 13, 2023.](https://www.sec.gov/Archives/edgar/data/1571123/000157112323000102/saicexhibit10220230607.htm)</u> |
| <u>[10.3](https://www.sec.gov/Archives/edgar/data/1571123/000157112323000102/saicexhibit10320230607.htm)[3](https://www.sec.gov/Archives/edgar/data/1571123/000157112323000102/saicexhibit10320230607.htm)</u>\* | <u>[Form of Performance Stock Unit Award Agreement of the Science Applications International Corporation 2023 Equity Incentive Plan. Incorporated by reference to Exhibit 10.3 to the Company's Current Report on Form 8-K filed with the SEC on June 13, 2023.](https://www.sec.gov/Archives/edgar/data/1571123/000157112323000102/saicexhibit10320230607.htm)</u> |
| <u>[10.3](https://www.sec.gov/Archives/edgar/data/1571123/000157112323000102/saicexhibit10420230607.htm)[4](https://www.sec.gov/Archives/edgar/data/1571123/000157112323000102/saicexhibit10420230607.htm)</u>\* | <u>[Science Applications International Corporation Amended and Restated 2013 Employee Stock Purchase Plan, effective June 7, 2023. Incorporated by reference to Exhibit 10.4 to the Company's Current Report on Form 8-K filed with the SEC on June 13, 2023.](https://www.sec.gov/Archives/edgar/data/1571123/000157112323000102/saicexhibit10420230607.htm)</u> |
| <u>[10.3](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000086/saicexhibit1020503202410q.htm)[5](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000086/saicexhibit1020503202410q.htm)</u>\* | <u>[First Amendment to the Science Applications International Corporation Amended and Restated 2013 Employee Stock Purchase Plan, effective March 5, 2024, incorporated by reference as Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q as filed with the SEC on June 3, 2024.](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000086/saicexhibit1020503202410q.htm)</u> |
| <u>[19](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000022/saic0131202510kexhibit19.htm)</u> | <u>[Insider Trading Policies and Procedures. Incorporated by reference to Exhibit 19 to the Company's Annual Report on Form 10-K as filed with the SEC on March 17, 2025.](https://www.sec.gov/Archives/edgar/data/1571123/000157112325000022/saic0131202510kexhibit19.htm)</u> |

---

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description of Exhibit** |
| <u>[21](saicfy2610kexhibit21.htm)</u> | <u>[Subsidiaries of Registrant.](saicfy2610kexhibit21.htm)</u> |
| <u>[23.1](saicfy2610kexhibit231.htm)</u> | <u>[Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.](saicfy2610kexhibit231.htm)</u> |
| <u>[31.1](saicfy2610kexhibit311.htm)</u> | <u>[Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](saicfy2610kexhibit311.htm)</u> |
| <u>[31.2](saicfy2610kexhibit312.htm)</u> | <u>[Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](saicfy2610kexhibit312.htm)</u> |
| <u>[32.1](saicfy2610kexhibit321.htm)</u> | <u>[Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](saicfy2610kexhibit321.htm)</u> |
| <u>[32.2](saicfy2610kexhibit322.htm)</u> | <u>[Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](saicfy2610kexhibit322.htm)</u> |
| <u>[97](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000045/saicexhibit970202202410k.htm)</u> | <u>[Policy Relating to Recovery of Erroneously Awarded Compensation. Incorporated by reference to Exhibit 97 to the Company's Annual Report on Form 10-K as filed with the SEC on March 20, 2024.](https://www.sec.gov/Archives/edgar/data/1571123/000157112324000045/saicexhibit970202202410k.htm)</u> |
| 101 | Interactive Data File. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |
| 104 | The cover page from this Annual Report on Form 10-K, formatted as Inline XBRL. |

---

\* Management contract or compensatory plan or agreement.

**Item 16. *Form 10-K Summary***

None.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_7)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
| Science Applications International Corporation | Science Applications International Corporation |
| By | /s/ Prabu Natarajan |
| | **Prabu Natarajan**<br>***Chief Financial Officer*** |

---

Dated: March 16, 2026

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **<u>Signature</u>** | **<u>Title</u>** | **<u>Date</u>** |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;James C. Reagan | Principal Executive Officer and Director | March 16, 2026 |
| **James C. Reagan** | Principal Executive Officer and Director | March 16, 2026 |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;Prabu Natarajan | Principal Financial Officer and<br>Principal Accounting Officer | March 16, 2026 |
| **Prabu Natarajan** | Principal Financial Officer and<br>Principal Accounting Officer | March 16, 2026 |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;Donna S. Morea | Chair of the Board | March 16, 2026 |
| **Donna S. Morea** | Chair of the Board | March 16, 2026 |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;Garth N. Graham | Director | March 16, 2026 |
| **Garth N. Graham** | Director | March 16, 2026 |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;Carolyn B. Handlon | Director | March 16, 2026 |
| **Carolyn B. Handlon** | Director | March 16, 2026 |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;Yvette M. Kanouff | Director | March 16, 2026 |
| **Yvette M. Kanouff** | Director | March 16, 2026 |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;Timothy J. Mayopoulos | Director | March 16, 2026 |
| **Timothy J. Mayopoulos** | Director | March 16, 2026 |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;Katharina G. McFarland | Director | March 16, 2026 |
| **Katharina G. McFarland** | Director | March 16, 2026 |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;Milford W. McGuirt | Director | March 16, 2026 |
| **Milford W. McGuirt** | Director | March 16, 2026 |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;Steven R. Shane | Director | March 16, 2026 |
| **Steven R. Shane** | Director | March 16, 2026 |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;John K. Tien Jr. | Director | March 16, 2026 |
| **John K. Tien Jr.** | Director | March 16, 2026 |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;David J. Urban | Director | March 16, 2026 |
| **David J. Urban** | Director | March 16, 2026 |

---

------

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**INDEX TO CONSOLIDATED FINANCIAL STATEMENTS**<br>

---

| | |
|:---|:---|
| **CONSOLIDATED FINANCIAL STATEMENTS** | **Page** |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Report of Independent Registered Public Accounting Firm](#i68c4e1d46e8b478fb5bd56210bcd1bf5_181)</u> <u>(</u>*<u>PCAOB ID: 42</u>*<u>)</u> | <u>F-[2](#i68c4e1d46e8b478fb5bd56210bcd1bf5_181)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Income](#i68c4e1d46e8b478fb5bd56210bcd1bf5_184)</u> | <u>F-[4](#i68c4e1d46e8b478fb5bd56210bcd1bf5_184)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Comprehensive Income](#i68c4e1d46e8b478fb5bd56210bcd1bf5_187)</u> | <u>F-[5](#i68c4e1d46e8b478fb5bd56210bcd1bf5_187)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Balance Sheets](#i68c4e1d46e8b478fb5bd56210bcd1bf5_190)</u> | <u>F-[6](#i68c4e1d46e8b478fb5bd56210bcd1bf5_190)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Equity](#i68c4e1d46e8b478fb5bd56210bcd1bf5_193)</u> | <u>F-[7](#i68c4e1d46e8b478fb5bd56210bcd1bf5_193)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Consolidated Statements of Cash Flows](#i68c4e1d46e8b478fb5bd56210bcd1bf5_196)</u> | <u>F-[8](#i68c4e1d46e8b478fb5bd56210bcd1bf5_196)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;<u>[Notes to the Consolidated Financial Statements](#i68c4e1d46e8b478fb5bd56210bcd1bf5_199)</u> | <u>F-[9](#i68c4e1d46e8b478fb5bd56210bcd1bf5_199)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 1—Business Overview and Summary of Significant Accounting Policies](#i68c4e1d46e8b478fb5bd56210bcd1bf5_202)</u> | <u>F-[9](#i68c4e1d46e8b478fb5bd56210bcd1bf5_202)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 2—Earnings Per Share, Share Repurchases and Dividends](#i68c4e1d46e8b478fb5bd56210bcd1bf5_295)</u> | <u>F-[18](#i68c4e1d46e8b478fb5bd56210bcd1bf5_295)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 3—Revenues](#i68c4e1d46e8b478fb5bd56210bcd1bf5_307)</u> | <u>F-[19](#i68c4e1d46e8b478fb5bd56210bcd1bf5_307)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 4—](#i68c4e1d46e8b478fb5bd56210bcd1bf5_328)[Acquisitions and](#i68c4e1d46e8b478fb5bd56210bcd1bf5_328)[Divestitures](#i68c4e1d46e8b478fb5bd56210bcd1bf5_328)</u> | <u>F-[22](#i68c4e1d46e8b478fb5bd56210bcd1bf5_328)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 5—Restructuring, Impairment and Other Exit Costs](#i68c4e1d46e8b478fb5bd56210bcd1bf5_331)</u> | <u>F-[24](#i68c4e1d46e8b478fb5bd56210bcd1bf5_331)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 6—Goodwill and Intangible Assets](#i68c4e1d46e8b478fb5bd56210bcd1bf5_334)</u> | <u>F-[24](#i68c4e1d46e8b478fb5bd56210bcd1bf5_334)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 7—Property, Plant, and Equipment](#i68c4e1d46e8b478fb5bd56210bcd1bf5_337)</u> | <u>F-[26](#i68c4e1d46e8b478fb5bd56210bcd1bf5_337)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 8—Stock-Based Compensation](#i68c4e1d46e8b478fb5bd56210bcd1bf5_343)</u> | <u>F-[26](#i68c4e1d46e8b478fb5bd56210bcd1bf5_343)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 9—Retirement Plans](#i68c4e1d46e8b478fb5bd56210bcd1bf5_346)</u> | <u>F-[29](#i68c4e1d46e8b478fb5bd56210bcd1bf5_346)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 10—Income Taxes](#i68c4e1d46e8b478fb5bd56210bcd1bf5_349)</u> | <u>F-[31](#i68c4e1d46e8b478fb5bd56210bcd1bf5_349)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 11—Debt Obligations](#i68c4e1d46e8b478fb5bd56210bcd1bf5_352)</u> | <u>F-[34](#i68c4e1d46e8b478fb5bd56210bcd1bf5_352)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 12—Derivative Instruments Designated as Cash Flow Hedges](#i68c4e1d46e8b478fb5bd56210bcd1bf5_355)</u> | <u>F-[36](#i68c4e1d46e8b478fb5bd56210bcd1bf5_355)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 13—Changes in Accumulated Other Comprehensive Income (Loss) by Component](#i68c4e1d46e8b478fb5bd56210bcd1bf5_358)</u> | <u>F-[37](#i68c4e1d46e8b478fb5bd56210bcd1bf5_358)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 14—Sale of Receivables](#i68c4e1d46e8b478fb5bd56210bcd1bf5_361)</u> | <u>F-[37](#i68c4e1d46e8b478fb5bd56210bcd1bf5_361)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 15—Operating Leases](#i68c4e1d46e8b478fb5bd56210bcd1bf5_364)</u> | <u>F-[38](#i68c4e1d46e8b478fb5bd56210bcd1bf5_364)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 16—Business Segment Information](#i68c4e1d46e8b478fb5bd56210bcd1bf5_367)</u> | <u>F-[39](#i68c4e1d46e8b478fb5bd56210bcd1bf5_367)</u> |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Note 17—Legal Proceedings and Commitments and Contingencies](#i68c4e1d46e8b478fb5bd56210bcd1bf5_370)</u> | <u>F-[41](#i68c4e1d46e8b478fb5bd56210bcd1bf5_370)</u> |

---

Financial statement schedules are omitted because they are not applicable or the required information is shown in our consolidated financial statements or the notes thereto.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

To the Stockholders and the Board of Directors of

Science Applications International Corporation

**Opinion on the Financial Statements** 

We have audited the accompanying consolidated balance sheets of Science Applications International Corporation (the Company) as of January 30, 2026 and January 31, 2025, the related consolidated statements of income, comprehensive income, equity and cash flows for each of the three years in the period ended January 30, 2026, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at January 30, 2026 and January 31, 2025, and the results of its operations and its cash flows for each of the three years in the period ended January 30, 2026, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of January 30, 2026, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated March 16, 2026 expressed an unqualified opinion thereon.

**Basis for Opinion**

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

**Critical Audit Matter**

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

---

| | |
|:---|:---|
| | ***Cost estimation for revenue recognition on certain contracts using a cost input measure of progress*** |
| *Description of the Matter* | The Company recognizes a significant portion of its revenues using a cost input measure of progress (cost-to-cost). Under the cost-to-cost measure of progress, revenue is recognized based on the ratio of costs incurred to the total estimated costs at completion. As described in Note 1 to the consolidated financial statements, recognizing revenue on long-term contracts involves significant estimates and judgments. Estimating costs at completion for certain contracts is complex due to the nature of the services being performed and the length of the contracts. Changes in estimates (as quantified in Note 3 to the consolidated financial statements) can routinely occur due to a variety of reasons including changes in scope, changes in cost estimates due to unanticipated cost growth or reassessments of risks impacting costs. Changes in estimates on these contracts, if significant, could have a material effect on the Company's results of operations. <br>Auditing the Company's accounting for revenue for certain contracts using the cost input measure of progress was complex due to the judgment involved in estimating the total estimated costs at completion for these contracts. Management estimates total costs at completion by making assumptions regarding the complexity of the work to be performed, the schedule and associated tasks, labor productivity and availability, increases in wages and prices of materials, execution by subcontractors, overhead cost rates, and other variables.  |
| *How We Addressed the Matter in Our Audit* | We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company's recognition of revenue using the cost input measure of progress. For example, we tested controls over the significant assumptions applied in determining the estimation of costs to be incurred on the contract and controls evaluating the appropriateness of changes in estimated costs to complete throughout the contract's period of performance. We also tested internal controls that management executes to validate the data used in determining this revenue was complete and accurate.<br>To test the accuracy of the Company's estimated costs at completion, our audit procedures included, among others, comparing estimates of labor costs, subcontractor costs, and materials to actual costs incurred to date, comparing estimated margins to margins on similar contracts, and agreeing the key terms to contract documentation. Our audit procedures also included, among others, evaluating the nature, timing and extent of the amounts of revenue and costs recorded to date, including any changes in estimated costs at completion from the prior period. For example, to test a change in estimate, we inspected underlying evidence for the reason for the change in estimate and the timing of such change and we recalculated the inception-to-date effect recorded. We also evaluated whether a lack of change in estimate was appropriate, where applicable, on contracts.  |

---

/s/ Ernst & Young LLP

We have served as the Company's auditor since 2018.

Tysons, Virginia

March 16, 2026

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**CONSOLIDATED STATEMENTS OF INCOME**<br>

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30,<br>2026** | January 31,<br>2025 | February 2,<br>2024 |
| | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) |
| Revenues | $**7262** | $7479 | $7444 |
| Cost of revenues | **6390** | 6587 | 6572 |
| Selling, general and administrative expenses | **350** | 339 | 373 |
| (Gain) loss on divestitures, net of transaction costs | **—** |  | (240) |
| Other operating (income) expense | **1** | (10) | (2) |
| Operating income | **521** | 563 | 741 |
| Interest expense, net | **128** | 126 | 120 |
| Other (income) expense, net | **6** | 9 | 1 |
| Income before income taxes | **387** | 428 | 620 |
| Provision for income taxes | **(29)** | (66) | (143) |
| Net income | $**358** | $362 | $477 |
| Earnings per share: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $**7.73** | $7.23 | $8.98 |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $**7.70** | $7.17 | $8.88 |

---

See accompanying notes to consolidated financial statements.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**<br>

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30, 2026** | January 31, 2025 | February 2, 2024 |
| | (in millions) | (in millions) | (in millions) |
| Net income | $**358** | $362 | $477 |
| Other comprehensive (loss) income, net of tax: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net unrealized (loss) gain on derivative instruments | **(4)** | (7) | (7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Defined benefit obligation adjustment | **—** | 3 | 1 |
| Total other comprehensive (loss) income, net of tax | **(4)** | (4) | (6) |
| Comprehensive income | $**354** | $358 | $471 |

---

See accompanying notes to consolidated financial statements.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**CONSOLIDATED BALANCE SHEETS**<br>

---

| | | |
|:---|:---|:---|
| | **January 30,<br>2026** | January 31,<br>2025 |
| | (in millions) | (in millions) |
| **ASSETS** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**182** | $56 |
| &nbsp;&nbsp;&nbsp;&nbsp;Receivables, net | **853** | 1000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | **122** | 78 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | **22** | 20 |
| Total current assets | **1179** | 1154 |
| Goodwill | **2944** | 2851 |
| Intangible assets, net | **761** | 779 |
| Property, plant, and equipment, net | **110** | 104 |
| Operating lease right of use assets | **193** | 164 |
| Other assets | **167** | 194 |
| Total assets | $**5354** | $5246 |
| **LIABILITIES AND EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $**500** | $631 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll and other employee benefits | **201** | 219 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued vacation | **115** | 120 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other accrued liabilities | **147** | 113 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt, current portion | **19** | 313 |
| Total current liabilities | **982** | 1396 |
| Debt, net of current portion | **2468** | 1907 |
| Operating lease liabilities | **198** | 173 |
| Deferred income taxes | **104** | 24 |
| Other long-term liabilities | **102** | 169 |
| Commitments and contingencies (Note 17) |  |  |
| Equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.0001 par value, 1 billion shares authorized, 44 million shares and 48 million shares issued and outstanding as of January 30, 2026 and January 31, 2025, respectively | **—** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | **—** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | **1492** | 1565 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income | **8** | 12 |
| Total stockholders' equity | **1500** | 1577 |
| Total liabilities and stockholders' equity | $**5354** | $5246 |

---

See accompanying notes to consolidated financial statements.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**CONSOLIDATED STATEMENTS OF EQUITY**<br>

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | Shares of <br>common stock | Additional <br>paid-in <br>capital | Retained<br> earnings | Accumulated<br> other<br> comprehensive<br>income (loss) | Non-controlling interest | Total |
| | (in millions) | (in millions) | (in millions) | (in millions) | (in millions) | (in millions) |
| **Balance at February 3, 2023** | **54** | $**637** | $**1035** | $**22** | $**10** | $**1704** |
| &nbsp;&nbsp;&nbsp;Net income |  |  | 477 |  |  | 477 |
| &nbsp;&nbsp;&nbsp;Issuances of stock | 1 | 18 |  |  |  | 18 |
| &nbsp;&nbsp;Other comprehensive loss, net of tax |  |  |  | (6) |  | (6) |
| &nbsp;&nbsp;Dividends of $1.48 per share |  |  | (80) |  |  | (80) |
| &nbsp;&nbsp;Stock-based compensation, net of shares withheld for taxes<sup>(1)</sup> |  | 45 |  |  |  | 45 |
| &nbsp;&nbsp;&nbsp;Repurchases of stock | (3) | (363) |  |  |  | (363) |
| &nbsp;&nbsp;Deconsolidation of non-controlling interest |  |  |  |  | (10) | (10) |
| **Balance at February 2, 2024** | **52** | **337** | **1432** | **16** | **—** | **1785** |
| &nbsp;&nbsp;&nbsp;Net income |  |  | 362 |  |  | 362 |
| &nbsp;&nbsp;&nbsp;Issuances of stock |  | 20 |  |  |  | 20 |
| &nbsp;&nbsp;Other comprehensive loss, net of tax |  |  |  | (4) |  | (4) |
| &nbsp;&nbsp;Dividends of $1.48 per share |  |  | (75) |  |  | (75) |
| &nbsp;&nbsp;Stock-based compensation, net of shares withheld for taxes<sup>(1)</sup> |  | 22 |  |  |  | 22 |
| &nbsp;&nbsp;&nbsp;Repurchases of stock | (4) | (379) | (154) |  |  | (533) |
| **Balance at January 31, 2025** | **48** | **—** | **1565** | **12** | **—** | **1577** |
| &nbsp;&nbsp;&nbsp;Net income |  |  | 358 |  |  | 358 |
| &nbsp;&nbsp;&nbsp;Issuances of stock |  | 22 |  |  |  | 22 |
| &nbsp;&nbsp;&nbsp;Other comprehensive loss, net of tax |  |  |  | (4) |  | (4) |
| &nbsp;&nbsp;Dividends of $1.48 per share |  |  | (70) |  |  | (70) |
| &nbsp;&nbsp;Stock-based compensation, net of shares withheld for taxes<sup>(1)</sup> |  | 42 |  |  |  | 42 |
| &nbsp;&nbsp;&nbsp;Repurchases of stock | (4) | (64) | (361) |  |  | (425) |
| **Balance at January 30, 2026** | **44** | $**—** | $**1492** | $**8** | $**—** | $**1500** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;In fiscal 2026, fiscal 2025 and fiscal 2024, the shares withheld for taxes related to stock-based compensation arrangements amounted to $22 million, $31 million, and $23 million, respectively.

See accompanying notes to consolidated financial statements.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**CONSOLIDATED STATEMENTS OF CASH FLOWS**<br>

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30,<br>2026** | January 31,<br>2025 | February 2,<br>2024 |
| | (in millions) | (in millions) | (in millions) |
| Cash flows from operating activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income | $**358** | $362 | $477 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by operating activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **149** | 140 | 142 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred income taxes | **81** | (3) | (17) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | **64** | 53 | 68 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Gain on divestitures | **—** |  | (247) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other | **1** | (7) | (6) |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) resulting from changes in operating assets and liabilities, net of the effect of the acquisitions and divestitures: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables | **161** | (86) | (46) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | **(44)** | 24 | (43) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and other accrued liabilities | **(101)** | 48 | 13 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll and employee benefits | **(28)** | (31) | 49 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease assets and liabilities, net | **(2)** | (6) | (4) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other assets and other long-term liabilities, net | **(30)** |  | 10 |
| Net cash provided by operating activities | **609** | 494 | 396 |
| Cash flows from investing activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for acquisition, net of cash acquired | **(203)** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Expenditures for property, plant, and equipment | **(32)** | (36) | (27) |
| &nbsp;&nbsp;&nbsp;&nbsp;Contributions to investments | **(11)** | (7) | (10) |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of marketable securities | **(9)** | (14) | (8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales of marketable securities | **7** | 12 | 6 |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from sale of equity method investments | **—** | 10 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from divestitures | **—** |  | 356 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash divested upon deconsolidation of joint venture | **—** |  | (8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | **—** |  | 5 |
| Net cash (used in) provided by investing activities | **(248)** | (35) | 314 |
| Cash flows from financing activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from borrowings | **2745** | 1499 | 160 |
| &nbsp;&nbsp;&nbsp;&nbsp;Principal payments on borrowings | **(2474)** | (1381) | (441) |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock repurchased and retired or withheld for taxes on equity awards | **(445)** | (558) | (382) |
| &nbsp;&nbsp;&nbsp;&nbsp;Dividend payments to stockholders | **(70)** | (75) | (79) |
| &nbsp;&nbsp;&nbsp;&nbsp;Issuances of stock | **22** | 20 | 17 |
| &nbsp;&nbsp;&nbsp;&nbsp;Debt issuance costs | **(9)** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | **(4)** | (3) |  |
| Net cash used in financing activities | **(235)** | (498) | (725) |
| Net increase (decrease) in cash, cash equivalents and restricted cash | **126** | (39) | (15) |
| Cash, cash equivalents and restricted cash at beginning of period | **64** | 103 | 118 |
| Cash, cash equivalents and restricted cash at end of period | $**190** | $64 | $103 |
| See accompanying notes to consolidated financial statements. | See accompanying notes to consolidated financial statements. | See accompanying notes to consolidated financial statements. | See accompanying notes to consolidated financial statements. |
| Supplementary cash flow disclosure: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $**101** | $121 | $125 |
| Non-cash investing activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in accrued property, plant, and equipment | $**2** | $2 | $(1) |
| Non-cash financing activities: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase (decrease) in accrued plan share repurchases | $**(1)** | $1 | $1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Increase in accrued excise taxes on plan share repurchases | $**3** | $5 | $3 |

---

See accompanying notes to consolidated financial statements.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

**Note 1—Business Overview and Summary of Significant Accounting Policies:**

***Overview***

*Description of Business.* Science Applications International Corporation (collectively, with its consolidated subsidiaries, the "Company") is a leading provider of technical, engineering and mission and enterprise information technology ("IT") services primarily to the U.S. government. The Company integrates emerging technology securely and in real-time into mission critical operations that modernize and enable national imperatives. The Company provides these services for large, complex projects with a targeted emphasis on higher-end, differentiated technology services and solutions that accelerate and transform secure and resilient digital environments through system development, modernization, integration, and sustainment to drive enterprise and mission outcomes.

Effective February 3, 2024, the first day of fiscal 2025, the Company completed a business reorganization which replaced its previous two operating sectors with five customer facing business groups supported by the enterprise organizations, including the Innovation Factory. The Company's five business groups, which are also its operating segments, are aggregated into two reportable segments for financial reporting purposes given the similarity in economic and qualitative characteristics, and based on the nature of the customers they serve. The Company's two reportable segments are the Defense and Intelligence segment and the Civilian segment.

The Defense and Intelligence segment provides a diverse portfolio of national security solutions to the Department of War ("DoW", formerly referred to as the Department of Defense) and the Intelligence Community of the United States Government.

The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments, in order to deliver services for citizen well-being, border security, and protecting lives. This includes integrating solutions into a spectrum of public service missions that impact travel, trade, health and the economy.

The offerings of both reportable segments entail the integration of emerging technologies into mission critical operations that modernize and enable national imperatives, including IT modernization, digital engineering, artificial intelligence ("AI"), mission systems support and advisory, training and simulation, and ground vehicles support. These services include end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment and security of the customers' entire IT infrastructure.

The Company's Innovation Factory supports the operating segments by developing enterprise-class solutions which are delivered to the Company's customers as stand-alone solutions or integrated with and aligned to product offerings through the operations of the business to meet complex customer needs and accelerate digital transformation. The Innovation Factory includes designated teams focused on AI, application development, network services, platforms and cloud, engineering, and cybersecurity. It uses a highly automated, cloud-hosted tool set to rapidly build, test and deploy solutions and works with customers to enhance solutions going forward.

Costs associated with corporate functions that are not allocable to the reportable segments are presented as Corporate activities. See Note 16—Business Segments Information for additional information.

Effective January 31, 2026, the first day of fiscal 2027, the Company completed a business reorganization that consolidated its five business groups into three. The reorganization is designed to simplify the Company's structure and optimize operations and customer focus for growth. The consolidated business groups will continue to report directly to the Company's Chief Executive Officer ("CEO") who will continue to be the chief operating decision maker ("CODM"). The Company does not expect the reorganization to have an impact on its reportable segments.

***Principles of Consolidation and Basis of Presentation***

References to "financial statements" refer to the consolidated financial statements of the Company, which include the statements of income and comprehensive income, balance sheets, statements of equity and statements of cash flows. These financial statements were prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). All intercompany transactions and account balances within the Company have been eliminated.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

Certain amounts in the prior year financial statements have been reclassified to conform to the current year presentation. "Contributions to investments" was previously presented in "Other" within "Cash flows from investing activities" on the consolidated statements of cash flows.

***Reporting Periods***

The Company utilizes a 52/53 week fiscal year ending on the Friday closest to January 31, with fiscal quarters typically consisting of 13 weeks. Fiscal 2026 began on February 1, 2025 and ended on January 30, 2026, fiscal 2025 began on February 3, 2024 and ended on January 31, 2025, and fiscal 2024 began on February 4, 2023 and ended on February 2, 2024.

***Operating Cycle***

The Company's operating cycle may be greater than one year and is represented by the average time intervening between the inception and the completion of contracts.

***Use of Estimates***

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting periods. Significant estimates inherent in the preparation of the financial statements may include, but are not limited to, estimated profitability of long-term contracts, income taxes, fair value measurements, fair value of goodwill and other intangible assets, pension and defined benefit plan obligations, and contingencies. Estimates have been prepared by management on the basis of the most current and best available information at the time of estimation and actual results could differ from those estimates.

***Revenue Recognition***

The Company provides technical, engineering and mission and enterprise IT services under long-term service arrangements primarily with the U.S. government, including subcontracts with other contractors engaged in work for the U.S. government. The Company also serves a number of state and local governments, foreign governments and U.S. commercial customers.

The Company provides services under various contract types, including fixed price contracts such as firm-fixed price ("FFP"), time-and-materials ("T&M") contracts including fixed-price-level-of-effort contracts, and cost reimbursement contracts such as cost-plus-fixed-fee, cost-plus-award-fee and cost-plus-incentive-fee contracts. The Company's service arrangements typically involve an annual base period of performance followed by renewal option periods that upon exercise are generally accounted for as separate contracts.

To determine the proper revenue recognition, the Company first evaluates whether there is a duly approved and enforceable contract with a customer, in which rights of parties and payment terms are identified and collectability is probable. The Company also evaluates whether two or more contracts should be combined and accounted for as a single contract and whether modifications to existing contracts should be accounted for as part of the original contract or as a separate contract. Contract modifications that create new enforceable rights and obligations are accounted for prospectively. Contract modifications that do not add distinct goods or services are accounted for through cumulative catch-up adjustments. Contract modifications that add distinct goods or services and increase the contract value by an amount that reflects the standalone selling price are accounted for as separate contracts.

The Company recognizes revenue when, or as, performance obligations under a contract are satisfied. A performance obligation is the unit of account for revenue recognition and refers to a promise in a contract to transfer a distinct service or good to the customer. The majority of the Company's contracts contain a single performance obligation involving a significant integration of various activities that are performed together to deliver a combined service or solution. Performance obligations may be satisfied over time or at a point in time, but the majority of the Company's performance obligations are satisfied over time. The Company selects the appropriate measure of progress for revenue recognition based on the nature of the performance obligation, contract type and other pertinent contract terms.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

Performance obligations satisfied over time may involve a series of recurring services, such as network operations and maintenance, operation and program support services, IT outsourcing services, and other IT arrangements where the Company is standing ready to provide support, when-and-if needed. Such performance obligations are satisfied over time because the customer simultaneously receives and consumes the benefits of the Company's performance as services are provided. Alternatively, performance obligations satisfied over time may involve the completion of a contract deliverable. Examples include systems integration, network engineering, network design, and engineering and build services. Deliverable-based performance obligations are satisfied over time when the Company's performance creates or enhances an asset that is controlled by the customer, or when the Company's performance creates an asset that is customized to the customer's specifications and the Company has a right to payment, including a reasonable profit margin, for work performed to date.

For series-services performance obligations, the Company measures progress using either a cost input measure (cost-to-cost), a time-elapsed output measure, or the as-invoiced practical expedient. A cost input measure or the as-invoiced practical expedient typically is applied to the Company's cost-reimbursable contracts. Revenue is recognized based on the ratio of costs incurred to total estimated costs at completion. Award or incentive fees are allocated to the distinct periods to which they relate. For fixed-price contracts, a time-elapsed output measure is applied to fixed consideration, such that revenue is recognized ratably over the period of performance. Where fixed-price contracts also provide for reimbursement of certain costs, such as travel or other direct costs, consideration may be attributed only to a distinct subset of time within the performance period. The Company's time-and-material, fixed price-level of effort, and certain cost-plus-fixed-fee contracts generally qualify for the as-invoiced practical expedient. Revenue on these contracts is recognized in the amount to which the Company has a contractual right to invoice.

For deliverable-based performance obligations satisfied over time, the Company recognizes revenue using a cost input measure of progress (cost-to-cost), regardless of contract type. Revenue is recognized based on the ratio of costs incurred to total estimated costs at completion.

The Company may incur costs associated with significant materials or hardware procurements that are not proportionate to the Company's progress in satisfying its performance obligations. For these contracts, costs are excluded from the measure of progress, and revenue is recognized equal to the costs incurred.

For performance obligations in which the Company does not transfer control over time, the Company recognizes revenue at the point-in-time when the customer obtains control of the related asset, usually at the time of shipment or upon delivery. The Company accrues for shipping and handling costs occurring after the point-in-time control transfers to the customer.

Recognizing revenue on long-term contracts involves significant estimates and judgments. The transaction price is the estimated amount of consideration the Company expects to receive for performance under the Company's contracts. Contract terms may include variable consideration, such as reimbursable costs, award and incentive fees, usage-based fees, service-level penalties, performance bonuses, or other provisions that can either increase or decrease the transaction price. Variable amounts are generally determined upon the Company's achievement of certain performance metrics, program milestones or cost targets and may be based upon customer discretion. When making estimates, the Company considers the customer, contract terms, the complexity of the work and related risks, the extent of customer discretion, historical experience and the potential of a significant reversal of revenue. The Company includes variable consideration in the transaction price only to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved.

For contracts with multiple performance obligations, the Company allocates transaction price to each performance obligation based on the relative standalone selling price of each distinct performance obligation within the contract. Since the Company typically provides customized services and solutions that are specific to a single customer's requirements, standalone selling price is most often estimated based on expected costs plus a reasonable profit margin.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

***Changes in Estimates on Contracts***

Changes in estimates of revenues, cost of revenues or profits related to performance obligations satisfied over time are recognized in operating income in the period in which such changes are made for the inception-to-date effect of the changes. Changes in these estimates can occur routinely over the performance period for a variety of reasons, which include: changes in scope; changes in cost estimates due to unanticipated cost growth or reassessments of risks impacting costs; changes in the estimated transaction price, such as variable amounts for incentive or award fees; and performance being better or worse than previously estimated.

A significant portion of the Company's contracts recognize revenue on performance obligations using a cost input measure (cost-to-cost), which requires estimates of total costs at completion. Estimating costs at completion is complex due to the nature of the services being performed and the length of certain contracts. Contract costs generally include direct costs, such as labor, subcontract costs and materials, and indirect costs identifiable with or allocable to a specific contract. Management must make assumptions regarding the complexity of the work to be performed, the schedule and associated tasks, labor productivity and availability, increases in wages and prices of materials, execution by the Company's subcontractors, overhead cost rates, and other variables. For contracts using a cost input measure, when total expected contract costs exceed total estimated contract revenues, the Company recognizes the total estimated loss in the quarter identified. Total estimated losses are inclusive of any unexercised options that are probable of award, only if they increase the amount of the loss. Contract costs incurred for U.S. government contracts, including indirect costs, are subject to audit and adjustment by the Defense Contract Audit Agency ("DCAA").

***Contract Balances***

The timing of revenue recognition may differ from the timing of billing and cash receipts from customers. Amounts are invoiced as work progresses, typically biweekly or monthly in arrears, or upon achievement of contractual milestones. The Company records a contract asset when revenue is recognized prior to invoicing, or a contract liability when cash is received in advance of recognizing revenue. A contract asset is a right to consideration that is conditional upon factors other than the passage of time. Contract assets include unbillable receivables and contract retentions, but exclude billed and billable receivables. Billed and billable receivables are rights to consideration, which are unconditional other than to the passage of time. Contract liabilities include customer advances, billings in excess of revenues and deferred revenue. Contract assets and liabilities are recorded net on a contract-by-contract basis and are generally classified as current based on the Company's contract operating cycle. Deferred revenue attributable to long-term contract material renewal options may be classified as non-current when the option renewal period will not occur within one year of the balance sheet date.

***Deferred Costs***

Certain eligible costs, such as costs to obtain and costs to fulfill the Company's service contracts, are capitalized when the costs relate directly to the contract, are expected to be recovered, and generate or enhance resources to be used in satisfying the performance obligation. These costs primarily consist of commissions, transition and set-up costs. Capitalized costs to obtain and fulfill a contract are amortized on a straight-line basis over the expected period of benefit, which generally includes the contract base period and anticipated renewals.

The Company performs periodic reviews to assess the recoverability of deferred contract transition and setup costs. The carrying amount of the asset is compared to the remaining amount of consideration the Company expects to receive for the services to which the asset relates, less the costs that relate directly to providing those services that have not yet been recognized. If the carrying amount is not recoverable, an impairment loss is recognized.

Pre-contract costs are deferred when eligible costs are incurred prior to the start of a contract and it is probable the costs will be recovered upon contract issuance. Pre-contract costs are expensed when the contract is executed.

Prepaid contract costs may be incurred for certain customer contracts to secure the use of assets or the receipt of services at a future date or over a period of time. For contracts using the as-invoiced practical expedient or a time-elapsed revenue recognition measure, prepaid contract costs are amortized on a straight-line basis over the expected period of benefit.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

***Costs Allocated to Contracts***

The Company classifies indirect costs as overhead (included in cost of revenues) or general and administrative expenses in the same manner as such costs are defined in the Company's Disclosure Statements under U.S. government Cost Accounting Standards ("CAS").

***Stock-based Compensation***

The Company issues stock-based awards as compensation to employees and directors. Stock-based awards include vesting stock awards, performance share awards, and stock options. These awards are accounted for as equity awards. The Company recognizes stock-based compensation expense, net of estimated forfeitures, on a straight-line basis over the underlying award's requisite service period, as measured using the award's grant date fair value. For performance share awards, the Company reassesses the probability of achieving the performance conditions at each reporting period end and adjusts compensation expense based on the number of shares the Company expects to ultimately vest. Under the Company's stock-based compensation arrangements, upon vesting, shares are often withheld from the award for the purposes of satisfying statutory withholding tax obligations.

***Income Taxes***

The Company accounts for income taxes under the asset and liability method of accounting, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax basis of assets and liabilities. Under this method, changes in tax rates and laws are recognized in income in the period such changes are enacted. The provision for federal, state, local and foreign income taxes is calculated on income before income taxes based on current tax law and includes the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Such provisions differ from the amounts currently payable because certain items of income and expense are recognized in different reporting periods for financial reporting purposes than for income tax purposes.

Recording the provision for income taxes requires management to make significant judgments and estimates for matters for which the ultimate resolution may not become known until the final resolution of an examination by taxing authorities or the statute of limitations lapses. Additionally, recording liabilities for uncertainty in income taxes involves significant judgment in evaluating the Company's tax positions and developing the best estimate of the taxes ultimately expected to be paid. Tax penalties and interest are included in income tax expense.

The Company has also recognized liabilities for uncertainty in income taxes when it is more likely than not that a tax position will not be sustained on examination and settlement with various taxing authorities. The Company records the largest amount of benefit that is more likely than not to be realized when the tax position is settled. To the extent the Company prevails in matters for which accruals have been established or is required to pay amounts in excess of reserves, the Company's effective tax rate in a given financial period may be materially impacted.

Deferred tax assets and liabilities are netted by taxable jurisdiction and classified as noncurrent on the consolidated balance sheets.

***Cash, Cash Equivalents and Restricted Cash***

Cash and cash equivalents are comprised of cash in banks and highly liquid instruments, which primarily consist of bank deposits and investments in institutional money market funds. The Company includes outstanding payments within "Cash and cash equivalents" and "Accounts payable" on the consolidated balance sheets and as of January 30, 2026 and January 31, 2025 these amounts were $25 million and $33 million, respectively. The Company does not invest in high yield or high risk securities. The cash in bank accounts at times may exceed federally insured limits.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

Restricted cash includes cash amounts held that are contractually restricted from use in operations, but are subject to future claims of creditors. The following table provides a reconciliation of cash, cash equivalents and restricted cash to amounts reported within the consolidated balance sheets for the periods presented:

---

| | | |
|:---|:---|:---|
| | **January 30, 2026** | January 31, 2025 |
| | (in millions) | (in millions) |
| Cash and cash equivalents | $**182** | $56 |
| Restricted cash included in other current assets | **3** | 3 |
| Restricted cash included in other assets | **5** | 5 |
| Cash, cash equivalents and restricted cash | $**190** | $64 |

---

***Receivables***

Receivables include billed and billable receivables, and unbilled receivables. The Company's receivables are primarily due from the U.S. government, or from prime contractors to which we are subcontractors and the end customer is the U.S. government, and are generally considered collectable from the perspective of the customer's ability to pay. The Company does not have a material credit risk exposure.

Unbilled receivables, substantially all of which are expected to be billed and collected within one year, are stated at their estimated realizable value and consist of costs and fees billable on contract completion or the occurrence of a specified event, other than the passage of time. Legal title to the related accumulated costs of contracts in progress generally vests with the U.S. government on the Company's receipt of progress payments. Progress payments received of $86 million and $82 million offset unbilled receivables as of January 30, 2026 and January 31, 2025, respectively. Contract retentions are billed when contract conditions have been met and may relate to uncompleted indirect cost negotiations with the U.S. government. Based on historical experience, the majority of retention balances are expected to be collected beyond one year. Retention is presented in "Other assets" on the consolidated balance sheets, see Note 3—Revenues. Write-offs of retention balances have not been significant.

Receivable balances are written-off in the period during which management determines they are uncollectable, and, at that time, such balances are removed from billed receivables and, if previously reserved, from the allowance.

***Business Combinations***

The Company records substantially all assets acquired and liabilities assumed in a business combination at fair value as of the acquisition date, which is determined using a cost, market or income approach. The excess amount of the aggregated purchase consideration paid over the fair value of the net of assets acquired and liabilities assumed is recorded as goodwill. Acquisition date fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as measured on the acquisition date.

The valuations are based on information that existed as of the acquisition date. During the measurement period that shall not exceed one year from the acquisition date, the Company may adjust provisional amounts recorded for assets acquired and liabilities assumed to reflect new information that the Company has subsequently obtained regarding facts and circumstances that existed as of the acquisition date.

***Acquisition and Integration Costs***

Acquisition-related costs that are not part of the purchase price consideration are generally expensed as incurred, except for certain costs that are deferred in connection with the issuance of debt. These costs typically include transaction-related costs, such as finder's fees, legal, accounting and other professional costs. Integration-related costs represent costs directly related to combining the Company and its acquired businesses. Integration-related costs typically include strategic consulting services, facility consolidation, employee related costs, such as retention and severance, costs to integrate information technology infrastructure, enterprise planning systems, processes, and other non-recurring integration-related costs. Acquisition and integration costs are presented within "Other operating (income) expense" on the consolidated statements of income.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

***Restructuring Costs***

The Company periodically initiates restructuring activities to support business strategies, realign resources, and enhance its operational efficiency. Restructuring costs may include severance and other employee related termination costs, costs associated with consolidating or closing facilities and consulting costs.

One-time involuntary employee termination benefits are recognized as a liability and measured at fair value when the plan of termination has been communicated to employees and certain other criteria are met. Ongoing employee termination benefit arrangements are recognized as a liability and measured at fair value when it is probable that amounts will be paid and such amounts are reasonably estimable. Other employee related termination costs include the impact of accelerated stock compensation expense for terminated employees that have a reduction in the requisite service period for their stock-based awards.

Costs to consolidate or close facilities primarily include lease obligation charges for exited facilities, including the impact of accelerated lease expense for right of use ("ROU") assets and accelerated depreciation expense for leasehold improvements with reductions in their estimated useful lives due to exited facilities.

***Leases***

The Company occupies most of its facilities under operating leases. Certain equipment is also leased under short-term or cancelable operating leases.

The Company recognizes ROU assets and a lease liabilities upon the commencement of its operating leases. The initial lease liability is equal to the future fixed minimum lease payments discounted using the Company's incremental borrowing rate on a secured basis. The lease term includes option renewal periods and early termination payments when it is reasonably certain that the Company will exercise those rights. The initial measurement of the ROU asset is equal to the initial lease liability plus any initial direct costs and prepayments, less any lease incentives.

The Company recognizes lease costs on a straight-line basis over the remaining lease term, except for variable lease payments that are expensed in the period in which the obligation for those payments is incurred.

For its facility leases, the Company combines and accounts for lease and non-lease components together as a single component. The Company does not recognize lease liabilities and ROU assets for leases with original terms of 12 months or less. ROU assets are evaluated for impairment as a long-lived asset.

***Goodwill and Intangible Assets***

Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the assets acquired and liabilities assumed. Goodwill and indefinite-lived intangible assets are not amortized, but rather are tested for potential impairment annually at the beginning of the Company's fourth quarter, or whenever events or changes in circumstances indicate that the carrying value may not be recoverable. There were no impairments during the periods presented.

The goodwill impairment test is performed at the reporting unit level. In the Company's qualitative assessment, an evaluation is performed to determine whether it is more likely than not that an impairment exists based on qualitative factors. Qualitative factors include macroeconomic, industry and market conditions, cost factors, overall financial performance, relevant entity-specific events, factors affecting the reporting unit, and share price.

The Company may additionally perform a quantitative assessment in which the fair value of the Company's reporting units are determined using either a market approach, income approach, or a combination of both, which involves the use of estimates and assumptions, including projected future operating results and cash flows, the cost of capital, and financial measures derived from observable market data of comparable public companies. The Company estimates and compares the fair value of each reporting unit to its respective carrying value including goodwill. If the fair value is less than the carrying value, the amount of impairment expense is equal to the difference between the reporting unit's fair value and the reporting unit's carrying value.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

Intangible assets with finite lives are amortized using the method that best reflects how their economic benefits are utilized or, if a pattern of economic benefits cannot be reliably determined, on a straight-line basis over their estimated useful lives. Intangible assets with finite lives are assessed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable at the asset group level.

***Property, Plant, and Equipment***

Property, plant, and equipment are carried at cost net of accumulated depreciation and amortization. Purchases of property, plant, and equipment, as well as costs associated with major renewals and betterments, are capitalized. Maintenance, repairs and minor renewals and betterments are expensed as incurred. When assets are sold or otherwise disposed of, the cost and related accumulated depreciation or amortization are removed and any resulting gain or loss is recognized. See Note 7—Property, Plant, and Equipment for depreciation and amortization methods and estimated useful lives by major asset class.

***Impairment of Long-lived Assets***

The Company evaluates its long-lived assets (including right of use lease assets) for potential impairment whenever there is evidence that events or changes in circumstances indicate that the carrying value may not be recoverable and the carrying amount of the asset exceeds its estimated future undiscounted cash flows (including sublease income) at the asset group level. When the carrying amount of the asset exceeds its estimated future undiscounted cash flows, an impairment loss is recognized to reduce the asset's carrying amount to its estimated fair value based on the present value of its estimated future cash flows.

In circumstances in which the Company has the ability and intent to sublease an exited facility, the Company performs an impairment test of the asset group (mainly consisting of right of use lease assets and leasehold improvements) on the earlier of the cease use date or sublease inception date by comparing the carrying amount of the asset group to the undiscounted cash flows associated with the asset group (mainly sublease income). When the carrying amount of the asset group exceeds its estimated future undiscounted cash flows, an impairment loss is recognized to reduce the asset group's carrying amount to its estimated fair value based on the present value of estimated future cash flows. In circumstances in which the Company does not have the ability or intent to sublease an exited facility, the Company adjusts the estimated useful life of the facility related assets to end on the cease use date and recognizes accelerated depreciation and amortization.

***Commitments and Contingencies***

Accruals for commitments and loss contingencies are recorded when it is both probable that they will occur and the amounts can be reasonably estimated. In addition, legal fees are accrued for cases where a loss is probable and the related fees can be reasonably estimated. Significant judgment is required to determine both the probability and the estimated amount of loss. The Company reviews these accruals quarterly and adjusts the accruals to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other updated information.

***Pension and Defined Benefit Plans***

The Company measures plan assets and benefit obligations as of the month-end that is closest to its fiscal year-end. Accounting and reporting for the Company's pension and defined benefit plans requires the use of assumptions, including but not limited to, a discount rate and an expected return on assets. These assumptions are reviewed at least annually based on reviews of current plan information and consultation with the Company's independent actuary and the plans' investment advisor. If these assumptions differ materially from actual results, the Company's obligations under the pension and defined benefit plans could also differ materially, potentially requiring the Company to record an additional liability. The Company's pension and defined benefit plan liabilities are developed from actuarial valuations performed each year.

***Fair Value Measurements***

The Company utilizes fair value measurement guidance prescribed by GAAP to value its financial instruments. The accounting standard for fair value measurements establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: observable inputs such as quoted prices in active markets (Level 1); inputs other than the quoted prices in active markets that are observable either directly or indirectly (Level 2); and

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions (Level 3).

The carrying amounts of cash and cash equivalents, receivables, accounts payable and other amounts included in other current assets and current liabilities that meet the definition of a financial instrument approximate fair value due to the short-term nature of these amounts. The carrying value of the Company's outstanding debt obligations approximates its fair value, which is calculated using Level 2 inputs, based on interest rates available for debt with terms and maturities similar to the Company's existing debt arrangements.

Non-financial assets acquired and liabilities assumed in a business combination are measured at fair value using income, market and cost valuation methodologies.

***Marketable Securities***

Investments in marketable securities consist of equity securities, which are recorded at fair value using observable inputs such as quoted prices in active markets (Level 1). The Company's investments are primarily held in a custodial account, which includes investments to fund its deferred compensation plan liabilities.

***Derivative Instruments Designated as Cash Flow Hedges***

Derivative instruments are recorded on the consolidated balance sheets at fair value. Unrealized gains and losses on derivatives designated as cash flow hedges are reported in other comprehensive income (loss) and reclassified to earnings in a manner that matches the timing of the earnings impact of the hedged transactions. Settlement amounts related to derivatives designated as cash flow hedges are presented within operating activities on the consolidated statement of cash flows.

The Company's fixed interest rate swaps which expired in fiscal 2026 were considered over-the-counter derivatives, and their fair value was calculated using a standard pricing model for interest rate swaps with contractual terms for maturities, amortization and interest rates. Level 2, or market observable inputs (such as yield and credit curves), are used within the standard pricing models in order to determine fair value. The fair value is an estimate of the amount that the Company would pay or receive as of a measurement date if the agreements were transferred to a third party. See Note 12—Derivative Instruments Designated as Cash Flow Hedges for further discussion on the Company's derivative instruments designated as cash flow hedges.

***Research and Development***

The Company conducts research and development activities under customer-funded contracts and with company-funded independent research and development ("IR&D") funds. IR&D efforts consist of projects involving basic research, applied research, development, and systems and other concept formulation studies. Company-funded IR&D expense is included in "Selling, general and administrative expenses" and was $13 million, $12 million and $4 million in fiscal 2026, 2025 and 2024, respectively. Customer-funded research and development activities performed under customer contracts are charged directly to cost of revenues for those particular contracts.

***Investments in Equity Securities***

The Company invests in certain companies that advance or develop new technologies applicable to its business. The Company also occasionally forms joint ventures as a part of its investment strategy for the purpose of bidding and executing on specific projects. Each investment is evaluated for consolidation under the variable interest entities ("VIEs") model and/or the voting interest model. The results of these investments are not material to the consolidated financial statements for the periods presented.

The Company applies the equity method of accounting to its unconsolidated investments when it has the ability to exercise significant influence over the entity and recognizes its proportionate share of the entities' net income or loss within "Other operating (income) expense" on the consolidated statements of income. Equity investments in entities over which the Company does not have the ability to exercise significant influence and whose securities do not have a readily determinable fair value are carried at cost net of other-than-temporary impairments.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

*Sale of Equity Method Investment*

On August 30, 2024, Morpheus Data, one of the Company's unconsolidated venture investments, completed a transaction to sell all its outstanding equity, including the Company's equity investment, to Hewlett Packard Enterprise (NYSE: HPE) for $10 million in cash. The Company recognized the cash as "Proceeds from sale of equity method investments" on the consolidated statements of cash flows. The transaction resulted in a pre-tax gain of $5 million which is included within "Other operating (income) expense" on the consolidated statements of income.

***Accounting Standards Updates***

*Accounting Standards Updates Recently Adopted*

In December 2023, the FASB issued ASU No. 2023-09, *Income Taxes (Topic 740): Improvements to Income Tax Disclosures.* The standard includes amendments that enhance annual income tax disclosures, primarily through standardization and disaggregation of rate reconciliation categories and income taxes paid by jurisdiction. The standard was effective for fiscal years beginning after December 15, 2024. The Company adopted this standard prospectively in fiscal 2026.

*Accounting Standards Updates Recently Issued But Not Yet Adopted*

In November 2024, the FASB issued ASU No. 2024-03, Income Statement – Reporting Comprehensive Income – Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. The standard includes new disclosure requirements relating to specified categories of expenses (purchases of inventory, employee compensation, depreciation, and amortization) that are included in certain expense captions presented on the face of the income statement. Early adoption is permitted. The amendments can be applied on a prospective or retrospective basis. In January 2025, the FASB clarified the effective date of the standard by issuing ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date. The standard is effective for fiscal years beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating the impact of adoption of this standard on its financial statement disclosures.

In September 2025, the FASB issued ASU No. 2025-06, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. The standard modernizes the accounting for internal-use software costs by removing all references to project stages and defining a probable-to-complete threshold to begin capitalizing costs. The standard also clarifies the disclosure requirements for capitalized internal-use software costs. The standard is effective for annual reporting periods, including interim reporting periods within those annual reporting periods, beginning after December 15, 2027. The amendment can be applied prospectively, retrospectively, or on a modified transition approach. Early adoption is permitted. The Company is currently evaluating the impact of adoption of this standard on its consolidated financial statements and related disclosures.

**Note 2—Earnings Per Share, Share Repurchases and Dividends:**

***Earnings Per Share ("EPS")***

Basic EPS is computed by dividing net income attributable to common stockholders by the basic weighted-average number of shares outstanding. Diluted EPS is computed similarly to basic EPS, except the weighted-average number of shares outstanding is increased to include the dilutive effect of outstanding stock options and other stock-based awards. The dilutive effect of outstanding stock options and other stock-based awards is computed using the treasury stock method.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

The following table provides a reconciliation of the weighted-average number of shares outstanding used to compute basic and diluted EPS for the periods presented:

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30,<br>2026** | January 31,<br>2025 | February 2,<br>2024 |
| | (in millions) | (in millions) | (in millions) |
| Basic weighted-average number of shares outstanding | **46.3** | 50.1 | 53.1 |
| Dilutive common share equivalents - stock options and other stock-based awards | **0.2** | 0.4 | 0.6 |
| Diluted weighted-average number of shares outstanding | **46.5** | 50.5 | 53.7 |

---

Antidilutive stock awards excluded from the weighted-average number of shares outstanding used to compute diluted EPS for fiscal 2026, 2025, and 2024 were immaterial.

***Repurchases***

The Company may repurchase shares in accordance with established repurchase plans. The Company retires its common stock upon repurchase with the excess over par value allocated to additional paid-in capital. When repurchases for the period exceed total additional-paid-in-capital, the excess repurchases are recorded as a reduction to retained earnings. The Company has not made any material purchases of common stock other than in connection with established share repurchase plans.

During fiscal 2026, the Company repurchased approximately 4.0 million shares of its common stock from the open market under its existing share repurchase plan for approximately $422 million. In December 2024, the Company's Board of Directors authorized the repurchase of up to $1.2 billion of the Company's outstanding common stock under its existing share repurchase plan. As of January 30, 2026, the Company has repurchased approximately 28.5 million shares of its common stock under the plan for approximately $2.5 billion, which included amounts previously authorized under the plan prior to December 2024.

***Dividends***

The Company declared and paid quarterly dividends of $0.37 per share every quarter for the years presented. Total dividends declared and paid were $1.48 per share during fiscal 2026, 2025 and 2024. Subsequent to the end of fiscal 2026, on March 12, 2026, the Company's Board of Directors declared a cash dividend of $0.37 per share of the Company's common stock payable on April 24, 2026 to stockholders of record on April 10, 2026.

**Note 3—Revenues:**

***Changes in Estimates on Contracts***

Aggregate net changes in estimates on contracts accounted for using the cost-to-cost method of accounting were recognized in operating income as follows:

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30,<br>2026** | January 31,<br>2025 | February 2,<br>2024 |
| | (in millions, except per share amounts) | (in millions, except per share amounts) | (in millions, except per share amounts) |
| Favorable adjustments | $**22** | $33 | $32 |
| Unfavorable adjustments | **(21)** | (18) | (32) |
| Net favorable adjustments | **1** | 15 |  |
| Income tax effect | **—** | (2) |  |
| Net favorable adjustments, after tax | **1** | 13 |  |
| Basic and Diluted EPS impact | $**0.02** | $0.26 | $— |

---

Revenues were $9 million, $14 million and $2 million higher for fiscal 2026, 2025 and 2024, respectively, due to net revenue recognized from performance obligations satisfied in prior periods.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

***Disaggregation of Revenues***

The Company's revenues are generated primarily from long-term contracts with the U.S. government including subcontracts with other contractors engaged in work for the U.S. government. The Company disaggregates revenues by customer, contract type and prime versus subcontractor to the federal government for each of its reportable segments.

Disaggregated revenues by customer were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** |
| | **Defense and Intelligence** | **Civilian** | **Total SAIC** |
| | (in millions) | (in millions) | (in millions) |
| Department of War | $**3770** | $**8** | $**3778** |
| Intelligence and other federal government agencies | **1782** | **1521** | **3303** |
| Commercial, state and local governments and international | **29** | **152** | **181** |
| Total | $**5581** | $**1681** | $**7262** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | Year Ended January 31, 2025 | Year Ended January 31, 2025 | Year Ended January 31, 2025 |
| | Defense and Intelligence | Civilian | Total SAIC |
| | (in millions) | (in millions) | (in millions) |
| Department of War | $3856 | $17 | $3873 |
| Intelligence and other federal government agencies | 1841 | 1601 | 3442 |
| Commercial, state and local governments and international | 29 | 135 | 164 |
| Total | $5726 | $1753 | $7479 |

---

---

| | | | |
|:---|:---|:---|:---|
|  | Year Ended February 2, 2024 | Year Ended February 2, 2024 | Year Ended February 2, 2024 |
| | Defense and Intelligence | Civilian | Total SAIC |
| | (in millions) | (in millions) | (in millions) |
| Department of War | $3814 | $26 | $3840 |
| Intelligence and other federal government agencies | 1986 | 1464 | 3450 |
| Commercial, state and local governments and international | 17 | 137 | 154 |
| Total | $5817 | $1627 | $7444 |

---

Disaggregated revenues by contract type were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** |
| | **Defense and Intelligence** | **Civilian** | **Total SAIC** |
| | (in millions) | (in millions) | (in millions) |
| Cost reimbursement | $**4429** | $**56** | $**4485** |
| Time and materials ("T&M") | **510** | **1123** | **1633** |
| Firm-fixed price ("FFP") | **642** | **502** | **1144** |
| Total | $**5581** | $**1681** | $**7262** |

---

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

---

| | | | |
|:---|:---|:---|:---|
|  | Year Ended January 31, 2025 | Year Ended January 31, 2025 | Year Ended January 31, 2025 |
| | Defense and Intelligence | Civilian | Total SAIC |
| | (in millions) | (in millions) | (in millions) |
| Cost reimbursement | $4548 | $88 | $4636 |
| Time and materials ("T&M") | 559 | 1088 | 1647 |
| Firm-fixed price ("FFP") | 619 | 577 | 1196 |
| Total | $5726 | $1753 | $7479 |

---

---

| | | | |
|:---|:---|:---|:---|
|  | Year Ended February 2, 2024 | Year Ended February 2, 2024 | Year Ended February 2, 2024 |
| | Defense and Intelligence | Civilian | Total SAIC |
| | (in millions) | (in millions) | (in millions) |
| Cost reimbursement | $4442 | $85 | $4527 |
| Time and materials ("T&M") | 491 | 972 | 1463 |
| Firm-fixed price ("FFP") | 884 | 570 | 1454 |
| Total | $5817 | $1627 | $7444 |

---

Disaggregated revenues by prime versus subcontractor were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** |
| | **Defense and Intelligence** | **Civilian** | **Total SAIC** |
| | (in millions) | (in millions) | (in millions) |
| Prime contractor to federal government | $**5073** | $**1391** | $**6464** |
| Subcontractor to federal government | **479** | **138** | **617** |
| Other | **29** | **152** | **181** |
| Total | $**5581** | $**1681** | $**7262** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | Year Ended January 31, 2025 | Year Ended January 31, 2025 | Year Ended January 31, 2025 |
| | Defense and Intelligence | Civilian | Total SAIC |
| | (in millions) | (in millions) | (in millions) |
| Prime contractor to federal government | $5198 | $1471 | $6669 |
| Subcontractor to federal government | 499 | 147 | 646 |
| Other | 29 | 135 | 164 |
| Total | $5726 | $1753 | $7479 |

---

---

| | | | |
|:---|:---|:---|:---|
|  | Year Ended February 2, 2024 | Year Ended February 2, 2024 | Year Ended February 2, 2024 |
| | Defense and Intelligence | Civilian | Total SAIC |
| | (in millions) | (in millions) | (in millions) |
| Prime contractor to federal government | $5355 | $1367 | $6722 |
| Subcontractor to federal government | 445 | 123 | 568 |
| Other | 17 | 137 | 154 |
| Total | $5817 | $1627 | $7444 |

---

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

***Contract Balances***

Contract balances for the periods presented were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | Balance Sheet line item | **January 30,<br>2026** | January 31,<br>2025 |
| | | (in millions) | (in millions) |
| Billed and billable receivables, net<sup>(1)</sup> | Receivables, net | $**490** | $526 |
| Contract assets - unbillable receivables | Receivables, net | **363** | 474 |
| Contract assets - unbillable receivables | Other assets | **23** | 29 |
| Contract assets - contract retentions | Other assets | **18** | 15 |
| Contract liabilities - current | Other accrued liabilities | **41** | 38 |
| Contract liabilities - non-current | Other long-term liabilities | $**2** | $— |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Net of allowance of $2 million and $3 million as of January 30, 2026 and January 31, 2025 respectively.

The changes in the Company's contract assets and contract liabilities during the current period primarily result from timing differences between the Company's performance, invoicing and customer payments. During fiscal 2026 and 2025, the Company recognized revenues of $28 million and $35 million relating to amounts that were included in the opening balance of contract liabilities as of January 31, 2025 and February 2, 2024, respectively.

***Deferred Costs***

Deferred costs for the periods presented were as follows:

---

| | | | |
|:---|:---|:---|:---|
|  | Balance Sheet line item | **January 30,<br>2026** | January 31,<br>2025 |
|  |  | (in millions) | (in millions) |
| Pre-contract costs | Other current assets | $**3** | $— |
| Prepaid contract costs | Prepaid expenses | **16** | 9 |
| Fulfillment costs | Other assets | **4** | 4 |
| Costs to obtain | Other assets | $**8** | $6 |

---

Pre-contract costs expensed in fiscal 2026 were immaterial, and pre-contract costs of $9 million were expensed during fiscal 2025. Prepaid contract costs of $34 million and $36 million were amortized during fiscal 2026 and 2025, respectively. Fulfillment costs of $3 million were amortized during fiscal 2026 and 2025. Costs to obtain of $2 million were amortized during fiscal 2026 and 2025.

***Remaining Performance Obligations***

Remaining performance obligations ("RPO") represent the transaction price of exercised contracts (both funded and unfunded) less inception to date revenue recognized. RPO does not include unexercised option periods and future task orders expected to be awarded under IDIQ contracts. As of January 30, 2026, the Company had approximately $6.2 billion of RPO. The Company expects to recognize revenue on approximately 78% of the RPO over the next 12 months and approximately 89% over the next 24 months, with the remaining recognized thereafter.

**Note 4—Acquisitions and Divestitures:**

***Acquisition of SilverEdge Government Solutions ("SilverEdge")***

On October 15, 2025, the Company acquired SilverEdge, an innovative provider of mission-driven technology solutions and products, for a preliminary purchase price of $203 million, net of $6 million cash acquired, subject to post-closing adjustments. The acquisition advances the Company's strategy to provide mission focused solutions and commercial products to its customers. The Company funded the transaction from increased borrowings (see Note 11—Debt Obligations for additional information) and cash on hand.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

As of January 30, 2026, the Company is in the process of finalizing the valuation and purchase price allocation related to this acquisition. The Company has preliminarily recorded goodwill and amortizable intangible assets of $93 million and $101 million, respectively. During the fourth quarter of fiscal 2026, the Company decreased goodwill by $16 million which consisted of $14 million in estimated fair value adjustments for acquired intangible assets and $2 million in other adjustments to operating assets and liabilities. Substantially all of the goodwill recorded is tax deductible. The goodwill is primarily associated with intellectual capital and acquired assembled workforce. The intangible assets consist of customer relationships of $90 million, developed technology of $9 million, and backlog of $2 million that will be amortized over a period of ten years, eight years, and one year, respectively.

During fiscal 2026, revenues of $27 million related to SilverEdge were recorded to the Defense and Intelligence reportable segment.

***FSA Amendment***

On February 4, 2023, the Company sold 0.1% of its 50.1% majority ownership interest in Forfeiture Support Associates J.V. ("FSA") to its sole joint venture partner for a nominal amount. In conjunction with the sale, the Company remeasured its retained investment in FSA to a fair value of $14 million. As a result of the sale and amendment to the joint venture operating agreement of FSA, the Company no longer controls the joint venture and accounts for its retained interest as an equity method investment as of the date of the transaction.

***Sale of Logistics and Supply Chain Management Business***

On May 6, 2023, the Company closed the sale of its logistics and supply chain management business ("Supply Chain Business") to ASRC Federal Holding Company, LLC ("ASRC Federal") for $356 million in cash. The sale enables the Company to focus its resources on long-term strategic growth areas. The Company recognized the cash as "Proceeds from divestitures" on the consolidated statements of cash flows in fiscal 2024. The Company recorded a pre-tax gain of $233 million, net of $7 million of transaction costs, which is included within "(Gain) loss on divestitures, net of transaction costs" on the consolidated statements of income in fiscal 2024.

The disposition did not represent a strategic shift in operations that will have a material effect on the Company's operations and financial results, and accordingly has not been presented as discontinued operations.

The major classes of assets and liabilities divested were as follows:

---

| | |
|:---|:---|
| | (in millions) |
| Assets: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables, net | $**46** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventories, net | **72** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | **1** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Goodwill | **60** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease ROU assets | **2** |
| Total assets divested | $**181** |
| Liabilities: |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable  | $**62** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued payroll and employee benefits | **1** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other accrued liabilities | **1** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | **1** |
| Total liabilities divested | $**65** |

---

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

**Note 5—Restructuring, Impairment and Other Exit Costs:**

Restructuring, impairment and other exit costs recognized were as follows:

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30, 2026** | January 31, 2025 | February 2, 2024 |
| | (in millions) | (in millions) | (in millions) |
| Restructuring costs: |  |  |  |
| &nbsp;&nbsp;&nbsp;Severance and other employee costs | $**8** | $1 | $10 |
| &nbsp;&nbsp;&nbsp;Other associated costs | **4** | 7 | 13 |
| Total restructuring costs<sup>(1)</sup> | **12** | **8** | **23** |
| Impairment of assets | **1** |  |  |
| Executive transition costs<sup>(2)</sup> | **22** |  |  |
| Total restructuring, impairment and other exit costs | $**35** | $8 | $23 |

---

(1) &nbsp;&nbsp;&nbsp;&nbsp;Restructuring costs in fiscal 2026 include $7 million recorded in the Defense and Intelligence reportable segment "Cost of revenues" and $5 million recorded in Corporate "Selling, general and administrative expenses." Restructuring costs in fiscal 2025 and fiscal 2024 were recorded in Corporate "Selling, general and administrative expenses."

(2) &nbsp;&nbsp;&nbsp;&nbsp;Executive transition costs are recorded in Corporate and are included in "Selling, general and administrative expenses."

During fiscal 2026, the Company incurred costs related to restructuring activities associated with the reorganization of its business groups and the optimization and consolidation of certain facilities. As part of these activities, the Company incurred severance and other employee costs and costs related to the consolidation and exit of certain facilities. Other employee costs include the impact of accelerated stock compensation expense for terminated employees. Executive transition costs represent costs associated with the immediate departure of the Company's CEO and other executives.

During fiscal 2025 and 2024, the Company incurred costs related to restructuring activities associated with the reorganization of its business sectors into business groups and for the optimization and consolidation of certain facilities. As part of these activities, the Company incurred severance and other employee costs, consulting costs, and costs related to the consolidation and exit of certain facilities. Other employee costs include the impact of accelerated stock compensation expense for terminated employees.

**Note 6—Goodwill and Intangible Assets:**

***Goodwill***

The following table presents the carrying value of goodwill by reportable segment:

---

| | | |
|:---|:---|:---|
| | **January 30,<br>2026** | January 31,<br>2025 |
| | (in millions) | (in millions) |
| Defense and Intelligence | $**2094** | $2001 |
| Civilian | **850** | 850 |
| Total | $**2944** | $2851 |

---

During fiscal 2026, goodwill increased by $93 million in the Defense and Intelligence reportable segment due to the acquisition of SilverEdge (see Note 4—Acquisitions and Divestitures for additional information).

As a result of the internal reorganization on February 3, 2024, the Company reallocated its goodwill to its five new goodwill reporting units. The Company performed a goodwill impairment test immediately before and after the reorganization, both of which resulted in no impairment. For the goodwill impairment test immediately after the reorganization, the Company performed a quantitative assessment of its goodwill as of February 3, 2024 for its five new goodwill reporting units. The Company estimated the fair value of each reporting unit using a 50:50 weighting of fair values derived from an income approach and market approach.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

Under the income approach, the Company estimated the fair value of its reporting units using a multi-year discounted cash flow model involving assumptions about projected future revenue growth, operating margins, income tax rates, capital expenditures, discount rate, and terminal value. Under the market approach, the Company estimated the fair value of its reporting units based on multiples of earnings derived from observable market data of comparable public companies.

During the fourth quarter of fiscal 2026, the Company completed its annual goodwill impairment testing using a qualitative assessment and determined that it was more likely than not that an impairment did not exist and that a quantitative analysis was not necessary.

***Intangible Assets***

Intangible assets, all of which were finite-lived, consisted of the following:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **January 30, 2026** | **January 30, 2026** | **January 30, 2026** | January 31, 2025 | January 31, 2025 | January 31, 2025 |
| | **Gross carrying value** | **Accumulated amortization** | **Net carrying value** | Gross carrying value | Accumulated amortization | Net carrying value |
| | (in millions) | (in millions) | (in millions) | (in millions) | (in millions) | (in millions) |
| Customer relationships | $**1551** | $**(804)** | $**747** | $1462 | $(688) | $774 |
| Developed technology | **19** | **(6)** | **13** | 10 | (5) | 5 |
| Backlog | **2** | **(1)** | **1** |  |  |  |
| Trade name | **—** | **—** | **—** | 1 | (1) |  |
| Total intangible assets | $**1572** | $**(811)** | $**761** | $1473 | $(694) | $779 |

---

During fiscal 2026, the gross carrying value of intangible assets increased by $99 million primarily due to the acquisition of SilverEdge (see Note 4—Acquisitions for additional information).

Amortization expense related to intangible assets was $119 million for fiscal 2026 and $115 million for fiscal 2025 and 2024. There were no impairments of intangible assets during the periods presented.

As of January 30, 2026, the estimated future annual amortization expense related to intangible assets is as follows:

---

| | |
|:---|:---|
| Fiscal Year | (in millions) |
| 2027 | $126 |
| 2028 | 108 |
| 2029 | 108 |
| 2030 | 105 |
| 2031 | 98 |
| Thereafter | 216 |
| Total | $761 |

---

Actual amortization expense in future periods could differ from these estimates as a result of future acquisitions, divestitures, impairments and other factors.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

**Note 7—Property, Plant, and Equipment:**

Property, plant, and equipment, depreciation and amortization methods, and estimated useful lives by major asset class were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Depreciation or<br>amortization method | Estimated useful lives (in years) | **January 30,<br>2026** | January 31,<br>2025 |
| | | | (in millions) | (in millions) |
| Computer and other equipment | Straight-line or<br>declining balance | 5-10 | $**101** | $98 |
| Capitalized software | Straight-line | 3-6 | **60** | 58 |
| Leasehold improvements | Straight-line | Shorter of lease term or 12 | **118** | 111 |
| Office furniture and fixtures | Straight-line | 3-10 | **20** | 16 |
| Buildings and improvements | Straight-line | 40 | **7** | 7 |
| Construction in process |  |  | **18** | 13 |
| Land |  |  | **1** | 1 |
| Property, plant, and equipment |  |  | **325** | 304 |
| Accumulated depreciation and amortization |  |  | **(215)** | (200) |
| Property, plant, and equipment, net |  |  | $**110** | $104 |

---

Depreciation and amortization expense for property, plant, and equipment was $30 million, $25 million and $26 million in fiscal 2026, 2025 and 2024, respectively.

**Note 8—Stock-Based Compensation:**

***Plan Summaries***

As of January 30, 2026, the Company had stock-based compensation awards outstanding under the following plans: "2023 Equity Incentive Plan" ("2023 EIP"), "2013 Equity Incentive Plan" ("2013 EIP"), "Management Stock Compensation Plan" ("MSCP"), "Key Executive Stock Deferral Plan" ("KESDP"), and the "Amended and Restated 2013 Employee Stock Purchase Plan" ("ESPP") which are herein referred to together as the "Plans." The Company issues new shares on the vesting of stock awards or exercise of stock options under these Plans. During fiscal year 2024, the Company terminated the Third Amended and Restated 2012 Long Term Performance Plan ("LTPP") and deregistered all remaining unissued shares thereunder.

On June 7, 2023, the Company's stockholders approved the 2023 EIP. The 2023 EIP authorized 2.2 million new shares of the Company's common stock, par value $0.0001 per share, to be issued as various types of stock-based compensation and cash awards. Awards previously issued and outstanding under the 2013 EIP will continue to remain outstanding and be subject to the terms of the 2013 EIP. After June 7, 2023, no new awards may be issued under the 2013 EIP and any awards that subsequently expire, are forfeited or canceled, are settled in cash, or are used to cover recipient tax obligations, will become available for issuance under the 2023 Plan. As of January 30, 2026, the total authorized shares of common stock for issuance under the 2023 EIP is 1.5 million.

The 2023 EIP and 2013 EIP both provide the Company's employees and directors the opportunity to receive various types of stock-based compensation and cash awards. The terms of the stock-based awards granted to employees and directors are the same, except that those for directors cliff vest within one year of the grant date. As of January 30, 2026, the Company has unvested stock awards under the 2023 EIP and 2013 EIP, unvested performance shares under the 2023 EIP, and outstanding stock options under the 2013 EIP. Vesting stock awards granted in fiscal 2020 and thereafter generally vest equally over three years, while vesting stock awards granted prior to fiscal 2020 generally vest equally over four years. Stock options generally become exercisable evenly over three years. The maximum contractual term for stock options is ten years, but historically the Company has granted stock options with a seven-year contractual term. As of January 30, 2026, remaining stock options expected to be exercised are immaterial. The requisite service period for stock-based awards is accelerated for employees meeting certain retirement eligibility conditions. Certain officers are eligible for continued vesting of previously granted awards upon termination of employment or voluntary retirement, subject to the conditions set forth in the Company's

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

Executive Severance, Change in Control and Retirement Policy effective September 5, 2023. Stock-based awards generally provide for accelerated vesting if there is a change in control (as defined in the 2023 EIP and 2013 EIP, as applicable). Vesting stock awards and performance share awards have forfeitable rights to dividends.

Performance shares are rights to receive shares of the Company's stock upon satisfaction of certain requirements. Performance-based stock awards include service, performance, and market conditions. For performance-based stock awards granted in fiscal 2023 and thereafter, the performance metrics are based on three year cumulative operating cash flows and a three year cumulative measure of earnings. The market conditions are based on the Company's total shareholder return over the three year performance period as compared to the total shareholder return for a specified group of companies over the same period. These awards cliff vest at the end of the third fiscal year following the grant date, subject to meeting the minimum service requirements and the achievement of the Company's performance metrics and market conditions, with the number of shares ultimately issued, if any, ranging up to 200% of the specified target shares. If performance is below a minimum threshold level of performance, no shares will be issued.

The Science Applications International Corporation KESDP was closed on December 31, 2014, and no further deferrals are allowed. Benefits from the KESDP are payable in shares of the Company's stock that may be held in trust for the purpose of funding benefit payments to KESDP participants. The MSCP provides for awards in share units to eligible employees. Benefits are payable in shares of the Company's stock that are held in a trust for the purpose of funding benefit payments to the participants. During fiscal 2017, all remaining outstanding awards in the MSCP vested. Vested deferred balances in both plans are paid on retirement based on the participant's payout election, or upon termination.

On June 7, 2023, the Company's stockholders approved an amended and restated ESPP which limits the total number of shares reserved for issuance to 2.0 million and extends the plan's expiration date from September 26, 2023 to the earlier of its termination by the Board of Directors or the issuance of all shares available for issuance thereunder. The ESPP allows eligible employees to purchase shares of the Company's common stock at a discount of up to 15% of the fair market value on the date of purchase. During the three fiscal years ended January 30, 2026, the ESPP discount was 5% of the fair market value on the date of purchase, thereby resulting in the ESPP being non-compensatory. As of January 30, 2026, 1.5 million shares of the Company's common stock are authorized for issuance under the ESPP.

***Expense and Related Tax Benefits Recognized***

Stock-based compensation expense and related tax benefits recognized under the Plans were:

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30,<br>2026** | January 31,<br>2025 | February 2,<br>2024 |
| | (in millions) | (in millions) | (in millions) |
| Stock-based compensation expense: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Vesting stock awards | $**43** | $37 | $45 |
| &nbsp;&nbsp;&nbsp;&nbsp;Performance share awards | **21** | 16 | 23 |
| Total stock-based compensation expense | $**64** | $53 | $68 |
| Tax benefits recognized from stock-based compensation | $**18** | $18 | $25 |

---

The Company did not have stock-based compensation expense for stock options for fiscal 2026 or fiscal 2025. Stock-based compensation expense for stock options was not material for fiscal 2024.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

***Vesting Stock Awards***

Vesting stock award activity for the fiscal year ended January 30, 2026 was:

---

| | | |
|:---|:---|:---|
| | Shares of stock under vesting stock awards | Weighted-average grant date fair value |
| | (in millions) | |
| Unvested at January 31, 2025 | 0.7 | $115.43 |
| &nbsp;&nbsp;&nbsp;&nbsp;Awards granted | 0.5 | 109.06 |
| &nbsp;&nbsp;&nbsp;&nbsp;Awards forfeited | (0.1) | 114.71 |
| &nbsp;&nbsp;&nbsp;&nbsp;Awards vested | (0.3) | 109.06 |
| Unvested at January 30, 2026 | **0.8** | $**114.11** |

---

The grant date fair value of vesting stock awards is based on the closing market price of the Company's common stock on the last trading day preceding the grant date. The weighted-average grant date fair value of the vesting stock awards granted in fiscal 2026, 2025 and 2024 was $109.06, $127.33 and $108.64, respectively. As of January 30, 2026 there was $41 million of unrecognized compensation cost, net of estimated forfeitures, related to vesting stock awards, which is expected to be recognized over a weighted-average period of 1.8 years. The fair value of vesting stock awards that vested in fiscal 2026, 2025 and 2024 was $38 million, $61 million and $48 million, respectively.

***Performance Share Awards***

Performance share award activity for the year ended January 30, 2026 was:

---

| | | |
|:---|:---|:---|
| | Shares of stock under performance shares | Weighted-average grant date fair value |
| | (in millions) | |
| Unvested at January 31, 2025 | 0.3 | $116.97 |
| &nbsp;&nbsp;&nbsp;&nbsp;Awards granted | 0.2 | 136.72 |
| &nbsp;&nbsp;&nbsp;&nbsp;Awards forfeited | (0.1) | 128.43 |
| &nbsp;&nbsp;&nbsp;&nbsp;Awards vested | (0.2) | 109.69 |
| &nbsp;&nbsp;&nbsp;&nbsp;Performance adjustments |  | 122.66 |
| Unvested at January 30, 2026 | **0.2** | $**137.76** |

---

The actual number of shares to be issued upon vesting ranges between 0-200% of the specified target shares. In the table above, the number of performance shares are presented at 100% of the specified target shares, except for awards that vested and the performance adjustment. The vested amount reflects the number of shares to be issued based on the actual achievement of the performance goals for shares that vested during the period. The performance adjustment amount reflects the increase or decrease in the number of performance shares vested compared to the number of performance shares that would have vested at target.

The weighted-average grant date fair value of the performance share awards granted in fiscal 2026, 2025 and 2024 was $136.72, $128.17 and $116.25, respectively. The grant date fair value of performance shares was determined using a Monte Carlo simulation model that incorporated multiple valuation assumptions, including the Company's expected total shareholder return relative to a specified group of companies defined within the award agreement. The primary assumptions included an expected volatility of 27.73%, 24.16%, and 27.35% for fiscal 2026, 2025 and 2024, respectively, and a risk-free interest rate of 3.59%, 4.46% and 3.68% for fiscal 2026, 2025 and 2024, respectively. The expected volatility was based on the historical volatility of the Company's stock price over a period commensurate with the expected term of the award as of the date of grant. The risk-free interest rate was based on the yield curve of a zero-coupon U.S. Treasury bond with a maturity equal to the expected term of the award on the date of grant.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

The fair value of performance share awards that vested in fiscal 2026 was $17 million. As of January 30, 2026 there was $10 million of unrecognized compensation cost, net of estimated forfeitures, related to performance share awards, which is expected to be recognized over a weighted-average period of 1.6 years.

**Note 9—Retirement Plans:**

***Defined Contribution Plans***

The Company sponsors the Science Applications International Corporation Retirement Plan (a qualified defined contribution 401(k) plan) and an employee stock ownership plan, in which most employees are eligible to participate. There are a variety of investment options available, including the Company's stock.

The Science Applications International Corporation Retirement Plan allows eligible participants to contribute a portion of their income through payroll deductions, and the Company makes matching company contributions and may also make discretionary contributions.

The Company contributions expensed for defined contribution plans were $89 million, $86 million and $82 million in fiscal 2026, 2025 and 2024, respectively.

***Deferred Compensation Plans***

The Company maintains the Science Applications International Corporation Deferred Compensation Plan ("DCP") which provides certain eligible employees and directors with an opportunity to defer some or all of their compensation on an unfunded, nonqualified basis. Participant deferrals are fully vested and diversified at the participant's direction among the investment options offered under the DCP. Participant accounts are credited with a rate of return based on the performance of the investment options selected. Distributions are made in cash. Deferred balances are paid on retirement based on the participant's payout election, or upon termination. The Company may provide discretionary contributions to participants, but no Company contributions have been made.

The Science Applications International Corporation 401(k) Excess Deferral Plan ("Excess Plan") was also closed on December 31, 2014, and no further deferrals are allowed. Participant deferrals are fully vested and diversified at the participant's direction among the investment options offered under the Excess Plan. Deferred balances are paid on retirement or termination.

***Defined Benefit Plans***

In connection with the acquisition of Engility Holdings, Inc. ("Engility") in fiscal 2019, the Company assumed two defined benefit plans sponsored by Engility for certain current and former employees: a Defined Benefit Pension Plan ("Pension Plan") and a Retiree Health Reimbursement Account Plan ("RHRA Benefit Plan"). Membership and participants' calculated pension benefits are frozen in the Pension Plan and membership in the RHRA Benefit Plan is frozen.

*Obligations and Funded Status*

The projected benefit obligation of the Pension Plan was $45 million and $46 million as of January 30, 2026 and January 31, 2025, respectively, and the fair value of the Pension Plan assets was $47 million and $44 million as of January 30, 2026 and January 31, 2025, respectively. The Pension Plan funded status was overfunded $2 million and underfunded $2 million as of January 30, 2026 and January 31, 2025, respectively.

The projected benefit obligation and underfunded status of the RHRA Benefit Plan was $7 million as of January 30, 2026 and January 31, 2025.

The funded status of the Defined Benefit Plans is included in "Other assets," "Other accrued liabilities," and "Other long-term liabilities" on the consolidated balance sheets.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

*Assumptions*

The Company uses the spot rate approach to measure liabilities and interest costs for defined benefit obligations. Under the spot rate approach, the Company uses individual spot rates along the yield curve that corresponds with the timing of each benefit payment.

The discount rates represent the estimated rate at which the Company could effectively settle its defined benefit obligations using a high-quality bond yield curve.

The assumed long-term rate of return on plan assets, which is the average return expected on the funds invested or to be invested to provide future benefits to pension plan participants, is determined by an annual review of historical returns on plan assets. In selecting the expected long-term rate of return on assets used for the Pension Plan, the Company considered its investment return goals stated in the Pension Plan's investment policy. This process included determining expected returns for the various asset classes that comprise the Pension Plan's target asset allocation.

The following assumptions were used to determine the benefit obligations and net periodic benefit costs:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **Pension Plan** | **Pension Plan** | **Pension Plan** | **RHRA Benefit Plan** | **RHRA Benefit Plan** | **RHRA Benefit Plan** |
| | **January 30, 2026** | January 31, 2025 | February 2, 2024 | **January 30, 2026** | January 31, 2025 | February 2, 2024 |
| Discount rate | **5.21%** | 5.50% | 5.16% | **4.85%** | 5.29% | 5.08% |
| Interest cost effective rate | **5.19%** | 5.04% | 4.82% | **5.02%** | 4.97% | 4.75% |
| Expected rate of return on assets | **5.25%** | 5.25% | 5.25% | **N/A** | N/A | N/A |

---

*Pension Plan Assets*

The Company's investment policy includes a periodic review of the Pension Plan's investment in the various asset classes. Risk management practices include regular evaluations of fund managers to ensure the risk assumed is commensurate with the given investment style and objectives. According to the plan's investment policy, performance will be evaluated across all time periods with a particular emphasis on longer-term returns relative to associated peers and benchmarks. During fiscal 2026, management approved and implemented a glide path asset allocation strategy that is designed to achieve and maintain a fully funded status, balancing Company contribution requirements with potential market risks. The glide path strategy provides for a variable asset allocation that is more heavily weighted toward fixed income securities as the Pension Plan's funding percentage increases.

The fair value measurement of plan assets by category is as follows:

---

| | | | |
|:---|:---|:---|:---|
| Asset Category | Fair Value Hierarchy | **January 30, 2026** | January 31, 2025 |
|  |  | (in millions) | (in millions) |
| Mutual funds |  |  |  |
| &nbsp;&nbsp;&nbsp;Equity | Level 1 | $**5** | $29 |
| &nbsp;&nbsp;&nbsp;Fixed income | Level 1 | **40** | 7 |
| Collective trust - fixed income | Level 2 | **—** | 7 |
| Guaranteed deposit account | Level 3 | **2** | 1 |
| Total |  | $**47** | $44 |

---

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

*Estimated Future Benefit Payments*

The following table sets forth the expected timing of benefit payments by fiscal year:

---

| | | | |
|:---|:---|:---|:---|
| Fiscal Year | **Pension Plan** | **RHRA Benefit Plan** | **Total** |
|  | (in millions) | (in millions) | (in millions) |
| 2027 | $5 | $1 | $6 |
| 2028 | 5 | 1 | 6 |
| 2029 | 4 | 1 | 5 |
| 2030 | 4 | 1 | 5 |
| 2031 | 4 | 1 | 5 |
| Five subsequent fiscal years | $18 | $2 | $20 |

---

**Note 10—Income Taxes:**

Substantially all of the Company's income before income taxes for the fiscal year ended January 30, 2026 and the two preceding fiscal years is subject to taxation in the United States. The provision for income taxes for each of the periods presented include the following:

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30,<br>2026** | January 31,<br>2025 | February 2,<br>2024 |
| | (in millions) | (in millions) | (in millions) |
| Current: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Federal | $**(64)** | $56 | $125 |
| &nbsp;&nbsp;&nbsp;&nbsp;State | **11** | 13 | 35 |
| &nbsp;&nbsp;&nbsp;&nbsp;Foreign | **1** |  |  |
| Deferred: |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Federal | **82** | (4) | (19) |
| &nbsp;&nbsp;&nbsp;&nbsp;State | **(1)** | 1 | 2 |
| Total | $**29** | $66 | $143 |

---

A reconciliation of the provision for income taxes to the amount computed by applying the statutory federal income tax rate to income before income taxes is as follows, in accordance with prospective adoption of ASU 2023-09:

---

| | | |
|:---|:---|:---|
| | Year Ended | Year Ended |
| | **January 30, 2026** | **January 30, 2026** |
| | Amount | Percent |
| | (dollars in millions) | (dollars in millions) |
| Amount computed at the statutory federal income tax rate | $**81** | **21.0%** |
| State income taxes, net of federal income tax effect<sup>(1)</sup> | **13** | **3.4%** |
| Tax credits |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development credits | **(10)** | **(2.5)%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other credits | **(1)** | **(0.4)%** |
| Non-taxable or non-deductible items |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-deductible compensation | **7** | **1.7%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | **(1)** | **(0.2)%** |
| Changes in unrecognized tax benefits | **(57)** | **(14.8)%** |
| Other | **(3)** | **(0.7)%** |
| Effective income tax rate | $**29** | **7.5%** |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;State taxes in Virginia and Texas contributed to the majority (greater than 50 percent) of the tax effect in this category.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

A reconciliation of the provision for income taxes to the amount computed by applying the statutory federal income tax rate to income before income taxes for each of the periods presented was as follows, before the adoption of ASU 2023-09:

---

| | | |
|:---|:---|:---|
| | Year Ended | Year Ended |
| | January 31,<br>2025 | February 2,<br>2024 |
| | (dollars in millions) | (dollars in millions) |
| Amount computed at the statutory federal income tax rate | $90 | $130 |
| State income taxes, net of federal tax benefit | 10 | 32 |
| Research and development and other federal credits | (22) | (17) |
| Non-deductible compensation | 3 | 10 |
| Excess tax benefits for stock-based compensation | (4) | (4) |
| Non-deductible goodwill |  | 13 |
| Foreign-derived intangible income | (15) | (22) |
| Other | 4 | 1 |
| Total | $66 | $143 |
| Effective income tax rate | 15.5% | 23.1% |

---

The effective income tax rate for fiscal 2026 is lower than the rate for fiscal 2025 primarily due to a $47 million benefit from an IRS audit settlement, pending final administrative approvals, covering fiscal years 2016 through 2019, and adjustments in liabilities for uncertain tax positions for the remaining open tax years.

Income taxes paid (net of refunds) consisted of the following:

---

| | |
|:---|:---|
| | Year Ended |
| | **January 30, 2026** |
| | (in millions) |
| U.S. Federal | $**10** |
| U.S. State and Local |  |
| &nbsp;&nbsp;&nbsp;&nbsp;California | **4** |
| &nbsp;&nbsp;&nbsp;&nbsp;Texas | **2** |
| &nbsp;&nbsp;&nbsp;&nbsp;Virginia | **3** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other | **2** |
| Foreign | **1** |
| Total cash paid for income taxes, net of refunds | $**22** |

---

Income taxes paid were $66 million and $165 million for the years ended January 31, 2025 and February 2, 2024, respectively.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

Deferred income taxes are recorded for differences in the basis of assets and liabilities for financial reporting purposes and tax reporting purposes. Deferred tax assets (liabilities) were comprised of:

---

| | | |
|:---|:---|:---|
| | **January 30,<br>2026** | January 31,<br>2025 |
| | (in millions) | (in millions) |
| Accrued vacation and bonuses | $**25** | $27 |
| Deferred compensation | **20** | 20 |
| Net operating loss and other carryforwards | **155** | 61 |
| Lease liability | **55** | 48 |
| Research and development expenditures | **21** | 197 |
| Other | **15** | 20 |
| Valuation allowance | **(7)** | (7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total deferred tax assets | **284** | 366 |
| Deferred revenue | **(31)** | (40) |
| Purchased intangible assets | **(297)** | (302) |
| Right of use assets | **(48)** | (41) |
| Other | **(12)** | (7) |
| &nbsp;&nbsp;&nbsp;&nbsp;Total deferred tax liabilities | **(388)** | (390) |
| Net deferred tax (liabilities) assets | $**(104)** | $(24) |

---

As of January 30, 2026, the Company has approximately $138 million of tax effected federal loss carryforwards, $9 million of tax effected state loss carryforwards and approximately $8 million of state credit carryforwards that will begin to expire in fiscal 2027. The valuation allowance of $7 million at January 30, 2026 relates to these state credit carryforwards.

The changes in the unrecognized tax benefits were:

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30,<br>2026** | January 31,<br>2025 | February 2,<br>2024 |
| | (in millions) | (in millions) | (in millions) |
| Unrecognized tax benefits at beginning of the year | $**110** | $117 | $158 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions for tax positions related to prior years | **2** | 1 | 5 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additions for tax positions related to the current year | **6** | 14 | 21 |
| &nbsp;&nbsp;&nbsp;&nbsp;Reductions for tax positions related to prior years | **(46)** | (8) | (59) |
| &nbsp;&nbsp;&nbsp;&nbsp;Reductions for settlements with taxing authorities | **(19)** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Reductions for prior year tax positions related to statute expiration | **(5)** | (14) | (8) |
| Unrecognized tax benefits at end of the year, excluding accrued interest and penalties | $**48** | $110 | $117 |
| Unrecognized tax benefits that, if recognized, would affect the effective income tax rate | $**43** | $104 | $111 |
| Accrued interest and penalties | $**7** | $17 | $13 |

---

The Company includes net interest and penalties as a component of income tax expense.

The Company files income tax returns in the United States and various foreign jurisdictions which may be subject to routine compliance reviews by the IRS and other taxing authorities. While the Company believes it has recorded appropriate accruals for uncertain tax positions in accordance with applicable accounting guidance, it is possible that tax authorities may assess additional taxes beyond the amounts accrued or that the recorded accruals could

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

exceed the final settlement amounts reached with those authorities. The audit of the Company's federal income tax returns for fiscal years 2016 through 2019 has been effectively settled, pending final administrative approvals from the IRS. Tax years 2023 through 2025 remain open and subject to examination by the IRS and other foreign and domestic taxing jurisdictions.

**Note 11—Debt Obligations:**

The Company's debt as of the periods presented was as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **January 30, 2026** | **January 30, 2026** | **January 30, 2026** | **January 30, 2026** | **January 30, 2026** | January 31, 2025 | January 31, 2025 | January 31, 2025 |
| | **Stated interest rate** | **Effective interest rate** | **Principal** | **Unamortized debt issuance costs** | **Net** | Principal | Unamortized debt issuance costs | Net |
| | | | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| Term Loan A Facility due June 2027 | **— %** | **— %** | $**—** | $**—** | $**—** | $1122 | $(2) | $1120 |
| Term Loan A Facility due September 2030 | **5.07%** | **5.15%** | **1100** | **(3)** | **1097** |  |  |  |
| Term Loan B3 Facility due February 2031 | **5.57%** | **5.71%** | **501** | **(3)** | **498** | 506 | (3) | 503 |
| Senior Notes due April 2028 | **4.88%** | **5.11%** | **400** | **(2)** | **398** | 400 | (3) | 397 |
| Senior Notes due November 2033 | **5.88%** | **6.09%** | **500** | **(6)** | **494** |  |  |  |
| Revolving Credit Facility due June 2027 | **— %** | **— %** | **—** | **—** | **—** | 200 |  | 200 |
| Total debt |  |  | $**2501** | $**(14)** | $**2487** | $2228 | $(8) | $2220 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less current portion |  |  | **19** | **—** | **19** | 313 |  | 313 |
| Total debt, net of current portion |  |  | $**2482** | $**(14)** | $**2468** | $1915 | $(8) | $1907 |

---

***Credit Facility***

As of January 30, 2026, the Company had a $2.6 billion secured credit facility (the "Credit Facility") consisting of a Term Loan A Facility due September 2030, a Term Loan B3 Facility due February 2031 (together, the "Term Loan Facilities"), and a $1.0 billion secured Revolving Credit Facility due September 2030 (the "Revolving Credit Facility").

The Company's Third Amended and Restated Credit Agreement ("Third Amended Credit Agreement") contains certain restrictive covenants applicable to the Company and its subsidiaries including a requirement to maintain a Senior Secured Leverage Ratio (as defined in the Third Amended Credit Agreement) of not greater than 4.00 to 1.00, unless a Permitted Acquisition (as defined in the Third Amended Credit Agreement) occurs in which case not greater than 4.25 to 1.00 for three consecutive quarters following such a transaction.

In fiscal 2025, the Company issued a $510 million senior secured term loan credit facility ("Term Loan B3 Facility due February 2031") which is subject to the same covenants and events of default as the Company's existing Term Loan Facilities. The entire Term Loan B3 Facility due February 2031 was immediately borrowed by the Company and used to settle outstanding term loan facilities. The Term Loan B3 Facility due February 2031 bears interest at a variable rate of interest equal to a base rate or a Secured Overnight Financing Rate ("SOFR") rate, plus the applicable interest rate margin of 0.75% for base rate loans and 1.75% for SOFR rate loans. Borrowings under the Term Loan B3 Facility due February 2031 amortize quarterly beginning on July 31, 2024 at 0.25% of the original borrowed amount with the remaining unamortized balance due in full upon its maturity on February 8, 2031 and may be prepaid at any time without penalty and is subject to the same mandatory prepayments, including from excess cash flow, as the Company's existing term loans under the Credit Facility.

During fiscal 2025, the Company incurred $6 million of debt issuance costs, of which $4 million was recognized in interest expense and the remaining $2 million deferred and amortized to interest expense through the maturity date of the Term Loan B3 Facility due 2031 utilizing the effective interest rate method.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

On September 30, 2025, the Company executed the Eighth Amendment to the Third Amended and Restated Credit Agreement ("Eighth Amendment"), which established a new $1.1 billion senior secured term loan credit facility due on September 30, 2030 ("Term Loan A Facility due September 2030"). The entire Term Loan A Facility due September 2030 was immediately borrowed by the Company and the proceeds were used to pay in full the outstanding principal balance and accrued interest under the Term Loan A Facility due June 2027, transaction related fees and expenses, and for general corporate purposes. The Term Loan A Facility due September 2030 is secured by substantially all of the assets of the Company and the Company's wholly owned domestic subsidiaries, and is guaranteed by each of the Company's wholly owned domestic subsidiaries. The Term Loan A Facility due September 2030 is subject to the same covenants and events of default as the Company's existing term loans under the Credit Facility.

Borrowings under the Term Loan A Facility due September 2030 amortize quarterly beginning on October 31, 2026 at 0.625% of the original borrowed amount, with such quarterly amortization increasing to 1.25% on October 31, 2027, and to 1.875% on October 31, 2028, with the remaining unamortized balance due in full upon maturity. The Term Loan A Facility due September 2030 may be prepaid at any time without penalty and is subject to the same mandatory prepayments, including from excess cash flow, as the Company's existing term loans under the Credit Facility.

The Eighth Amendment also established a new $1.0 billion revolving credit facility with a termination date of September 30, 2030 ("Revolving Credit Facility due September 2030") that replaced the Revolving Credit Facility due June 2027.

The Term Loan A Facility due September 2030 and the Revolving Credit Facility due September 2030 bear interest at a variable rate of interest equal to a base rate or a Secured Overnight Financing Rate (SOFR) rate, plus the applicable interest rate margin of 0% to 0.75% for base rate loans and 0.75% to 1.75% for SOFR rate loans, dependent on the Company's leverage ratio. The Eighth Amendment eliminated the 0.10% credit spread adjustment used in the calculation of SOFR rate loans on the Term Loan A Facility due 2027 and the Revolving Credit Facility due June 2027.

The scheduled principal repayments for the Term Loan Facilities may be reduced or eliminated by annual mandatory prepayments of a portion of the Company's Excess Cash Flow (as defined in the Third Amended Credit Agreement). Mandatory prepayments are allocated to the Term Loan Facilities on a pro rata basis and reduce the remaining scheduled principal installments for each facility.

During fiscal 2026, the Company made scheduled principal repayments of $46 million and $5 million on the Term Loan A Facility due June 2027 and the Term Loan B3 Facility due February 2031, respectively. During fiscal 2025, the Company made scheduled principal repayments of $77 million and $4 million on the Term Loan A Facility due June 2027 and the Term Loan B3 Facility due February 2031, respectively. During fiscal 2024, the Company made scheduled principal repayments of $31 million on the Term Loan A Facility due June 2027 and voluntary principal prepayments of $160 million and $90 million on the Term Loan B Facility due October 2025 and the Term Loan B2 Facility due March 2027, respectively. During fiscal 2024, the Company wrote off deferred debt issuance costs of $2 million associated with the voluntary principal prepayments which were recognized in interest expense. The Company made no principal repayments on the Term Loan A Facility due 2030 in the periods presented.

During fiscal 2026, 2025, and 2024, the Company borrowed $1.9 billion, $1.4 billion, and $160 million and repaid $2.1 billion, $1.2 billion, and $160 million under its revolving credit facilities, respectively. There was no balance outstanding on the Revolving Credit Facility as of as of January 30, 2026. Any obligations under the Revolving Credit Facility are secured by liens on substantially all of the assets of the Company and its subsidiaries. The Revolving Credit Facility is available to the Company through September 2030. Commitment fees for undrawn amounts under the Revolving Credit Facility range from 0.125% to 0.25% per annum based on the Company's leverage ratio.

As of January 30, 2026, the Company was in compliance with the covenants under its Credit Facility.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

***Senior Notes***

On September 25, 2025, the Company issued $500 million of unsecured 5.875% Senior Notes due 2033 ("Senior Notes due November 2033") through a private offering. Proceeds received from the offering were used to repay all indebtedness outstanding under the Revolving Credit Facility due June 2027 and fees and expenses from the offering, with remaining proceeds to be used for general corporate purposes, including working capital to fund growth and strategic projects and transactions. The Senior Notes due November 2033 were issued pursuant to an indenture, dated September 25, 2025 and are the senior unsecured obligations of the Company and are fully and unconditionally guaranteed by each of the Company's existing and future domestic subsidiaries that guarantee the Company's obligations under its credit facilities and certain other indebtedness. Interest is payable semi-annually on May 1 and November 1 of each year, commencing on May 1, 2026. The principal is due on November 1, 2033.

At any time prior to November 1, 2028, the Company may redeem some or all of the Senior Notes due November 2033 at a price equal to 100% of the principal amount, plus accrued and unpaid interest, plus an applicable "make-whole premium." On or after November 1, 2028, the Company may redeem in whole or in part the Senior Notes due November 2033 at set redemption prices, plus accrued and unpaid interest. At any time on or prior to November 1, 2028, the Company may redeem up to 40% of the original aggregate principal amount of the Senior Notes due November 2033 with the net cash proceeds from certain equity offerings at a redemption price equal to 105.875% of the outstanding principal amount, together with accrued and unpaid interest. Upon the occurrence of certain events constituting a change of control, the Company may be required to make an offer to repurchase all of the Senior Notes due November 2033 then outstanding at a price equal to 101% of the principal amount thereof, plus accrued and unpaid interest.

The Company incurred $12 million of debt issuance costs associated with the Eighth Amendment and the Senior Notes due November 2033, of which $1 million was recognized in interest expense and the remaining $11 million deferred and amortized to interest expense through the maturity date of the facility utilizing the effective interest rate method.

The Company's Senior Notes due 2028 have 4.875% interest payable semi-annually on April 1 and October 1 of each year, and the principal is due April 2028.

Maturities of debt as of January 30, 2026 are:

---

| | |
|:---|:---|
| Fiscal Year | Total |
|  | (in millions) |
| 2027 | $19 |
| 2028 | 31 |
| 2029 | 489 |
| 2030 | 88 |
| 2031 | 899 |
| Thereafter | 975 |
| Total principal payments | $2501 |

---

**Note 12—Derivative Instruments Designated as Cash Flow Hedges:**

The Company's derivative instruments designated as cash flow hedges consist of:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | | | Fair Value of Asset<sup>(1)</sup> at | Fair Value of Asset<sup>(1)</sup> at |
| |<br>Pay Fixed Rate |<br>Receive Variable Rate |<br>Settlement and Termination | **January 30,<br>2026** | January 31,<br>2025 |
| | | | | (in millions) | (in millions) |
| Interest rate swaps | 2.96% | Term SOFR | Monthly through October 31, 2025 | **—** | 6 |

---

(1)The fair value of the fixed interest rate swap asset is included in "Other assets" on the consolidated balance sheets.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

In fiscal 2026, the Company's interest rate swaps expired. Prior to the expiration, the Company was party to fixed interest rate swap instruments with a notional value of $685 million that were designated and accounted for as cash flow hedges to manage risks associated with interest rate fluctuations on a portion of the Company's floating rate Credit Facility borrowings. The counterparties to all swap agreements were financial institutions.

See Note 13—Changes in Accumulated Other Comprehensive Income by Component for the unrealized change in fair values on cash flow hedges recognized in other comprehensive income (loss) and the amounts reclassified from accumulated other comprehensive income (loss) into earnings for the current and comparative periods presented.

**Note 13—Changes in Accumulated Other Comprehensive Income by Component:**

The following table presents the changes in accumulated other comprehensive income (loss) attributable to the Company's defined benefit plans and fixed interest rate swap cash flow hedges that are discussed in Note 9—Retirement Plans and Note 12—Derivative Instruments Designated as Cash Flow Hedges, respectively.

---

| | | | |
|:---|:---|:---|:---|
| | Unrealized Gains (Losses) on Fixed Interest Rate Swap Cash Flow Hedges<sup>(1)</sup> | Defined Benefit Obligation Adjustment<sup>(2)</sup> | Total |
| | (in millions) | (in millions) | (in millions) |
| Balance at February 3, 2023 | $18 | $4 | $22 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income before reclassifications | 14 | 2 | 16 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive income | (24) |  | (24) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax impact | 3 | (1) | 2 |
| Net other comprehensive (loss) income | (7) | 1 | (6) |
| **Balance at February 2, 2024** | $**11** | $**5** | $**16** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income before reclassifications | 5 | 5 | 10 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive income | (14) | (1) | (15) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax impact | 2 | (1) | 1 |
| Net other comprehensive (loss) income | (7) | 3 | (4) |
| **Balance at January 31, 2025** | $**4** | $**8** | $**12** |
| &nbsp;&nbsp;&nbsp;&nbsp;Other comprehensive income before reclassifications | 1 | 1 | 2 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amounts reclassified from accumulated other comprehensive income | (7) | (1) | (8) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income tax impact | 2 |  | 2 |
| Net other comprehensive (loss) income | (4) |  | (4) |
| **Balance at January 30, 2026** | $**—** | $**8** | $**8** |

---

(1)The amount reclassified from accumulated other comprehensive income (loss) is included in "Interest expense, net."

(2)The amount reclassified from accumulated other comprehensive income (loss) is included in "Other (income) expense, net."

**Note 14—Sale of Receivables:**

The Company has a Master Accounts Receivable Purchase Agreement ("MARPA Facility"), for the sale of up to a maximum amount of $300 million of certain designated eligible receivables with the U.S. government. The receivables sold under the MARPA Facility are without recourse for any U.S. government credit risk. The MARPA Facility automatically renews each year unless one of the parties gives prior notice to terminate.

The receivable transfers under the MARPA Facility have been recognized as sales, as the receivables had been legally isolated from the Company, the financial institution had a right to pledge or exchange the assets received and we do not maintain effective control over the transferred receivables. The fair value of the sold receivables approximated their book value due to their short-term nature.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

The Company does not retain an ongoing financial interest in the transferred receivables other than cash collection and administrative services. The Company estimated that its servicing fee was at fair value and therefore has not recognized a servicing asset or liability as of January 30, 2026 and January 31, 2025. Proceeds from the sale of receivables are reflected as cash flows from operating activities on the consolidated statements of cash flows.

During fiscal 2026, 2025 and 2024, the Company incurred purchase discount fees of $12 million, $14 million and $9 million, respectively, which are presented in "Other (income) expense, net" on the consolidated statements of income.

MARPA Facility activity consisted of the following:

---

| | | |
|:---|:---|:---|
| | Year Ended | Year Ended |
| | **January 30, 2026** | January 31, 2025 |
| | (in millions) | (in millions) |
| Beginning balance | $**164** | $205 |
| &nbsp;&nbsp;&nbsp;Sale of receivables | **4076** | 4324 |
| &nbsp;&nbsp;&nbsp;Cash collections | **(4076)** | (4365) |
| Outstanding balance sold<sup>(1)</sup> | **164** | 164 |
| &nbsp;&nbsp;Cash collected, not remitted<sup>(2)</sup> | **(26)** | (49) |
| Remaining sold receivables to be collected from customers<sup>(3)</sup> | $**138** | $115 |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;For fiscal 2026, there was no net impact to cash flows from operating activities from sold receivables. For fiscal 2025, the Company recorded a net decrease of $41 million to cash flows from operating activities from sold receivables.

(2)&nbsp;&nbsp;&nbsp;&nbsp;Primarily represents the cash collected on behalf of but not yet remitted as of January 30, 2026 and January 31, 2025. This balance is included in "Accounts payable" on the consolidated balance sheets.

(3)&nbsp;&nbsp;&nbsp;&nbsp;Remaining sold receivables balance is included in "Receivables, net" on the consolidated balance sheets.

**Note 15—Operating Leases:**

Total operating lease cost is comprised of the following:

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30, 2026** | January 31, 2025 | February 2, 2024 |
| | (in millions) | (in millions) | (in millions) |
| Operating lease cost | $**48** | $48 | $56 |
| Variable lease cost | **12** | 13 | 13 |
| Short-term lease cost | **3** | 2 | 2 |
| Total lease cost | $**63** | $63 | $71 |

---

Lease cost is included primarily in "Cost of revenues" and "Selling, general and administrative expenses" on the consolidated statements of income.

The Company's ROU assets and lease liabilities consisted of the following:

---

| | | | |
|:---|:---|:---|:---|
| | Balance Sheet line item | **January 30, 2026** | January 31, 2025 |
| | | (in millions) | (in millions) |
| Operating lease ROU asset | Operating lease right of use assets | $**193** | $164 |
| Operating lease current liability | Other accrued liabilities | **21** | 20 |
| Operating lease non-current liability | Operating lease liabilities | **198** | 173 |
| Total operating lease liabilities |  | $**219** | $193 |

---

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

Other supplemental operating lease information consists of the following:

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30, 2026** | January 31, 2025 | February 2, 2024 |
| | (in millions) | (in millions) | (in millions) |
| Cash paid for amounts included in the measurement of operating lease liabilities | $**50** | $54 | $59 |
| ROU assets obtained in exchange for new operating lease obligations | $**60** | $51 | $43 |

---

Maturities of operating lease liabilities as of January 30, 2026 were as follows:

---

| | |
|:---|:---|
| Fiscal Year | Total |
|  | (in millions) |
| 2027 | $33 |
| 2028 | 30 |
| 2029 | 43 |
| 2030 | 32 |
| 2031 | 26 |
| Thereafter | 113 |
| Total minimum lease payments | 277 |
| Less: imputed interest | (58) |
| Present value of operating lease liabilities | $219 |

---

The weighted-average remaining lease term and the weighted-average discount rate was 7 years and 5.3% as of January 30, 2026, respectively, and 7 years and 5.2% as of January 31, 2025, respectively.

As of January 30, 2026, the Company had rental commitments of $29 million for facility leases that have not yet commenced. These operating leases have a weighted-average lease term of approximately 11 years.

**Note 16—Business Segments Information:**

Effective February 3, 2024, the first day of fiscal 2025, the Company completed a business reorganization which replaced its previous two customer facing operating sectors with five customer facing business groups supported by the enterprise organizations, including the Innovation Factory. The five business groups represent the Company's operating segments and have been aggregated into two reportable segments (Defense and Intelligence, and Civilian) given the similarity in economic and qualitative characteristics, and based on the nature of the customers they serve. The Company defines its operating segments based on the way the CODM, currently the Company's CEO, manages the operations for the purpose of allocating resources and assessing performance.

The Defense and Intelligence segment provides a diverse portfolio of national security solutions to the DoW and the Intelligence Community of the United States Government.

The Civilian segment provides solutions to the civilian markets, encompassing federal, state, and local governments, in order to deliver services for citizen well-being, border security, and protecting lives. This includes integrating solutions into a spectrum of public service missions that impact travel, trade, health and the economy.

The offerings of both reportable segments entail the integration of emerging technologies into mission critical operations that modernize and enable national imperatives, including IT modernization, digital engineering, AI, mission systems support, training and simulation, and ground vehicles support. These services include end-to-end solutions spanning the design, development, integration, deployment, management and operations, sustainment and security of the customers' entire IT infrastructure.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

Costs associated with corporate functions that are not allocable to the reportable segments are presented as Corporate.

The CODM reviews and evaluates segment operating performance using segment "Revenues" and "Adjusted operating income (loss)". Adjusted operating income is a performance measure that primarily excludes the impact of non-recurring transactions and activities that the Company does not consider to be indicative of its ongoing operating performance. Adjusted operating income is calculated by taking operating income and excluding depreciation and amortization, acquisition, integration, restructuring, and impairment costs, and any other material non-recurring costs. The CODM uses revenues and adjusted operating income to assess the financial performance of each operating segment against pre-established performance targets and to allocate resources for strategic business decisions, including investments in certain products or services, potential acquisitions or divestitures, and capital deployment. Labor base is the significant expense that is regularly provided to the CODM, and primarily includes direct labor on customer contracts.

The segment information for the periods presented was as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** | **Year Ended January 30, 2026** |
| | **Defense and Intelligence** | **Civilian** | **Corporate** | **Total SAIC** |
| | (in millions) | (in millions) | (in millions) | (in millions) |
| Revenues | $**5581** | $**1681** | $**—** | $**7262** |
| &nbsp;&nbsp;Labor base | **1645** | **497** | **—** | **2142** |
| &nbsp;&nbsp;Other operating expenses<sup>(1)</sup> | **3458** | **956** | **4** | **4418** |
| Adjusted operating income (loss) | $**478** | $**228** | $**(4)** | $**702** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Year Ended January 31, 2025 | Year Ended January 31, 2025 | Year Ended January 31, 2025 | Year Ended January 31, 2025 |
| | Defense and Intelligence | Civilian | Corporate | Total SAIC |
| | (in millions) | (in millions) | (in millions) | (in millions) |
| Revenues | $5726 | $1753 | $— | $7479 |
| &nbsp;&nbsp;Labor base | 1627 | 500 |  | 2127 |
| &nbsp;&nbsp;Other operating expenses<sup>(1)</sup> | 3590 | 1037 | 20 | 4647 |
| Adjusted operating income (loss) | $509 | $216 | $(20) | $705 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Year Ended February 2, 2024 | Year Ended February 2, 2024 | Year Ended February 2, 2024 | Year Ended February 2, 2024 |
| | Defense and Intelligence | Civilian | Corporate | Total SAIC |
| | (in millions) | (in millions) | (in millions) | (in millions) |
| Revenues | $5817 | $1627 | $— | $7444 |
| &nbsp;&nbsp;Labor base | 1597 | 482 |  | 2079 |
| &nbsp;&nbsp;Other operating expenses<sup>(1)</sup> | 3716 | 939 | 51 | 4706 |
| Adjusted operating income (loss) | $504 | $206 | $(51) | $659 |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;"Other operating expenses" includes cost of revenues, selling, general and administrative expenses, and other operating income or loss which are not regularly provided to the CODM. This excludes labor base which is presented separately.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

The table below includes a reconciliation of total "Adjusted operating income" to "Income before income taxes" for the years ended January 30, 2026, January 31, 2025, and February 2, 2024.

---

| | | | |
|:---|:---|:---|:---|
| | Year Ended | Year Ended | Year Ended |
| | **January 30,<br>2026** | January 31,<br>2025 | February 2,<br>2024 |
| | (in millions) | (in millions) | (in millions) |
| Adjusted operating income | $**702** | $705 | $659 |
| &nbsp;&nbsp;Depreciation of property, plant, and equipment | **30** | 25 | 26 |
| &nbsp;&nbsp;Amortization of intangible assets | **119** | 115 | 115 |
| &nbsp;&nbsp;Acquisition, integration, restructuring and impairment costs | **16** | 6 | 24 |
| &nbsp;&nbsp;Depreciation included in restructuring and impairment costs | **(1)** | (1) | (1) |
| &nbsp;&nbsp;Recovery of acquisition, integration, restructuring and impairment costs<sup>(1)</sup> | **(6)** | (3) | (6) |
| &nbsp;&nbsp;Executive transition costs, net of recoveries | **16** |  |  |
| &nbsp;&nbsp;Costs related to the settlement of federal tax audits | **7** |  |  |
| (Gain) loss on divestitures, net of transaction costs | **—** |  | (240) |
| &nbsp;&nbsp;Interest expense, net | **128** | 126 | 120 |
| &nbsp;&nbsp;Other (income) expense, net | **6** | 9 | 1 |
| Income before income taxes | $**387** | $428 | $620 |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Adjustment reflects the portion of acquisition, integration, restructuring and impairment costs recovered through our indirect rates in accordance with U.S. government Cost Accounting Standards.

Asset information by segment is not a key measure of performance used by the CODM.

Substantially all of the Company's revenues and tangible long-lived assets are generated and located in the United States. As such, financial information by geographic location is not presented.

In each of fiscal 2026, 2025 and 2024, 98% of the Company's total revenues were attributable to prime contracts with the U.S. government or to subcontracts with other contractors engaged in work for the U.S. government.

**Note 17—Legal Proceedings and Other Commitments and Contingencies:**

***Legal Proceedings***

The Company is involved in various claims and lawsuits arising in the normal conduct of its business, none of which the Company's management believes, based on current information, is expected to have a material adverse effect on the Company's financial position, results of operations or cash flows.

In April 2022 and October 2023, the Company received Federal Grand Jury Subpoenas in connection with a criminal investigation being conducted by the U.S. Department of Justice, Antitrust Division ("DOJ"). As required by the subpoenas, the Company has provided the DOJ with a broad range of documents related to the investigation, and the Company's collection and production process remains ongoing. The Company is fully cooperating with the investigation. At this time, it is not possible to determine whether the Company will incur, or to reasonably estimate the amount of, any fines, penalties or further liabilities in connection with the investigation pursuant to which the subpoenas were issued.

In June 2017, the Company filed a patent infringement complaint in the United States Court of Federal Claims against the United States and three other parties, alleging infringement of the Company's Enhanced Rapid Engagement and Vision in Ambient Lighting patents. In fiscal 2026, the Company executed a favorable settlement agreement with all parties. As part of the settlement, the Company was awarded $15 million and recognized $9 million as a recovery for costs previously incurred within "Selling, general and administrative expenses" within the Company's consolidated statements of income during fiscal 2026. In addition, the Company recognized $6 million of costs that was contingent on the settlement of the patent infringement matter.

------

<u>[**Table of Contents**](#i68c4e1d46e8b478fb5bd56210bcd1bf5_178)</u>

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**<br>**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS**<br>

***AAV Termination for Convenience***

On August 27, 2018, the Company received a stop-work order from the United States Marine Corps on the Assault Amphibious Vehicle ("AAV") contract and on October 3, 2018 the program was terminated for convenience by the customer. In fiscal 2025, the Company entered into a $21 million termination settlement agreement with the customer to recover the contract costs associated with the termination, which resulted in an increase to "Revenues" of $13 million on the Company's consolidated statements of income in fiscal 2025. The settlement agreement releases the customer from all obligation and claims from the Company. Proceeds for the full settlement amount were received in the first quarter of fiscal 2026.

***Government Investigations, Audits and Reviews***

The Company is routinely subject to investigations and reviews relating to compliance with various laws and regulations with respect, in particular, to its role as a contractor to federal, state and local government customers and in connection with performing services in countries outside of the United States. U.S. government agencies, including the DCAA, the Defense Contract Management Agency and others, routinely audit and review a contractor's performance on government contracts, indirect rates and pricing practices, and compliance with applicable contracting and procurement laws, regulations and standards. They also review the adequacy of the contractor's compliance with government standards for its business systems. Adverse findings in these investigations, audits, or reviews can lead to criminal, civil or administrative proceedings, and the Company could face disallowance of previously billed costs, penalties, fines, compensatory damages, and suspension or debarment from doing business with governmental agencies. Due to the Company's reliance on government contracts, adverse findings could also have a material impact on the Company's business, including its financial position, results of operations and cash flows.

The indirect cost audits by the DCAA of the Company's business remain open for certain prior years and the current year. Although the Company has recorded contract revenues based on an estimate of costs that the Company believes will be approved on final audit, the Company does not know the outcome of any ongoing or future audits. If future completed audit adjustments exceed the Company's reserves for potential adjustments, the Company's profitability could be materially adversely affected.

As of January 30, 2026, the Company believes it has adequately reserved for estimated net amounts to be refunded to customers for potential adjustments for indirect cost audits and compliance with CAS.

***Letters of Credit and Surety Bonds***

The Company has outstanding obligations relating to letters of credit of $8 million as of January 30, 2026, principally related to guarantees on insurance policies. The Company also has outstanding obligations relating to surety bonds in the amount of $19 million, principally related to performance and payment bonds on the Company's contracts.

## Exhibit 10.1

![](saicfy2610-kex101001.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12010 Sunset Hills Rd, Reston VA 20190 703.676.4300 \| saic.com 1 February 18, 2026 James C. Reagan Delivered via electronic communication Dear Jim: On behalf of Science Applications International Corporation (SAIC) and our Board of Directors, I am delighted to extend you an offer to take on the permanent role of Chief Executive Officer (CEO), transitioning from your current position serving as the Interim CEO. This recognizes your leadership and SAIC's confidence in your ability to have an impact on the company's long-term success and growth objectives. The effective start date will be February 17, 2026. Your primary place of work will be 12010 Sunset Hills Road, Reston, VA. Your annual base salary will be $1,200,000, payable in accordance with the Company's regular payroll practice, subject to all applicable tax withholdings and deductions. Your target short-term incentive ("STI") for SAIC's fiscal year 2027 (January 31, 2026 – January 29, 2027) is 150% of your base salary. Your fiscal year 2027 STI award will not be pro-rated with respect to your tenure with SAIC in recognition of your time served as interim CEO for the period between January 31, 2026 until the effective start date. The STI is payable, upon certain approvals, in cash and is based on achievement of corporate and individual performance goals. Your target long-term incentive ("LTI") is $7,500,000. The target LTI is currently delivered in SAIC stock, comprised of 40% restricted stock units ("RSUs"), and 60% performance stock units ("PSUs"). These percentages are subject to review and change annually. Your target LTI award will be granted in April 2026 and is subject to the terms outlined in your award agreement. RSUs and PSUs represent the right to receive common stock of SAIC at a future date, provided that certain vesting and/or performance conditions are met. The RSUs will vest over the passage of time, generally in equal annual installments (1/3 per year) over a period of three years beginning on the first anniversary of the grant date. PSUs cliff-vest at the end of the three-year performance period. Both require that you have continuous employment with SAIC and satisfy other applicable grant requirements. All equity awards are required to be formally acknowledged by the recipient. Awards not acknowledged by the deadline will be subject to forfeiture. SAIC will continue to provide you with physical security for your local, domestic and international business travel.

------

![](saicfy2610-kex101002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2 Your role will be deemed eligible to participate as an "Eligible Officer" in the SAIC Executive Severance, Change in Control and Retirement Policy, which specifies the compensation and benefits payable in connection with certain termination events for Eligible Officers of SAIC as described in the policy. Your role will also continue to be eligible to participate in SAIC's deferred compensation plan, SAIC's standard employee benefit programs and executive health program. This letter supersedes and replaces the interim CEO offer letter dated as of October 23, 2025 (the "Interim CEO Offer Letter") (including, but not limited to, any provision related to your termination of employment), as well as all prior verbal and/or written representations, which may have been made to you. The acceptance of this offer to take on the permanent role of CEO ends your appointment as the Interim CEO and ends the effectiveness of the Interim CEO Offer Letter. As a result, the previously granted long-term incentive award of $2,000,000 will vest immediately per the terms of the Interim CEO Offer Letter and subsequent RSU award agreement. No other entitlements are due to you as part of the transition. We are excited to have you join us permanently and lead our team. Should you have any questions regarding this offer, please do not hesitate to contact me. Best Regards, /s/ Kathleen McCarthy Kathleen McCarthy SAIC Executive Vice President and Chief Human Resources Officer Accepted by (sign below): /s/ James C. Reagan James C. Reagan Date Signed: February 18, 2026

------

## Ex-21

**Exhibit 21**

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Subsidiaries of Registrant** | **Subsidiaries of Registrant** | **Subsidiaries of Registrant** | **Subsidiaries of Registrant** | **Jurisdiction of Incorporation or Organization** |
| SAIC International Holdings, Inc. | SAIC International Holdings, Inc. | SAIC International Holdings, Inc. | SAIC International Holdings, Inc. | Delaware |
|  | TASC Services Corporation | TASC Services Corporation | TASC Services Corporation | Delaware |
|  | Science Applications International Corporation (UK) Limited | Science Applications International Corporation (UK) Limited | Science Applications International Corporation (UK) Limited | United Kingdom |
|  | ATAC Services, LLC | ATAC Services, LLC | ATAC Services, LLC | Delaware |
| SAIC Gemini Huntsville, LLC | SAIC Gemini Huntsville, LLC | SAIC Gemini Huntsville, LLC | SAIC Gemini Huntsville, LLC | Delaware |
|  | Odyssey Drive I, Ltd. | Odyssey Drive I, Ltd. | Odyssey Drive I, Ltd. | California |
| Valinar, LLC | Valinar, LLC | Valinar, LLC | Valinar, LLC | Delaware |
| Halfaker and Associates, LLC | Halfaker and Associates, LLC | Halfaker and Associates, LLC | Halfaker and Associates, LLC | Virginia |
| Engility Services (Canada) ULC | Engility Services (Canada) ULC | Engility Services (Canada) ULC | Engility Services (Canada) ULC | Canada |
| Koverse, Inc. | Koverse, Inc. | Koverse, Inc. | Koverse, Inc. | Delaware |
| Silveredge Intermediate, LLC | Silveredge Intermediate, LLC | Silveredge Intermediate, LLC | Silveredge Intermediate, LLC | Delaware |
|  | Silveredge Government Solutions, LLC | Silveredge Government Solutions, LLC | Silveredge Government Solutions, LLC | Delaware |
| | | Varen Technologies, LLC | Varen Technologies, LLC | Delaware |
| | | Savli Group, LLC | Savli Group, LLC | Maryland |
| | | Exceptional Software Strategies, LLC | Exceptional Software Strategies, LLC | Maryland |
| | | QVine, LLC | QVine, LLC | Virginia |
| | | CTS Buyer, LLC | CTS Buyer, LLC | Delaware |
| | | | Counter Threat Solutions, LLC | Virginia |
| | | | Gardetto Engineering, LLC | Maryland |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in the following Registration Statements:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Form S-8 No. 333-191436

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Form S-8 No. 333-203222

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)Form S-8 No. 333-229254

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4)Form S-8 No. 333-272484

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5)Form S-8 POS No. 333-229254

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(6)Form S-8 No. 333-273014

of our reports dated March 16, 2026, with respect to the consolidated financial statements of Science Applications International Corporation and the effectiveness of internal control over financial reporting of Science Applications International Corporation included in this Annual Report (Form 10-K) of Science Applications International Corporation for the year ended January 30, 2026.

/s/ Ernst & Young LLP

Tysons, Virginia

March 16, 2026

## Exhibit 31.1

**Exhibit 31.1**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, James C. Reagan, certify that:

1. I have reviewed this Annual Report on Form 10-K for the period ended January 30, 2026 of Science Applications International Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 16, 2026

---

| |
|:---|
| /s/&nbsp;&nbsp;&nbsp;&nbsp;James C. Reagan |
| **James C. Reagan** |
| **Chief Executive Officer** |

---

## Exhibit 31.2

**Exhibit 31.2**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO**

**SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Prabu Natarajan, certify that:

1. I have reviewed this Annual Report on Form 10-K for the period ended January 30, 2026 of Science Applications International Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 16, 2026

---

| |
|:---|
| /s/&nbsp;&nbsp;&nbsp;&nbsp;Prabu Natarajan |
| **Prabu Natarajan** |
| **Chief Financial Officer** |

---

## Exhibit 32.1

**Exhibit 32.1**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report of Science Applications International Corporation (the "Company") on Form 10-K for the period ended January 30, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, James C. Reagan, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 16, 2026

---

| |
|:---|
| /s/&nbsp;&nbsp;&nbsp;&nbsp;James C. Reagan |
| **James C. Reagan** |
| **Chief Executive Officer** |

---

## Exhibit 32.2

**Exhibit 32.2**

**SCIENCE APPLICATIONS INTERNATIONAL CORPORATION**

**CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Annual Report of Science Applications International Corporation (the "Company") on Form 10-K for the period ended January 30, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Prabu Natarajan, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: March 16, 2026

---

| |
|:---|
| /s/&nbsp;&nbsp;&nbsp;&nbsp;Prabu Natarajan |
| **Prabu Natarajan** |
| **Chief Financial Officer** |

---

<br>